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Genetic Polymorphisms contribute to phenotypic differences e.g. disease risks 
and drug responses amongst individuals. It remains a great challenge to identify the 
causative variants from more than 100 million known human polymorphisms for a 
particular phenotype. Characterization of the role of genetic polymorphisms in 
modulating gene expression or protein function will facilitate our understanding of the 
underlying molecular mechanisms. In this study, I would like to determine the 
architecture of polymorphisms in the human genome. The result indicates that genetic 
polymorphisms are selectively constrained in coding regions, as they show lowest density, 
higher percentage of rare alleles and lowest level of population differentiation. 
Polymorphisms are over-represented in genes involved in immune responses and are 
putatively functional modulating gene regulation or splicing patterns.  
After investigating the overall architecture of SNPs in the genome, I further 
elucidate the potential functions and expression phenotype associations of the miRNA-
related polymorphisms in both normal individuals and HCC patients. Using the genotype 
and expression data in the lymphoblastoid cell lines from four populations of the 
HapMap project, I identify two SNPs in pre-miRNAs that are associated with mature 
miRNA expression and one SNP in mature miRNA that is associated with differential 
expression of a putative target gene. A total number of 415 3’UTR SNPs show 
associations with gene expression and potentially affect the miRNA bindings. The 
analysis of the miRNA expression and genotypes of 17 HCC patients of The Cancer 
Genome Atlas (TCGA) project identifies that four SNPs in the pre-miRNAs show 
associations with mature miRNA expression. Moreover, the genotypes of 879 SNPs in 39 
 IX 
 
genes are associated with expression of 212 mature miRNAs. The expression-associated 
SNPs are enriched in CNOT6, AGO2, DROSHA and SMAD3, which play important 
roles in the miRNA regulation pathway. 
Lastly, I explore circulating miRNAs as potential non-invasive biomarkers for 
HCC. I first profile 751 miRNAs in the plasma samples of 10 normal healthy individuals 
and 19 HCC patients. After identifying the de-regulated and clinically relevant miRNAs, 
I proceed to validating 98 miRNAs in 40 normal, 30 chronic carriers and 36 HCC 
patients. Finally, 44 miRNAs are identified to be potential biomarkers for chronic 
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Chapter 1: Introduction 
1.1 Genetic polymorphisms in the human genome 
1.1.1 Overview  
 
Genetic polymorphisms, which represent alternative forms of DNA sequence, 
contribute to the 0.1% difference between genomic sequences of two unrelated 
individuals [1, 2]. To date, more than 112 million human polymorphisms have been 
identified in the human genome (NCBI dbSNP database, Build 142, 
http://www.ncbi.nlm.nih.gov/projects/SNP/snp_summary.cgi?build_id=142).  
Different forms of genetic variants have been identified. Using next generation 
sequencing (NGS), researchers characterized approximately 38 million single nucleotide 
polymorphisms (SNPs), 1.4 million short insertions and deletions (INDELs) and 14,000 
larger deletions in 1092 individuals from 14 human populations [3]. Similar with 
previous finding [4], SNPs account for more than 90% of genomic variants and are the 
major form of human polymorphisms.  
1.1.2 Potential functions  
 
Some polymorphisms affect clinical phenotypes and are causatively associated 
with disease risks or drug responses amongst individuals. However, to identify the causal 
variant(s) for a particular phenotype remains a great challenge, simply due to the fact that 
not all the genetic variants are functionally important. Therefore, determining the single 
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or a group of causative variants from a pool of more than one hundred million 
polymorphisms for a phenotypic difference is like ‘finding a needle in a haystack’.  
Due to the difficulties of identifying the causative variants, it is important to 
understand the underlying molecular mechanisms for genetic variants leading to 
phenotypic differences. Functionally important polymorphisms exert effects on gene 
expression or protein function, affect cellular phenotypes e.g. apoptosis and finally 
contribute to disease risks or drug responses. The very first step, to understand the effects 
of polymorphisms on molecular functions, lays the foundation for elucidating phenotype 
association.   
Non-synonymous SNPs (nsSNPs) have been extensively investigated by many 
research groups, because they change amino acid composition of proteins. On the other 
hand, synonymous SNPs and non-coding variants could affect messenger RNA (mRNA) 
stability, transcriptional or translational efficiency. A great number of polymorphisms 
had been associated with gene expression levels in various cell lines and tissues [5-13]. 
Though there is increasing evidence that both coding and non-coding variants could be 
functionally significant, to experimentally characterize the polymorphisms is time-
consuming and not applicable for genome-wide studies. On the other hand, a variety of 
bioinformatics tools have been developed to predict the potential functions of genetic 
variants, including non-synonymous SNPs  disrupting protein structures and/or functions 
[14-16], SNPs in 3’ un-translated regions (3’UTR) affecting microRNA (miRNA) target 
sites [17, 18], etc. These methods help us to prioritize the potentially functional SNPs for 
experimental validation and understand how functional SNPs could contribute to 
phenotypic changes.  
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1.1.3 Natural selections 
 
Natural selection can cause a change in SNP allele frequency, for example, 
adaptation to cold climate increases the frequency of a SNP that determines the earwax 
type in local populations [19]. The allele frequency and genotype data in different 
populations have been widely used to detect signatures of natural selections and identify 
functionally important variants [20-22]. Akey et al. investigated the patterns of 
population differentiation of all the genomic SNPs, and identified 174 candidate gene loci 
containing 253 SNPs showing signatures of purifying or positive selections [20]. A later 
study using HapMap Phase II data found that negative selections preferentially target 
non-synonymous sites, while both non-synonymous sites and 5’ un-translated regions 
(5’UTRs) show an excess of highly differentiated SNPs, which suggest the evidence of 
positive selections as well. The authors also found that variants under selection pressures 
(either positive or negative) occur more frequently in disease-related genes [22]. In 
addition to population differentiation, researchers also utilized ‘long-range haplotype’ 
methods to identify a list of targets undergoing recent positive selection (RPS) [21]. All 
these previous studies prioritized SNPs showing signatures of natural selections as 
candidate causal variants for phenotypic differences and/or disease risks.  
In spite of a great number of studies on human polymorphisms, there are still gaps 
in our knowledge about the functionally important variants. The bioinformatics 
prediction of functional variants un-avoidably generate large number of candidate 
polymorphisms including false positives, while only a subset of the predicted SNPs have 
effects on gene and/or protein functions. On the other hand, previous studies in natural 
selections identified candidate genes or genomic regions, but seldom investigated the 
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underlying mechanisms of the candidate variants affecting molecular functions and 
contributing to phenotypic differences. Interrogation of potential functions and natural 
selections is important for investigating genetic polymorphisms. However, previous 
studies combining both potential functions and natural selection approaches either 
focused on a single group of potentially functional SNPs e.g. SNPs that affect miRNA 
binding sties [20], or investigated SNPs within regulatory sequences without evaluating 
the changes by the variants [21, 22]. Therefore, a systematic study about the distribution, 
functional effects and natural selection of the human polymorphisms is required to 
expand our understanding about their contributions to phenotypes. In this thesis, we also 
elaborate on the genes that are enriched by SNPs showing both potential functions and 
natural selections, and determine how these polymorphisms could affect certain 











1.2 Polymorphic microRNA regulation 
 
There is increasing evidence from both genome-wide association study (GWAS) 
and expression quantitative trait loci (eQTL) studies about the functional significance of 
polymorphisms outside the coding sequences. While genetic variants can mediate gene 
expression via several mechanisms, their involvement in miRNA regulation has attracted 
increasing attentions.  
1.2.1 MicroRNA 
 
MiRNAs are endogenous small non-coding RNAs, with approximately 22-
nucleotide length in their mature forms, that mediate post-transcriptional gene regulation 
[23]. In animals, miRNAs bind to the 3’UTRs with complementary sequence, and 
mediate mRNA cleavage or translational inhibition [24]. To date, nearly 2000 miRNA 
primary transcripts are identified in the human genome, according to the statistics of 
miRBase release 21 [25]. As key players in the gene regulation, miRNAs and their targets 
are involved in a variety of pivotal biological processes [26].  
In the human genome, miRNAs reside in both inter-genic and genic regions, and 
are transcribed by RNA polymerase II into primary forms, with more than 1 kilo base 
pairs (kb) in their lengths [27]. A number of genes are involved in miRNA biogenesis, in 
which primary miRNAs (pri-miRNAs) are processed to short mature forms. In nucleus, 
Drosha, an RNAase III protein, initiates the processing by cleaving the pri-miRNA into a 
~70 nucleotide long, stem-loop precursor miRNA (pre-miRNA) [28]. During this step, 
Drosha and its co-factor, DGCR8 form a micro-processor and mediate the cleavage [29]. 
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Pre-miRNA is then exported by Exportin-5 (XPO5) from nucleus to cytoplasm [30]. 
Upon release into cytoplasm, pre-miRNA is cleaved into mature miRNA duplex by 
another RNAase III protein, Dicer [31]. The miRNA duplex is loaded to Argonaute 
(AGO) proteins and incorporated into the RNA-induced silencing complex (RISC) [32], 
in which the duplex is unwound and one strand, namely the passenger strand, is 
degraded. The guide strand remains bound to the AGO proteins and mediates the 
recognition of targets by sequence complementarily. In this step, there are other factors 
being recruited by AGO proteins to induce translational repression or mRNA degradation 
[27]. Processing body components in the cytoplasm interact with AGO proteins and are 
involved in the miRNA-mediated gene silencing [33, 34]. 
1.2.2 Genetic polymorphisms involved in miRNA regulation 
1.2.2.1 Polymorphisms in miRNA genes 
 
Genetic variants within pre-miRNAs have been associated with disease risks in 
independent studies. For example, a common SNP in mir-146a precursor could affect 
mature miRNA production and showed association with papillary thyroid carcinoma 
(PTC) risk [35]. On a genome-wide scale, researchers utilized the SNP information from 
dbSNP database to investigate the distribution of SNPs in miRNA genes. Based on 
dbSNP126 data, 65 SNPs were identified in pre-miRNAs and occurred less frequently 
than those in the flanking regions of the pre-miRNAs. In addition, only three SNPs were 
detected in the seed regions, defined as the 2
nd
 to the 7
th
 nucleotides in the mature 
miRNAs and critical for target recognition [36]. Later studies by Gong et al. [37]and Han 
et al. [38] discovered hundreds of polymorphisms within pre-miRNAs, and found 44% 
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and 63% human pre-miRNAs were polymorphic [37, 38]. Despite the increasing number 
of SNPs identified in the miRNA loci, recent studies confirmed the previous finding that 
miRNAs are more conserved than their flanking regions [37], and the seed sequences are 
the least polymorphic, as represented by the lowest SNP density among different parts of 
the miRNA genes [38].  
1.2.2.2 Polymorphisms in miRNA targets 
  
 Since the discovery of miRNAs, there have been tremendous efforts in 
characterizing miRNA target polymorphisms.  Polymorphic miRNA targets have been 
associated with a variety of human diseases including neurodegenerative diseases, 
various types of cancers, etc [39]. In addition to the independent studies investigating 
single or a group of candidate SNPs, genome-wide research on polymorphisms in 
miRNA target sites was conducted by a few groups, as summarized in Table 1.2.1 
(published in [40]). Investigation of SNPs in target sites is more tedious than discovering 
SNPs within miRNA genes, because the miRNA target regions are not well characterized 
in the human genome. Both bioinformatics algorithms and experimental approaches are 
extensively used for identifying miRNA targets, and the database resources for the 
predicted targets, e.g. TargetScan (http://www.targetscan.org), could largely facilitate the 






Table 1.2.1 Summary of studies on SNPs in miRNA targets (published in[40]). 
Study 3'UTR SNP 
resource 
Tools for identifying SNPs in 
putative targets verified targets 
Chen et al. [41] dbSNP125 PicTar-like algorithm  
Saunders et al. [36] dbSNP126 TargetScanS Tarbase  
Bao et al. [17] dbSNP126 TargetScanS - 
Yu et al. [42] dbSNP126 PicTar - 
Landi et al. [43] dbSNP 
PicTar, DIANA-MicroT, 
miRBase, miRanda, TargetScan, 
MicroInspector 
- 
Hariharan et al. [44] dbSNP123 RNAFold - 
Duan et al. [45] dbSNP129 TargetScanS and PITA Tarbase  
Hiard et al. [18] dbSNP 
Prediction of SNPs that alter 
canonical sites matching miRNA 
seed regions, or conserved 
octamers in 3'UTRs 
- 
Thomas et al. [46] HapMap 
Release 22 
SVM prediction model - 
Hu et al. [47] dbSNP130 TargetScan - 
Richardson et al. 
[48] 
dbSNP132 miRanda miRecords 
Gong et al. [37] dbSNP 132 TargetScan and miRanda - 
Zhang et al. [49] 
HapMap 
release 27 
Prediction of SNPs that disrupt 
or create canonical site motif 
complementary to seed regions 
- 






Liu et al. [51] dbSNP135 miRanda - 
 
 To date, most of studies focused on SNPs in 3’UTRs, because in animals, 
miRNAs preferentially hybridize to 3’UTR of transcripts  [24]. Conventional miRNA 
target prediction algorithms, e.g. PicTar, TargetScan, MiRanda, have been extensively 
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used to identify 3’UTR sequences that match the seed sequences of mature miRNAs [36, 
41]. SNP that creates a novel binding site or disrupts a putative target was identified to be 
functionally important. A different approach was used by Hariharan et al., who predicted 
the functions of the SNPs based on their influence on the secondary structures of the 
binding sites [44]. On the other hand, though experimentally verified miRNA-mRNA 
interactions lead to more accurate prediction of the functional SNPs, fewer studies 
incorporated these evidences (Table 1.2.1). Recent advances in technology combining 
cross-linking immunoprecipitation (CLIP) and high-throughput sequencing facilitated the 
discovery of a great number of miRNA target sites [52]. However, to our knowledge, 
most of the studies about polymorphic miRNA targets did not utilize the experimentally 
characterized targets identified using CLIP-sequencing.  
Although different approaches were used for prediction of miRNA targets, there 
was a consistent finding that revealed the signature of purifying selection in miRNA 
target regions, compared to the flanking sequences [36, 41, 42]. On the other hand, 
several SNPs that affect verified target sites undergo positive selection, as detected by 
high levels of population differentiation or long-range haplotype [36, 37, 41, 48]. The 
evidences from previous studies suggest that polymorphisms in miRNA binding sites 
(miRBS) are targeted by positive and negative selections. Therefore, they might cause 
deleterious effects that influence disease risks, or contribute to differences amongst 




1.2.2.3 Polymorphisms in the miRNA machinery genes 
 
 Compared to the polymorphic miRNAs and polymorphic miRNA targets, there 
are fewer comprehensive studies about the polymorphic miRNA machinery pathway. 
Previous studies focused on single or several SNPs that might affect important genes e.g. 
Dicer, XPO5 in miRNA machinery pathway, and investigated their associations with 
disease phenotypes [53-55].  
Systematic study of polymorphic miRNA machinery was first conducted by Hiard 
et al. and the finding was incorporated into Patrocles database. 237 SNPs and 17 copy 
number variations (CNVs) in coding regions or splice sites of the 52 miRNA machinery 
genes were identified and deposited in the database [18]. Another study by Venkatash et 
al. focused on the SNPs in the seven processing body genes using in silico bioinformatics 
prediction. The authors identified various deleterious SNPs that may affect protein 









1.3 MicroRNAs and HCC 
1.3.1 Hepatocellular carcinoma 
 
 Liver cancer, the sixth most common cancer type, and the third leading cause of 
cancer deaths, accounted for 748,000 cases and 695,000 deaths worldwide annually [57]. 
In the United States, the largest annual increase was observed in liver cancer from 2006 
to 2010 [58]. There is gender difference of the incidence rate, which is more than twice in 
males compared to females. Geographical variations of the rates show that East and 
South-East Asian regions have the highest incidence rate, and approximately half of the 
cases and liver cancer-related deaths occur in China [59]. The major form of liver cancer 
is hepatocellular carcinoma (HCC), accounting for 85 to 90% of primary liver cancer 
cases [60]. 
1.3.1.1 Risk factors for HCC 
 
Risk factors include Hepatitis B virus (HBV),  Hepatitis C virus (HCV), aflatoxin 
exposure, alcoholic disease and nonalcoholic fatty liver disease (NAFLD) [61] (Figure 
1.3.1). Chronic viral infection contributes to the majority of HCC, in which more than 
half are attributable to HBV while 25% is caused by HCV infection [62]. High 
prevalence of HBV infection in China leads to the high incidence rate, while HCV is the 
major risk factor for HCC in Western Europe, North America and Japan [63]. The 
molecular mechanisms of viral infection leading to development of HCC were 
extensively investigated though not comprehensively understood. The HBV genome is 
able to integrate into the host genome, cause structural changes on both viral and human 
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genomic sequences, and ultimately lead to tumorigenic processes [64]. HCV does not 





1.3.1.2 Diagnosis of HCC and chronic hepatitis B 
 
Diagnosis of HCC at early stage could facilitate the effective treatment and 
improve the survival. Conventionally, HCC is diagnosed using a combination of hepatic 




ultra-sound imaging and serum α-fetoprotein (AFP) [63]. Liver biopsy is used to confirm 
suspicious lesions for HCC. However, needle biopsy is an invasive measure and only 
applies to circumstances when the diagnosis by other methods is not clear [65].  
For early detection of HCC, serum marker AFP is commonly used. However, the 
accuracy of AFP is unsatisfactory, based on the 41-65% sensitivity and 80-94% achieved 
at the cutoff value 20 ng/mL [66]. Moreover, the level of APF could be elevated in liver 
cirrhotic patients without HCC [67]. There is an urgent need to explore non-invasive 
serum marker with better diagnostic performance.  
In addition to early detection of HCC, diagnosis of HBV infection is also 
important because HBV infection is the leading cause of HCC. Blood test for HBV 
antigens and antibodies were commonly used for routine screening, and HBV DNA is 
commonly used to assess viral load and disease activity [68].  
1.3.1.3 Treatment for HCC 
 
Established treatment for HCC includes liver resection, liver transplantation and a 
chemotherapeutic drug, sorafenib (Figure 1.3.1). Liver resection is a curative treatment, 
applicable to HCC patients with preserved liver function and able to achieve long-term 
survival after surgery [69]. However, only 5-40% HCC patients are eligible for surgical 
resection [63]. Liver transplantation offers the best survival outcome [70], however is 
limited by the availability of donor liver. Sorafenib serves as palliative management of 
HCC and only prolonged survival of patients with advanced HCC by three months[71].   
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Due to the difficulties in early detection and effective treatment of HCC, 
researchers have spent tremendous efforts on understanding the complex molecular 
mechanisms leading to HCC. The genetic basis of HCC has always garnered researchers’ 
interests. The signatures of gene expression, methylation, non-coding RNAs, mutations, 
polymorphisms have been extensively investigated. In this thesis, I focus on the genetic 
variants and miRNAs in HCC, and our current knowledge in this field is summarized in 
the next section.    
1.3.2 MiRNA de-regulation in HCC 
 
 Aberrant miRNA expression has been identified in a variety of human cancers 
[72]. Key components involved in miRNA biogenesis and processing pathways are 
perturbed during cancers [73]. In HCC, seven miRNA biogenesis genes are under-
expressed [74]. In addition to the repression of miRNA biogenesis, aberrant methylation 
patterns have been linked to de-regulation of miRNAs [75]. Since an early study by 
Murakami et al. in 2006 [76], who identified 3 up- and 5 down-regulated miRNAs, there 
have been a number of studies profiling genome-wide miRNA expression in HCC, and 
almost the same number of up- and down-regulated miRNAs were reported in HCC 
tissues [77]. Several commonly de-regulated miRNAs, which are implicated in 
hepatocarcinogenesis, are discussed in the following paragraphs.  
 Let-7 family members were found to be under-expressed in HCC tissues [77]. 
Down-regulation of let-7 is mediated by an oncogene c-myc [78] and/or by the X protein 
in HBV genome during tumorigenesis [79]. Let-7 members mediate expression of genes 
implicated in HCC. For example, let-7c and let-7g target Bcl-xL, an anti-apoptotic 
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member of the Bcl-2 family, hence the de-regulation of let-7 influences the apoptotic 
pathway [80]. STAT3, a target of let-7a, is up-regulated as a consequence of under-
expression of let-7a in HCC, and promotes cell proliferation [79]. In addition, down-
regulation of let-7g attenuates its suppressive effect on cell proliferation via regulating c-
myc and a tumor suppressor gene p16 [81]. To summarize, under-expression of let-7 
members could affect the cell proliferation and apoptotic pathways in HCC.  
 MiR-122 is the most abundant miRNA in liver tissue and involved in liver 
development and diseases [82]. Down-regulation of miR-122 was observed in HCC 
tumor tissues by several studies [83-85]. Cyclin G1, a gene involved in cell cycle, was 
validated as a direct target of miR-122, and showed inverse correlation with miR-122 
expression in HCC cell line [83]. MiR-122 also targets a Bcl-2 member, Bcl-w, and 
regulates apoptosis in HCC [86]. Moreover, miR-122 has been associated with cell 
invasion and migration [87], and inhibits viral replication and cell proliferation in HBV-
related HCC [88].  
 MiR-221 and miR-222 belonging to the same miRNA family are up-regulated in 
HCC [83, 89-92]. Tumor suppressor genes, PTEN and TIMP3 are direct targets of the 
two miRNAs and the repression of these miRNA targets is associated with enhanced cell 
migration [93]. A cell-cycle inhibitor, p27, another validated target of miR-221 and miR-
222, is down-regulated by the miRNAs and implicated in tumorigenesis in HCC [91, 94].  
 MiR-224 is one of the most up-regulated miRNA in HCC [95, 96], and promotes 
cell proliferation, migration and invasion [96, 97]. Apoptosis inhibitor-5 (API-5) is a 
validated target of miR-224 and inversely correlates with miR-224 expression in HCC 
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patients [95]. In addition, AKT signaling pathway is affected by up-regulation of miR-
224 and inhibition of PPP2R1B [97]. 
 In addition to the differential expression between HCC and non-tumorous liver 
tissues, miRNA expression has been associated with clinical factors and exhibits 
prognostic potential in HCC. A 20-miRNA profile was identified to be significantly 
associated with metastasis and survival [98]. In non-tumours and tumorous liver tissues 
of HCC patients, 13 and 56 miRNAs are related to recurrence-free survival respectively 
[99]. A study investigating nine commonly de-regulated miRNAs in HCC identified that 
miR-21, miR-31, miR-122, and miR-221 are associated with survival, while miR-21 and 
miR-221 are associated with tumor stage and independent predictors of overall survival 
[100]. Moreover, several studies revealed that expression of miR-125b, miR-29, miR-22, 
miR-99a, miR-199b, miR-124 and miR-372 predict disease-free survival and/or overall 
survival [101-107].  
 The significant findings of aberrant miRNA expression in HCC tissues inspired 
researchers to explore these miRNAs as diagnostic and/or prognostic markers for HCC. 
However, the use of tissue miRNA expression for diagnosis is not as practical as non-
invasive serum marker e.g. AFP. Instead, circulating miRNAs in body fluids (e.g. plasma, 
urine) are considered as the best candidates for detection of cancer.  
1.3.3 Circulating miRNAs in HCC 
 
MiRNAs have been detected in the body fluids including plasma at relatively 
stable levels and could be used for distinguishing cancer patients from normal individuals 
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[108]. Exosomal miRNAs derived from tumor cells could enhance the recipient cell 
growth in HCC [109]. Moreover, miRNAs could be released into blood circulation as a 
consequence of cell death [110]. The research in discovering circulating miRNAs as  
non-invasive biomarkers just emerged in recent years, while a number of studies have 
demonstrated their potential as biomarker in a variety of cancers including lung cancer, 
prostate cancer, gastric cancer, etc [73].   
In Table 1.3.1, the aberrantly expressed miRNAs in plasma or serum of HCC 
patients, as reported in 17 recent studies, are summarized. In these studies, plasma or 
serum miRNA expression levels were compared between HCC (and other liver diseases 
e.g. cirrhosis) and normal healthy group. The majority of the differentially expressed 
miRNAs are elevated in HCC samples. Up-regulation of miR-21, miR-206 and miR-18a, 
and down-regulation of miR-26a and miR-199a were reported in more than one study, 
and considered as common signatures in HCC samples. However, discrepancies exist for 
miR-122, miR-222, miR-223, miR-92a and miR-192 expression changes. The 
inconsistencies might be contributed by the heterogeneity of HCC patients in different 








Table 1.3.1  Summary of de-regulated circulating miRNAs in HCC. MiRNAs in bold were 
investigated by more than one study and the same trends of de-regulation were identified. 
MiRNAs in red were found to be de-regulated in opposite trends by different studies.  




miR-92a 10 HCC, 10 normal ↓  [111] 
miR-1, miR-25, miR-92a,  
miR-206, miR-375, let-7f 
55 HCC, 50 normal ↑ [112] 
miR-122, miR-223, miR-26a,  
miR-27a  204 HCC, 60 cirrhosis, 75 chronic 
hepatitis B, 68 normal 
↓ 
[113] 
miR-192, miR-21,  miR-801 ↑ 
miR-16, miR-199a 
105 HCC, 107 chronic liver 
disease, 71 normal 
↓ [114] 
miR-21, miR-122, miR-223 
101 HCC, 48 chronic hepatitis B, 
89 normal 
↑  [115] 
miR-885-5p 
46 HCC, 26 cirrhosis, 23 chronic 
hepatitis B, 24 normal 
↑  [116] 
miR-122 48 HCC, 48 HBV, 24 normal ↑ [117] 
miR-21, miR-221, miR-222 46 HCC, 20 normal ↑ [118] 
miR-18a 
101 HCC, 30 hepatitis/cirrhosis, 60 
normal 
↑ [119] 
miR-15b, miR-130b 57 HCC, 29 hepatitis B, 30 normal ↑ [120] 
miR-483-5p  49 HCC, 49 normal ↑ [121] 
miR-101 25 HCC, 20 normal ↑ [122] 
miR-125b 20 HCC, 24 chronic hepatitis B, 22 




miR-18a, miR-100, miR-145,  




miR-200a, miR-222 ↓ 
miR-143, miR-215 95 HCC, 118 hepatitis, 127 normal ↑ [125] 
miR-206, miR-141, miR-433,  












There are two groups performing genome-wide profiling of miRNAs in HCC 
patients. An early study by Zhou et al. in 2011 utilized miRNA microarray to measure 
miRNA expression in HCC plasma samples, and identified seven candidate miRNAs that 
could distinguish HCC from non-HCC (normal healthy, cirrhosis, hepatitis B) groups 
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[113]. Although the panel of the seven miRNAs shows high accuracy of diagnosing HCC, 
two down-regulated miRNAs, miR-122 and miR-223, are inconsistently up-regulated in 
HCC and chronic hepatitis in another study [115]. Tan et al. utilized Illumina sequencing 
to comprehensively investigate the serum miRNA signatures in HBV-related HCC, and 
identified a panel of eight miRNAs with diagnostic potential [126]. Down-regulation of 
MiR-26a and miR-122 are consistent with Zhou et al.’s finding from genome-wide 
miRNA profiling, while opposite trends of de-regulation are observed for miR-192 
between the two studies [113, 126].  
Except the two genome-wide studies, independent studies focused on single or 
several circulating miRNAs, based on the knowledge of their implications in HCC or 
other cancers. A few miRNAs have been extensively studied, for example,  miR-21 was 
found to be de-regulated in other cancers [128] and show consistent up-regulation in 
HCC by several studies [113, 115, 118]. Circulating miR-122 has been associated with 
both HCC and liver pathologies. Two genome-wide studies described above showed that 
miR-122 is consistently under-expressed in HCC sera. However, Xu et al. and Qi et al. 
observed up-regulation of circulating miR-122 in HCC compared to normal group [115, 
117]. By integrating the miRNA expression in plasma samples from subjects with 
chronic hepatitis B (CHB), it was observed that miR-122 is significantly elevated during 
chronic HBV infection, hence is a good candidate biomarker for liver injury, but not 
specific to HCC [117]. Lastly, the miR-223 expression in HCC and liver diseases was 
investigated by several studies, but the trends of de-regulation were not consistent. 
Down-regulation of miR-223 was observed in HCC, CHB and cirrhotic patients [113, 
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123] . However, findings by Xu et al. and Wang et al. indicate that the same miRNA is 
up-regulated in HCC and/or CHB patients [115, 124].  
In addition to identifying circulating miRNAs as diagnostic markers for HCC, 
several studies investigated their potential as prognostic markers. Expression of miR-221 
in serum is associated with tumor size, cirrhosis and tumor stage, and high expression 
level of miR-221 is associated with lower overall survival rate [118]. Serum miR-1, 
which is not differentially expressed between patients with HCC and cirrhosis, is an 
independent predictor of overall survival rate [129]. Plasma miR-139 is under-expressed 
in HCC compared to CHB, and associated with 1-year survival rate in HCC patients 
[130]. Last but not least, elevation of serum miR-24 is associated with HBV-related HCC 
and an independent parameter of overall survival and disease-free survival [127].  
1.3.4 Genetic polymorphisms that affect miRNAs in HCC 
 
 Despite the expansion of our knowledge about miRNA-related SNPs in the 
human genome, their involvement in HCC was not comprehensively understood yet. The 
previous findings of miRNA-related SNPs associated with HCC are summarized in the 
following paragraphs. 
Common SNPs in pre-miRNAs, including rs11614913 in mir-196a-2, rs3746444 
in mir-499, rs2910164 in mir-146a and rs6513497 in mir-646 have been investigated by 
several research groups. The C to T change of mir-196a-2 SNP, rs11614913, is associated 
with decreased HCC risk in several studies [131-134], and shows association with 
differential expression of mature miR-196a [132]. The TT+TC genotypes of rs3746444 in 
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mir-499 are associated with higher risk of HBV-related HCC [135]. Rs2910164 in mir-
146a, a common SNP associated with other cancer types [35, 136], shows association 
with HCC risk in Asian male population [133]. Lastly, significant association was 
identified between G allele of miR-646 SNP rs6513497 and decreased risk of HCC [137].  
The SNPs upstream the pre-miRNAs were also characterized in several studies. In 
addition to rs11614913 within mir-196a-2, another promoter SNP, rs12304647, 
associated with the same miRNA,  shows protective effect against HCC development by 
its CC genotype [138]. Rs999885 in the promoter region of MCM7, the host gene of mir-
106b-25 cluster, shows association with the expression of the miRNA cluster and HCC 
disease risk [139, 140]. Moreover, a promoter SNP, rs4938723, upstream mir-34b/c, may 
contribute to increased risk of HCC by its variant genotypes [141, 142]. 
In addition to the SNPs within or upstream miRNA genes, the 3’UTR SNPs that 
could alter miRNA binding sites also gained research interests. There has not been any 
comprehensive study of all the 3’UTR SNPs in the HCC patients, while researchers 
focused on the polymorphisms in one or several candidate genes of interests. Li et al. 
studied SNPs in RAD52, a gene involved in maintenance of genomic stability, and 
identified that rs7963551 in a let-7 binding site could affect mRNA expression and is 
associated with HBV-related HCC risk [143]. A functional SNP in TLR4 gene, 
rs1057317, was experimentally validated to alter miR-34a binding, and shows association 
with HCC risk in a Chinese group [144]. Moreover, a recent study showed that 
rs3208684 in the 3’UTR of Bcl-xl, an anti-apoptotic gene, could disrupt a let-7b binding 
site, increase Bcl-xl expression level, and affect drug resistance in HCC [145]. The 
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previous findings suggest that SNPs could alter the disease risk and/or outcome in HCC 
via affecting miRNA bindings of genes involved in different tumorigenic pathways.   
Global repression of miRNA processing pathway was observed in human cancer 
and contributes to tumorigenesis [146]. Key components in miRNA biogenesis were 
found to be de-regulated in HCC and associated with poor prognosis [74]. The genetic 
variants in these genes can affect the miRNA machinery pathway and have been 
associated with disease risks in cancers [147, 148], however only a few studies examined 
these polymorphisms in HCC. Liu et al. selected three 3’UTR SNPs that potentially 
affect miRNA bindings in three miRNA processing genes (DICER1, RAN and PIWIL1). 
The authors identified rs1057035 in DICER1 being significantly associated with 
decreased risk of HBV-related HCC [149]. A later study focused on six SNPs in five 
miRNA machinery genes and observed significant association between rs11077 in 
3’UTR of XPO5 and poor survival outcome in HCC patients [150].   
To summarize, evidences of associations between miRNA-related SNPs and HCC 
disease risks indicate that genetic polymorphisms could affect miRNA production and 
their target gene regulation, further contribute to hepatocarcinogenesis. However, there 
lacked a genome-wide study that comprehensively characterized the functional effects of 
miRNA-related SNPs in HCC. The knowledge about the SNP-mediated miRNA de-





1.4 Aims of this study 
 
 When this project was started, our understanding of the overall architecture of 
genetic polymorphisms, especially those that affect miRNA regulation, in the human 
genome remained fragmentary. Although aberrant miRNA expression has been 
extensively studied in HCC, polymorphisms affecting miRNA de-regulation are not fully 
understood and a reliable non-invasive biomarker for HCC is still lacking.   
To address the above gaps in knowledge, I embark on this project with three main 
aims:  
1. Determine the architecture of polymorphisms in the human genome 
Genetic variants that contribute to phenotypic differences via affecting the gene 
functions tend to be targeted by natural selections. Hence, the distribution, 
potential functions and natural selections on the polymorphisms will be elucidated 
in this study to identify the candidate variants and genes that could contribute to 
inter-individual differences. 
2. Characterize polymorphisms that affect miRNA regulation 
Polymorphisms within miRNA genes, targets and miRNA machinery genes affect 
expression patterns of both miRNAs and their target genes, and contribute to 
phenotypic differences. The potential functions and associations with miRNA or 
gene expression of miRNA-related SNPs are explored in this thesis to facilitate 





3. Identify potential non-invasive biomarker for HCC 
Plasma miRNAs are de-regulated in HCC and liver pathologies hence could be 
used as non-invasive marker for detection of the diseases. In this thesis, miRNA 
signatures are characterized in patients with HCC, CHB, compared to normal 
healthy individuals to facilitate the development of potential diagnostic and 






Chapter 2: Materials and Methods 
2.1 Genetic variant information 
2.1.1 Polymorphism information from dbSNP database 
 
All the human polymorphisms were retrieved from the FTP site of dbSNP 
database (ftp://ftp.ncbi.nlm.nih.gov/snp/). According to the validation status and 
chromosomal locations, we excluded the un-validated polymorphisms and those 
annotated to more than one genomic location. Based on the annotation in NCBI Genome 
Build 37.1 (ftp://ftp.ncbi.nlm.nih.gov/genomes/H_sapiens/ARCHIVE/BUILD.37.1/), the 
polymorphisms were mapped to different genic regions (5’UTR, coding region, intron 
and 3’UTR). Polymorphisms outside genic regions were classified as inter-genic variants. 
Two major forms of genetic polymorphisms, SNPs and INDELs, were 
investigated in this study. SNP or INDEL density in a particular genic region e.g. 5’UTR 
was calculated as the number of SNPs or INDELs divided by the length of that region. 
For genes with multiple transcripts, the mean densities were taken. Genes lacking any 
polymorphisms in the entire genic regions were defined as non-polymorphic genes. We 
further identified 512 highly polymorphic genes according to two criteria: 1) the SNP 
densities were ranked among the top 5% highest densities of all the human genes; 2) the  
number of polymorphisms identified in the entire gene length was higher than expected 
using a binomial model. For the second criterion, take a gene with length l and x SNPs as 
an example, the binomial probability of detecting at least x SNPs in length l based on the 
genomic SNP density (4.43 SNPs/kb) was calculated and subjected to Bonferroni 
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correction. Genes with significant enrichment of SNPs (corrected P-value<0.05) satisfied 
the second criterion.  
2.1.2 Allele frequency and population differentiation using HapMap data 
 
Allele frequency data were downloaded from HapMap release 28 
(http://HapMap.ncbi.nlm.nih.gov/downloads/genotypes/2010-08_phaseII+III/forward/). 
Nine out of the eleven global populations were combined into three population groups 
according to their geographical origins: East Asian group including CHB (Han Chinese in 
Beijing, China), CHD (Chinese in Metropolitan Denver, Colorado) and JPT (Japanese in 
Tokyo, Japan), European group including CEU (Utah residents with ancestry from 
northern and western Europe) and TSI (Toscani in Italia), African group including LWK 
(Luhya in Webuye, Kenya), ASW (African ancestry in Southwest USA), MKK (Maasai 
in Kinyawa, Kenya) and YRI (Yoruba in Ibadan, Nigeria).  For each bi-allelic SNP, the 
ancestral allele was defined as the allele identical to the chimpanzee sequence at the 
aligned locus and the information was retrieved from the SNPAncestralAllele table in 
dbSNP database (Build 131). On the other hand, the other allele was termed as the 
derived allele, whose frequency in the three population groups was then calculated.  
FST statistics [20] based on the pooled allele frequencies in the three population 
groups was calculated for each genotyped and polymorphic locus. The pairwise 
comparison of FST between different genomic regions was conducted by Mann-Whitney 
test. We next focused on two groups of SNPs: 1) 2.41% SNPs with FST=0 showing no 
population differentiation; 2) 7.79% SNPs with FST>0.3 termed as high-FST SNPs. The 
two groups of SNPs were further categorized into different genic regions, and the fold 
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enrichment was calculated as the percentage of zero- or high-FST SNPs in a particular 
genic region (e.g. 5’UTR) divided by the percentage of all the genotyped SNPs in the 
same region. Fold enrichment significantly deviated from 1 indicates that that zero- or 
high-FST SNPs are under- or over-represented in a particular genic region. We further 
conducted Fisher’s exact test to assess whether the zero- or high-FST SNPs are 
significantly enriched in certain genic regions.  
2.1.3 Genotype information from 1000 Genomes 
 
Short polymorphisms (SNPs and INDELs) mapped to pre-miRNAs (miRBase 
release 16) and 3’UTR of protein-coding transcripts were retrieved from dbSNP database. 
We downloaded the genotypes of the pre-miRNA and 3’UTR SNPs in 179 individuals 
from YRI, CEU, CHB and JPT populations, included in the pilot phase of 1000 genomes 
project, at the FTP site of 1000 genomes database (ftp://ftp-
trace.ncbi.nih.gov/1000genomes/ftp/pilot_data/release/2010_07/low_coverage/snps/) 
[151].  
2.1.4 Genotype and somatic mutation information from TCGA database 
 
The genotype information from non-tumorous liver tissues of HCC patients from 
The Cancer Genome Atlas (TCGA) project were determined by whole-genome sequence 
(WGS) and retrieved from Cancer Genomics Hub (https://cghub.ucsc.edu/). According to 
the data availability, we analysed polymorphisms in 17 HCC patients with whole-genome 
sequencing data from their non-tumorous liver tissues. The clinical characteristics of the 
17 patients were summarized in Table 2.1. 
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Table 2.1 Clinical characteristics of the 17 HCC patients from TCGA project. 
Clinical characteristics Phenotypes # % 
Race 
White 13 76% 
Asian 1 6% 
Black or African American 2 12% 




Male 9 53% 
Female 8 47% 
Age (mean ± s.d.)   64.2±17.7 
survival status 
Alive 10 59% 
Dead 7 41% 
Viral infection 
HBV 3 18% 
HCV 2 12% 
HBV&HCV 0 0% 
Tumor Grade 
1 0 0% 
2 11 65% 
3 3 18% 
Stage 
Stage I 6 35% 
Stage II 6 35% 
Stage III 4 24% 
Stage IV 0 0% 
Vascular Invasion 
None 10 59% 
Micro 3 18% 
Macro 1 6% 
 
BAM files from WGS of non-tumorous liver tissues (NT) or blood samples (NB) 
of the HCC patients were downloaded. Using the ‘mpileup’ command in Samtools [152] 
and Genome Reference Consortium Human genome build 37 (GRCh37) as the reference,  
genetic variants were called from the non-tumorous liver tissues or blood samples of the 
HCC patients and stored in variant call format (vcf). The downloading of the sequencing 
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data and SNP calling were accomplished by our collaborators, A/Prof Henry Yang and 
Guo Jing.  
 Based on the genomic locations, SNPs within the pre-miRNAs (miRBase build 
21), and in the 52 genes involved in the miRNA machinery, as obtained from the 
Patrocles database [18], were extracted using vcftools [153]. According to their 
chromosome coordinates and nucleotide changes, the polymorphisms were annotated to 
dbSNP database (build 137). Genotype information was obtained from the vcf files 
generated from the alignment files via Samtools, as described above. 
In addition to investigating the genetic polymorphisms, we also retrieved the 
somatic mutation data of the HCC patients from TCGA database (https://tcga-
data.nci.nih.gov/tcga/) on 03/08/2014.The level 2 data were deposited in the mutation 
annotation file (maf), and included the somatic mutations specific to tumor tissues, as 
identified from whole-genome or whole-exome sequencing of the paired tumor and non-
tumorous tissues of 202 HCC patients. All the somatic mutations within the 52 miRNA 
machinery genes were extracted. Lastly, we determined the potential functions of the 
missense mutations by employing the SIFT algorithm [154]. 
2.2 Natural selections and potential functions 
2.2.1 Natural selections 
 
Using genotype data, previous study showed the signatures of negative selection 
in particular genic regions by excess of rare derived alleles [41]. Based on the allele 
frequency data in HapMap project, we identified enrichment of rare SNPs (derived allele 
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frequency<0.05 in the HapMap population group) in certain genic regions using the 
Fisher’s exact test, and the regions with statistically significant enrichment of rare SNPs 
tend to be targeted by negative selection.  
 SNPs showing signatures of recent positive selection (RPS) were identified using 
linkage disequilibrium (LD) or haplotype-based methods as described in previous studies 
[155, 156]. For simplicity, these polymorphisms were termed as RPS SNPs.  
 A total of 481 ultra-conserved elements (UCEs) were defined in a previous study 
as the sequences sharing 100% identify between human, mouse and rat genomes [157]. 
These elements show evolutionary conservation and signature of strong negative 
selection. The authors also found that 97% of the elements show an average of 95.7% 
identity with the orthologous sequences in the chicken genome. We mapped the 481 
sequences to the reference genome (NCBI genome build 37.1) using BLAST [158] and 
identified 71 UCEs overlapping with coding sequences. These 71 coding UCEs were 
termed as the evolutionarily conserved coding sequences.  
2.2.2 Prediction of potential functions of genic and promoter SNPs 
 
 The potential functions of SNPs were determined by querying the in-house data 
sources of pfSNP database (http://pfs.nus.edu.sg/), which integrates a variety of 
bioinformatics prediction algorithms [159]. We examined the SNPs in different genic 
regions for their potential effects on gene regulation or protein function, as described in 
the following paragraphs. 
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SNPs in putative promoters, which were defined as 5 kb upstream transcription 
start sites were assessed for their potential functions to alter putative transcription factor 
binding sites (TFBSs). Using the tool MATCHTM in TRANSFAC database [160], the 
sequences containing the promoter SNPs were scanned for potential TFBS, as obtained 
from TRANSFAC 11.3 database. SNPs with alternative alleles that correspond to 
different transcription factor binding patterns were identified to be potentially functional. 
Non-synonymous SNPs that are potentially deleterious to protein function were 
retrieved from three sources: Polyphen-2 database (http://genetics.bwh.harvard.edu/pph2/) 
[15], LS-SNP database (http://modbase.compbio.ucsf.edu/LS-SNP/) [14] and SNPs3D 
database (http://www.snps3d.org/) [16].  
For identification of SNPs that either create or destroy potential exon splice 
enhancer (ESE) or exon splice silencer (ESS) sites, an algorithm developed in PS Scan 
(ftp://ftp.expasy.org/databases/prosite/tools/ps_scan) was adopted to identify motifs from 
sequences in batch format.  All the possible ESE and ESS motifs were downloaded from 
the supplementary information of various publications [161-164], converted to Prosite 
compatible format and then uploaded onto the PS Scan program together with the 
sequences surrounding the coding SNPs.  The PS scan program then scanned these 
sequences for possible ESE/ESS motifs. SNPs having alternative alleles with different 
putative ESE/ESS patterns were determined to be potentially functional. 
Intronic SNPs within 400 bp of exon-intron boundaries were assessed for their 
potential functions to create or destroy intronic splice regulatory elements (ISREs) using 
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PS scan program and putative ISRE motifs described in a previous study [165]. SNPs that 
change the patterns of putative ISREs were identified as potentially functional.  
SNPs potentially alter miRNA targets were retrieved from PolymiRTS 
(http://compbio.uthsc.edu/miRSNP/) [17] and Patrocles 
(http://www.patrocles.org/Patrocles_targets.htm) [18] databases.  
In this section, the prediction of functional effects of promoter, coding and 
intronic SNPs on changing regulatory elements was accomplished by our ex-colleague 
and collaborator, Dr Wang Jingbo.  
2.2.3 Prediction of potential functions of 3’UTR SNPs 
 
In addition to the potentially functional SNPs reported in PolymiRTS [17] and 
Patrocles [18] database , we also predicted the effects of 3’UTR SNPs on miRNA 
targeting using miRanda algorithm [166] through the following steps. The flanking 
sequences (20bp up- and downstream) of 3’UTR polymorphisms were downloaded from 
dbSNP database (ftp://ftp.ncbi.nih.gov/snp/organisms/human_9606/rs_fasta/), and 
sequences containing the reference and alternative alleles were generated for each SNP. 
MiRanda algorithm [166] was applied to predicting the putative miRNA targets in both 
sequences. Sequences (containing either allele) were identified as putative miRNA 
binding sites according to the default miRanda setting of ≥140 for alignment and ≤ -7 for 
free energy score. The differences in the alignment and free-energy scores between the 
two sequences for the same SNP were calculated. SNPs that cause changes in alignment 
scores greater than 16 and in free-energy scores more than 2.85 between the 2 alleles 
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were identified to significantly affect miRNA bindings. The two thresholds represent the 
3rd quartiles of the empirical distributions derived from our preliminary analyses 
including all the 3’UTR SNPs. In this part, prediction of miRNA targets via miRanda 
algorithm was accomplished by our colleague and collaborator, Thurnherr Thomas.  
We further determined the potentially functional 3’UTR SNPs in experimentally 
characterized miRNA target sites. MiRNA binding sites were experimentally 
characterized by AGO Photoactivatable-Ribonucleoside-Enhanced Crosslinking and 
Immunoprecipitation (PAR-CLIP) from HEK293 cell lines in a previous study [167]. The 
miRNA targets were obtained from starBase (http://starbase.sysu.edu.cn/) [168] and 
clusters with less than 5 reads were excluded. The 3’UTR SNPs residing in the 
sequencing clusters identified by PAR-CLIP were considered to be functionally 
significant, as they might affect experimentally characterized binding sites.  
2.2.4 Gene function annotation 
 
Genes containing SNPs that show evidences of natural selections and/or 
potentially functional SNPs were selected for further investigation of their biological 
functions. The Database for Annotation, Visualization and Integrated Discovery (DAVID) 
[169, 170] was utilized for functional annotations of these genes of interests. The 
enrichment of the genes in PANTHER protein family, Gene Ontology (GO) -molecular 
function, GO-biological process and KEGG pathway was identified. P-values after 
Benjamini-Hochberg correction were reported and corrected P<0.05 was used as the 
cutoff for statistical significance. 
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2.3 MiRNA and target gene expression 
2.3.1  MiRNA and gene expression in HapMap individuals 
 
Expression levels of 835 mature miRNAs in lymphoblastoid cell lines (LCLs) 
derived from YRI and CEU individuals were retrieved from GEO database 
(http://www.ncbi.nlm.nih.gov/geo/) under accession ID GSE15875.  
Whole-genome transcript expression in LCLs from individuals of YRI, CEU, 
CHB and JPT populations had been profiled by several groups of researchers using 
microarray and/or RNA sequencing platforms [6, 10, 11]. The normalized microarray 
expression data in all the four populations were retrieved from GEO database 
(http://www.ncbi.nlm.nih.gov/geo/) under accession ID GSE6536 [6]. Expression data in 
CHB and JPT individuals were pooled. In addition, Montgomery et al. [11] used 
microarray to measure gene expression levels in CEU individuals, and the normalized 
expression data in ArrayExpress database (http://www.ebi.ac.uk/arrayexpress) under 
accession number E-MTAB-198 were downloaded.  
In two previous studies, RNA-sequencing (RNA-seq) was performed to measure 
gene expression in YRI and CEU populations [10, 11]. In this study, we downloaded the 
raw sequencing data from GEO database under accession number GSE19480 for samples 
in YRI population, and ArrayExpress database under accession number E-MTAB-197 for 
CEU samples. The RNA-seq data were re-processed followed by calculation of transcript 
expression. First, TopHat [171] was used to map the single- or paired-ended reads to 
NCBI genome build 37.1, and reads with mapping quality less than 10 were removed. 
Then cufflinks [172] was used to estimate transcript levels in different individuals. For 
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YRI individuals whose expression levels were measured by Pickrell et al. in two 
sequencing centers and RNA was prepared at different concentrations, correction for 
centre and concentration effects was performed, as described in the previous study [10]. 
After estimation of expression levels, transcripts with median expression of 0 were 
removed and only those with at least 30 individuals showing reliable expression data 
were kept. Finally, the ranks of expression values for each transcript were quantile-
normalized and used for the genotype-expression association analysis, as described in 
section 2.4.  The expression data processing was conducted in R.  
2.3.2 MiRNA expression in TCGA HCC patients 
 
The miRNA expression datasets of HCC patients were downloaded from TCGA 
database (https://tcga-data.nci.nih.gov/tcga/), under category liver hepatocellular 
carcinoma. Level 3 miRNA-sequencing data were retrieved on 03/08/2014, including 17 
non-tumorous liver tissue samples (NT) from HCC patients. These tissues had 
corresponding whole-genome sequencing data from the same non-tumorous tissues or 
blood samples. The raw read counts were obtained from the isoform quantification files. 
Only the reads that map to mature miRNA sequences were included. We divided the raw 
read counts by the total number of reads mapped to all the mature miRNAs, and 
calculated the normalized expression as number of reads per million.  The expression 




2.4 Genotype-expression association analysis 
2.4.1 MiRNA SNPs associated with mature miRNA or gene expression 
 
In both HapMap (LCLs from normal individuals) and TCGA (normal solid tissues 
from HCC patients) groups, we employed linear regression model to assess the 
associations between mature miRNA expression and genotypes of SNPs within pre-
miRNAs where the mature sequences are derived from. The genotypes were coded as 0 
for homozygous reference alleles, 1 for heterozygous and 2 for homozygous alternative 
alleles. The SNP genotype was the predictor variable in the linear regression model.  In 
this model, we determined whether the change in to alternative allele numbers can predict 
the expression of miRNAs.  
In addition to linear regression test, I performed the Spearman's rank correlation 
between the genotypes and expression, because the correlation test was less sensitive to 
extreme expression outlier that may drastically affect the result by linear regression test 
and generate false positives. Both linear regression and Spearman’s rank correlation tests 
were employed in previous publication by other researchers [6].  At the cutoff of P-
value<0.05 by both tests, 2 significant associations were identified in LCLs of normal 
individuals, while 4 were found in non-tumorous liver tissues of HCC patients. For the 4 
expression-associated SNPs found in HCC patients, only two genotypes were identified 
for each SNP. In order to assess the differences in miRNA expression between subjects 
with different genotypes, Mann-Whitney test was performed.  
We further investigated the association between SNPs within mature miRNA and 
whole-genome transcript expression. In this study, the transcript expression in the 
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HapMap samples was used to identify the expression-associated SNPs. We determined 
one significant association at P<0.05 by both linear regression and spearman’s correlation 
test. The statistical analysis in this section was conducted in R. 
2.4.2 3’UTR SNPs associated with mature miRNA expression 
  
The association between 3’UTR SNP genotype and transcript expression was 
investigated in the HapMap samples, using linear regression test. Multiple SNPs can be 
detected in the same 3’UTR. To control the family-wise error rate, we performed 
multiple test correction using a permutation-based method as described in [6]. 10,000 
permutations were conducted, and for each single replicate, the maximum of all 
permutated statistics i.e. over all the SNPs was used to construct the empirical 
distribution. Comparing each observed test statistic against this empirical distribution 
generated the corrected P-value (correction for family-wise error). At the significance 
level of 0.001, we identified 1280 3’UTR SNPs associated with host gene expression. 
The statistical analysis in this section was performed in R.  
2.4.3 MiRNA machinery gene SNPs associated with mature miRNA expression 
 
In the HCC patients of TCGA project, we detected 7976 SNPs in the 52 miRNA 
machinery genes from the WGS data. The associations between these polymorphisms and 
426 expressed miRNAs in HCC patients were analyzed using linear regression model. 
Due to the small sample size (n=17) and possible effects by extreme expression outliers, 
we performed 10,000 permutations of the miRNA expression, and calculated the 
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empirical P-value. Using P<0.05, 7832 SNPs (98%) were associated with miRNA 
expression. However, based on our knowledge about potentially functional SNPs, at most 
40% SNPs could have potential effects on gene functions. Hence, I applied the most 
stringent cut-off P<0.001 (based on 10,000 permutations) to identify 879 SNPs (11%) 
that were likely to affect miRNA machinery gene functions and further alter miRNA 
expression.  
Due to thousands of SNPs were tested for each miRNA, a corrected P-value was 
calculated for each observation using the following steps: 10,000 permutations were 
performed, and for each single replicate, the maximum of all permutated statistics i.e. 
over all the SNPs was used to construct the empirical distribution. Comparing each 
observed test statistic against this empirical distribution generated the corrected P-value 
(correction for family-wise error). In this section, no association passed the significance 
level P-value<0.001. In order to reduce false negatives and identify candidate SNPs for 
experimental validation, we took a more conservative cutoff of corrected P-value<0.05 
and identified nine SNPs being significantly associated with five miRNA expression. All 
the statistical analysis was conducted using PLINK [173]. 
2.5 Circulating miRNA expression profiling 
2.5.1 Samples from normal healthy, CHB and HCC subjects 
 
 To identify circulating miRNA de-regulation in HCC, we included patients with 
HCC, chronic hepatitis B (CHB) and normal healthy (NH) controls in this project. They 
were divided into two cohorts: the first cohort included 10 NH individuals and 19 HCC 
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patients for discovering candidate miRNAs de-regulated in HCC (discovery phase); the 
second cohort included 40 NH, 36 HCC and 30 CHB patients for validating the candidate 
miRNAs (validation phase).  
Whole blood samples were obtained from 55 patients (19 in the discovery phase 
and 36 in the validation phase) diagnosed of HCC in National Cancer Centre with 
approval from the Institutional Review Board (IRB) (NCC IRB No: NC08-12). Informed 
consents from the patients were obtained prior to blood collection. The clinical 
characteristics of the two cohorts were summarized in table 2.2.  
In collaboration with Health Sciences Authority, we recruited normal healthy 
donors as controls. The inclusion criteria were: 
1. The subjects needed to be in good health and fulfilled the blood donor criteria by 
Health Sciences Authority. They were between 16 and 60 years old, with weight 
at least 45kg, haemoglobin level of at least 12.5g/dl, and did not have any 
symptoms of infection for at least 1 week.  
2. Only Chinese subjects more than 30 years old were included, because the 
majority of the HCC patients were Chinese in the local cohorts (Table 2.2), and 
the age ranged from 30 to 83 years old.  
3. We only included the subjects who were not infected by human 
immunodeficiency virus (HIV) or HBV, as determined by serological tests before 
blood donation.  




Table 2.2  Clinical characteristics of HCC patients in the discovery and validation cohorts. 





N % n % 
Gender 
Male  18 95% 33 92% 
Female  1 5% 3 8% 
Age      63.2±9.9 61.6±13.7 
Ethnicity 
Chinese  18 95% 30 86% 
Others  1 5% 5 14% 
Viral infection  
HBV    12 63% 15 63% 
HCV   0  0% 4 17% 
None    7 37% 5 21% 
Histological Grade 
low 
1 3 16% 1 4% 
2 8 42% 12 43% 
high 
3 6 32% 15 54% 
4 2 11%   0% 
Tumor Size     7.5±3.4 7.1±4.4 
Encapsulation 
Yes   12 67% 17 57% 
No    6 33% 13 43% 
Degree of 
Encapsulation 
Incomplete   8 73% 6 50% 
Complete    3 27% 6 50% 
Tumor Necrosis 
Yes   12 67% 22 69% 
No    6 33% 10 31% 
Vascular Invasion 
Yes   8 42% 11 37% 
No    11 58% 19 63% 
Multifocality 
Yes   8 42% 10 31% 
No    11 58% 22 69% 
Normal liver cirrhosis 
Yes   7 37% 13 42% 
No    12 63% 18 58% 
Steatosis 
Yes   7 100% 7 39% 
No   0 0% 11 61% 
Stage  
early 1 9 47% 12 57% 
late 
3A  9 47% 3 14% 




For CHB group, we collected blood samples from subjects who routinely visited 
Singapore General Hospital (SGH) every three months and were tested positive for 
hepatitis B surface antigen. The hepatitis B carriers were symptomless carriers and did 
not develop HCC, NAFLD or cirrhosis within last six months.  
The blood collection from non-HCC individuals was accompanied by informed 
consent and approval from IRB (SingHealth IRB No: CIRB 2013/455/B) was obtained 
before recruitment. The blood samples were collected in BD vacutainer® blood 
collection tubes containing EDTA. The characteristics of normal healthy individuals and 
hepatitis B carriers were summarized in table 2.3. 
Table 2.3  Characteristics of hepatitis B carriers and normal healthy individuals. 
  Phenotypes 
Normal Healthy (N=40) Hepatitis B (N=30) 
# % # % 
Ethnic group Chinese 40 100% 30 100% 
Gender 
Male 40 100% 18 60% 
Female 0 0% 12 40% 
Age (mean±s.d.) 55.7±4.6 55.1±10.3 
 
 
2.5.2 Plasma sample preparation 
 
 Whole blood samples were stored at 4°C in ice box immediately after collection. 
They were processed within one hour using the following steps. First, blood samples 
were centrifuged at 1900 ×g and 4°C for 10 minutes. The upper phase containing plasma 
was transferred to a clean falcon tube without disturbing the buffy coat phase.  In order to 
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remove cell debris, a high-speed centrifugation was then conducted at 16000 ×g and 4°C 
for 10 minutes. The clear supernatant was transferred to new microcentrifuge tubes and 
stored at -80°C.  
 
2.5.3 RNA isolation 
 
For each sample, total RNA was extracted from 250 μl plasma using the 
miRCURY™ RNA isolation kit – biofluids (Exiqon, Vedbaek, Denmark). Plasma was 
thawed on ice and centrifuged at 3000 ×g and 4°C for 5 minutes in a microcentrifuge. An 
aliquot of 200 μl of plasma per sample was transferred to a new microcentrifuge tube and 
60 μl of lysis solution BF containing 1μg carrier-RNA and RNA spike-in template 
mixture (including UniSp2, UniSp4 and UniSp5) was added to the sample. The tube was 
vortexed and incubated for 3 minute at room temperature, and 20 μl protein precipitation 
solution BF was added. The tube was then vortexed, incubated for 1 minute at room 
temperature and centrifuged at 11000 ×g for 3 minutes. The clear supernatant was 
transferred to a new collection tube, followed by addition of 270 μl isopropanol. The 
solutions were vortexed and transferred to a binding column. The column was incubated 
for 2 minutes at room temperature, and emptied using a vacuum-manifold. 100 μl wash 
solution 1 BF was added to the column. The liquid was removed using a vacuum-
manifold, and 700 μl wash solution 2 BF was added. The liquid was removed using a 
vacuum-manifold again followed by addition of 250 μl wash solution and spinning of the 
column at 11000×g. The dry columns were transferred to a new collection tube and 50 μl 
RNase free H2O was added directly on the membrane of the spin column. The column 
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was incubated for 1 minute at room temperature followed by centrifugation at 11000 ×g. 
The RNA was stored at -80°C. 
2.5.4 Quality control 
 
Before profiling of genome-wide or candidate miRNAs in plasma samples, a 
quality control (QC) step was performed.  Reverse transcription (RT) with 10 μl reaction 
volume was conducted on 2 ul total RNA using the miRCURY LNA™ Universal RT 
microRNA PCR, Polyadenylation and cDNA synthesis kit (Exiqon).  Each reverse 
transcription (RT) was performed in duplicates, including an artificial RNA spike-in 
(UniSp6).  We diluted the cDNA by 50× and profiled the miR-23a, miR-30c, miR-103, 
miR-142-3p, and miR-451 expression. Each miRNA was assayed once in a 10 μl reaction 
according to the miRCURY LNA™ Universal RT microRNA polymerase chain reaction 
(PCR) protocol. A negative control without template was included from the RT step, and 
profiled using all the QC assays.  Reactions were performed in 384 well plates in a 
LightCycler® 480 Real-Time PCR System (Roche). The data were collected and 
analyzed using the Roche LC software, and the 2
nd
 derivative method was used to 
determine the quantification cycle (Cq) values. 
In the QC analysis, we identified consistent RNA extraction and RT efficiencies 
by evaluating the expression levels of the spike-in controls. Samples showing low spike-
in signals were excluded and replaced with backup samples in the same biological groups. 
Hemolysis was assessed by the difference between Cq values of miR-23a and miR-451 in 
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each sample, and the samples showing the difference more than 7 had a high risk of 
hemolysis and were replaced.  
2.5.5 MiRNA profiling 
 
In the discovery phase, 19 μl RNA was reverse transcribed in 95 μl reaction using 
the miRCURY LNA™ Universal RT microRNA PCR, Polyadenylation and cDNA 
synthesis kit (Exiqon). In the validation phase, 4 μl RNA was reverse transcribed in 20 μl 
reaction using the same kit. Same as the QC analysis step, cDNA was diluted 50× and 
assayed in 10 ul PCR reactions and each miRNA was assayed once by qPCR on the 
microRNA Ready-to-Use panels and ExiLENT SYBR® Green mastermix. In the 
discovery phase, qPCR was conducted on human panel I+II, while in the validation 
including 98 candidate assays, a customized Pick & Mix panel was used. After inclusion 
of a negative control without template from reverse transcription, amplification and 
analysis were performed using the same procedure described in the QC step.  
2.5.6 Data processing 
 
The amplification efficiency was calculated using algorithms similar to the 
LinReg software and the raw Cq values were exported. Negative control evaluation was 
performed by removing the Cq values within 5 of the negative control. In order to 
identify the best normalizer, NormFinder software [174] was used to evaluate the 
stability of the miRNAs expressed in all the samples. The global mean of all the 
commonly expressed miRNAs was also included. In both phases, the global mean of all 
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the commonly expressed miRNAs outperformed any of the single miRNAs and was used 
as the normalizer. The normalized expression was then calculated using the following 
formula:  
Normalized Cq = average Cq (Global mean) – assay Cq (sample) 
In the discovery phase, the global mean was calculated as the mean expression of 
the 109 commonly expressed miRNAs, while in the validation phase, the global mean 
was based on the 59 common miRNAs.  
The work described in 2.5.3-2.5.6 performed by Exiqon servicing facility in 
Denmark. The raw Cq values and normalized expression data enclosed in the project 
report were used for the following analysis.  
2.6 Statistical analysis of circulating miRNA expression data 
2.6.1 MiRNA de-regulation 
 
To compare the miRNA expression between biological groups (HCC, CHB, NH), 
pairwise Student’s t-test was performed followed by Benjamini-Hochberg multiple test 
correction. MiRNAs that show fold change>2 and corrected P-value<0.05 were identified 
as significantly differentially expressed miRNAs.  
To evaluate the diagnostic performance of plasma miRNAs for discriminating 
disease groups from controls, receiver operating characteristic curves (ROC) were 
constructed based on single miRNA expression. The area under curves (AUCs) and their 
95% confidence intervals were calculated. At different cutoffs, the sensitivities and 
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specificities were determined. The optimal cutoff was identified when the sum of 
sensitivity and specificity was the highest. All the ROC analysis was conducted in R 
using ‘pROC’ and ‘ROCR’ packages.  
I further explored combination of miRNA expression levels as potential 
diagnostic marker. A logistic regression model was employed. The disease/control group 
was the response variable and the candidate miRNA expression levels were included as 
the explanatory variables. Stepwise model selection using the Akaike information 
criterion (AIC) with bi-directional elimination was performed in the R package ‘stepAIC’. 
The combination of miRNAs was determined as the miRNAs included in the final model. 
ROC analysis was then performed for the combinatory miRNA expression in R, as 
described in the previous paragraph.    
2.6.2 Clinicopathological associations 
 
The clinical characteristics of the HCC patients in this study were summarized in 
Table 2.2. We investigated the associations between all the plasma miRNAs with the 
clinical characteristics in both cohorts independently.  
Due to the limitations of the study group size, no multiple test correction was 
performed in this section. P-value<0.05 and fold change>2 was used as the cutoffs in 
most of the analyses. The statistical tests for each of the clinical phenotypes were 
described below.  
For binary clinical parameters e.g. gender with male and female, the differences 
in miRNA expression between the two groups were determined using Student’s t-test. 
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Viral infection has three possible phenotypes (HBV, HCV and no infection), thus one-
way analysis of variance (ANOVA) test was performed. The dependent variable was the 
miRNA expression and the factor was the viral infection status. After identifying 
significant differences between the three groups, we conducted pairwise comparison 
using Student’s t-test.  Ordinal logistic regression test was conducted to assess the 
association between histological grade and single miRNA expression. The response 
variable was the histological grade (1-4) while predictor was each miRNA expression. 
No other covariates were included in this model. Lastly, correlation between tumor size 
and miRNA expression was determined using Spearman’s rank correlation test. All the 
statistical analyses were performed in R.   
2.6.3 Survival analysis 
 
 Both the overall survival time and relapse-free survival time were associated with 
plasma miRNA expression using the Cox proportional hazards test. For relapse-free 
survival, if the patient underwent relapse, we used the time to first relapse instead to time 
to death as the survival time. In the patients’ cohorts included in this thesis, the survival 
rate was 56% and the relapse rate was 41%. 
 In the Cox proportional hazards model, the logarithm of hazard ratio is a function 
of explanatory variable i.e. miRNA expression. First, I employed a univariate model and 
only included single miRNA expression in plasma as the explanatory variable. In 
addition, I evaluated the association between survival and other clinical characteristics, as 
listed in Table 2.2.  
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Using Cox proportional hazards test, the hazard ratios and their 95% confidence 
intervals were determined. In addition, we compared the survival time of patients with 
high miRNA expression (more than the median miRNA expression in all the patients) 
and low expression (less than the median expression) using the Kaplan-Meier analysis. 
MiRNAs with P-value<0.05 by Cox proportional hazards test and no intersection of the 
Kaplan-Meier curves were considered to be significantly associated with survival time. 
The ‘survival’ package in R was used in this section.  
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Chapter 3: Results 
3.1 Architecture of polymorphisms in the human genome 
3.1.1 Polymorphisms are most constrained in coding regions 
 
More than 14 million polymorphisms are identified and validated in the human 
genome (dbSNP131). Protein-coding genes contain 38% genetic polymorphisms, and 
within genic regions, more than 95% polymorphisms reside in introns. Coding exons, 
which account for approximately 3% of the genic lengths, contain 2.55% of genic SNPs 
and 0.35% of INDELs (Figure 3.1.1). In addition, both SNPs and INDELs show the 
lowest average densities within coding sequences (Figure 3.1.2a). It is observed that in 
coding regions, the density of in-frame INDELs is 44% of that for genic INDELs with the 
same lengths, while INDELs that cause frame-shift occur at only 5% of the genic level. It 
indicates that both SNPs and INDELs are selectively constrained within coding 
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Figure 3.1.2 SNP density, allele frequency, and natural selections in different genic 
regions. a. Average SNP and INDEL densities (# polymorphisms per kb) in the four regions 
(5’UTR, coding regions, introns and 3’UTR) of human genes. b. Percentage of SNPs with 
different DAFs in the four genic regions, as measured in HAPMAP individuals from African 
populations.  c. Percentage of synonymous (syn) and non-synonymous (nonsyn) SNPs with 
different DAFs, as measured in HAPMAP individuals from African populations. d. Fold 
enrichment of SNPs showing signatures of negative selection (FST=0) or recent positive 
selection (RPS) in different genic regions.  
*** P-value<0.001, ** P-value<0.01, * P-value<0.05, ns: not significant 
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The derived allele frequencies (DAFs) for SNPs in different regions are compared 
using allele frequency data from the HapMap individuals. In all the three population 
groups (African, East Asian and European), coding regions contain significantly higher 
percentage of rare SNPs, defined as DAF<0.05 (Figure 3.1.2b, Figure 3.1.3a, b). Within 
coding regions, nsSNPs show 1.4 to 1.6 fold enrichment of rare alleles, compared with 
synonymous ones (Figure 3.1.2c, Figure 3.1.3c, d). As negative selection increases the 
fraction of rare alleles [175], our results from the analysis of allele frequency suggest that 
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Figure 3.1.3 Enrichment of rare SNPs in coding regions and non-synonymous sites. 
Percentage of SNPs with different DAFs in the four genic regions, as measured in HAPMAP 
individuals from a. East Asian populations and b. European populations. Percentage of 
synonymous (syn) and non-synonymous (nonsyn) SNPs with different DAFs, as measured in 
individuals from    c. East Asian populations d. European population 
*** P-value<0.001, ** P-value<0.01, * P-value<0.05, ns: not significant 
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We further examine the signatures of natural selections from another perspective 
by investigating population differentiation, which is measured across the different 
population groups (African, East Asian and European) using FST statistics [20]. Previous 
studies reported that increased FST shows the evidence of positive selection [175], while 
decrease in FST reflects negative selection [22]. By comparing the FST scores of SNPs in 
different regions, we find that coding SNPs show significantly lower median FST than that 
in non-coding regions (0.05 vs 0.08, P-value<0.001 by Mann-Whitney test). In addition, 
SNPs that show no population differentiation (FST=0) are significantly over-represented 
in coding exons (fold enrichment=3.9, P-value<0.001 by Fisher’s exact test) (Figure 
3.1.2d). It indicates that in addition to having the lowest density and highest percentage 
of rare alleles, coding SNPs are also least differentiated amongst population groups.  
Lastly, we investigate the patterns of recent positive selection (RPS), as identified by LD 
or haplotype-based methods described in [155, 156]. It is observed that SNPs under RPS 
are under-represented in exons, and most constrained in coding sequences, because 
compared to the genomic percentage, there is 22% reduction in percentage of RPS SNPs 
within coding region i.e. 0.78 fold enrichment (Figure 3.1.2d). On the other hand, introns 
contain a slightly higher (7%) percentage of positively selected SNPs than expected i.e. 
1.07 fold enrichment, and are more likely to be targeted by RPS 
3.1.2 Potentially functional SNPs are under natural selections 
 
Putative functions of SNPs in different genic regions and putative promoters, 
defined as 5 kb upstream transcription start site, are predicted using a variety of 
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bioinformatics algorithms (see section 2.2.2). In total, nearly 400,000 SNPs, accounting 
for 7% genic and putative promoter SNPs, could potentially alter gene expression and/or 
function. More than 90% of human genes contain at least one putatively functional SNP 
(Figure 3.1.4.a). On average, each transcript contains 7 SNPs that may alter TFBS in its 
promoter region, 8 intronic and two exonic SNPs that change putative splicing regulatory 
elements i.e. ESE, ESS, ISRE, 1 SNP that is potentially deleterious to protein function 





We next examine whether the putatively functional SNPs are selectively 
constrained. By comparing the percentage of rare derived alleles (DAF<0.05) between 
the functional and non-functional SNPs in the same genic regions, we observe that SNPs 
with potential functions show enrichment of rare alleles, except for the promoter SNPs, 
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Percentage of genes with 
potentially functional SNPs
Figure 3.1.4 Distribution of potentially functional SNPs in the human genome. a. Percentage 
of human genes containing different numbers of potentially functional SNPs. b. Average numbers 
of SNPs with different potential functions in each transcript. c. Percentage of SNPs with different 
functions among all the RPS SNPs.                                                                                                   
TFBS: SNPs that alter transcription factor binding sites, del ns: deleterious nsSNP, ESE/ESS: 
SNPs that alter exon splice enhancer/silencer, ISRE: SNPs that alter intronic splicing regulatory 
elements, miRBS: SNPs that alter miRNA binding sites. 
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functional groups (Figure 3.1.5 a-c). In particular, deleterious nsSNPs exhibit 
approximately 1.5-fold enrichment of rare alleles, compared to the other nsSNPs, and this 




We next investigate the signatures of RPS in putatively functional SNPs. It is 
observed in the previous section that RPS SNPs are under-represented in exons, 
especially coding regions (Figure 3.1.2d). The analysis of putatively functional SNPs 
reveals that deleterious nsSNPs contain significantly lower percentage of RPS SNPs 
compared to the non-deleterious nsSNPs (3.3% vs 5.5%, P-value<0.001 by Fisher’s exact 
test), hence they are less likely to be recently positively selected. On the other hand, there 

































































































Figure 3.1.5 Natural selections on potentially functional SNPs. Percentage of rare alleles 
among the potentially functional and non-functional SNPs in the same genic regions, as 
measured in HAPMAP individuals from a. African populations, b. East Asian populations,    
c. European populations. d. Percentage of SNPs under RPS among functional and non-
functional SNPs in the same genic regions. 
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that alter TFBS, ESE/ESS or miRBS and non-functional ones (Figure 3.1.5d). It is found 
that intronic regions are more likely to be under RPS (Figure 3.1.2d), and within introns, 
SNPs that alter ISREs show higher percentage of RPS SNPs (Figure 3.1.5d). The 
functional and selected SNPs in introns account for more than half of all the potentially 
functional and RPS SNPs in the human genome (Figure 3.1.4c), hence could play 
important roles in gene regulation leading to advantageous phenotypes.   
3.1.3 Polymorphisms are under-represented in fundamental biological processes 
 
SNP densities in different genic regions (5’UTR, coding region, intron and 
3’UTR) of more than 20,000 protein-coding genes in the human genome are calculated in 
this thesis. The majority (76%) of the genes show SNP densities less than 20/kb in all the 
genic regions. On the other hand, there are a substantial number of genes being highly 
polymorphic e.g. the highest coding SNP density is 569.82 SNPs/kb in hemoglobin beta 
gene. 
Despite the large number of polymorphisms in human genes, no polymorphism is 
identified in 149 genes, which are termed as non-polymorphic genes in this thesis. More 
than half of the non-polymorphic genes are not well annotated yet, and genetic variants 
are not discovered in these regions possibly due to the poor annotation. Nevertheless, it is 
observed that the non-polymorphic genes are significantly over-represented in histone 2A 
and 2B families, which are involved in nucleosome assembly (Figure 3.1.6, grey bars). 
They are key participants in the epigenetic control of gene regulation and was found to be 






Considering the strong selective constraints in the coding regions, we next focus 
on the coding sequences and identify that 20% of the human genes do not contain any 
nsSNPs or coding INDELs. These genes are termed as functionally conserved genes in 
this thesis, as the protein sequences are not affected by any SNP or INDEL. This group of 
genes show enrichment in a variety of functional terms, including RNA splicing, 
regulation of transcription, translational elongation and nucleosome assembly, and 
modulate gene expression, splicing patterns, as well as the processing of gene products 
(Figure 3.1.6).  
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Functionally conserved genes Functionally conserved and 
non-polymorphic genes
Functionally conserved genes with 
ultra-conserved coding sequences
Figure 3.1.6 Conserved genes are involved in fundamental biological processes. Corrected P-
values for the significant enriched functional terms involving genes with no nsSNP or INDEL in 
their coding regions, termed as functionally conserved genes.                                                     
Grey bar: functionally conserved and non-polymorphic genes. Black bar: functionally conserved 
genes with ultra-conserved elements in their coding sequences. 
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We further investigate the conservation of human genes by focusing on the ultra-
conserved elements, defined as more than 200 bp genomic regions with 100% sequence 
identity between human, mouse and rat genomes [157]. There are 70 genes that contain 
ultra-conserved elements (UCEs) in their coding sequences, and are involved in 
regulation of transcription, RNA splicing and pattern specification, while functionally 
conserved genes are also enriched in these processes (Figure 3.1.6). The result indicates 
that these fundamental biological processes for gene regulation and development are 
maintained during evolution, and the genes involved in these pathways are least 
polymorphic within the human genome and between species.  
3.1.4 Highly polymorphic genes are involved in immune responses  
 
Using the calculated SNP densities, we identify 512 highly polymorphic genes in 
the human genome (see section 2.1.1). Functional analysis shows that they are 
significantly over-represented in immune-response pathways and involved in 
pathogenesis of autoimmune diseases, e.g. Graft-versus-host disease, type I diabetes 
mellitus, etc (Figure 3.1.7). These genes show significant enrichment in major 
histocompatibility complex (MHC) class I-related and class II-related protein families 
and are involved in antigen presentation and processing. MHC class I and II genes are 
located on 6q21.3, the most polymorphic region in the human genome, and subjected to 
selective advantages leading to a more diverse immune response or escaping from 







Within MHC class I and II families, we identify more than 2000 potentially 
functional SNPs. The abundance of putatively functional SNPs might be due to the great 
number of polymorphisms in the MHC regions, hence we compare the percentage of 
SNPs with different functions in the MHC class I and class II genes with that in other 
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Figure 3.1.7 Highly polymorphic genes are enriched in immune-response pathways.   




genes. It is found that compared to other genes, there is lower percentage of deleterious 
nsSNPs in the coding regions, while SNPs with other potential functions are over-
represented in the MHC genes (Figure 3.1.8).  Moreover, none of the deleterious nsSNPs 
shows signature of RPS or high level of population differentiation (FST>0.3). On the other 
hand, more than 60% of the RPS and putatively functional SNPs may affect TF binding.  
In total, more than 1,000 promoter SNPs potentially alter TFBSs, and 55 are RPS SNPs 
and may change 111 TFBSs upstream 14 MHC class I and class II genes. 
 
Except the immune-response pathways, drug metabolism pathway contains an 
excess of highly polymorphic genes, including those in cytochrome P450 (CYP450) 
family (Figure 3.1.7). The highly polymorphic CYP450 genes are also involved in 
arachidonic acid and caffeine metabolism pathways. Last but not least, we observe that 
17 highly polymorphic genes are enriched in blood circulation pathway (Figure 3.1.7), 
including HBB, which contains the most polymorphic coding sequences, and mutations 


























Figure 3.1.8 Enrichment of SNPs 
with different potential functions 
in MHC class I and class II genes. 
Fold enrichment was calculated as 
the percentage of functional SNPs in 
certain genic regions in the MHC 
class I and class II genes divided by 




In this section, we conduct a genome-wide study about all the genetic 
polymorphisms in the human genome, and identify that coding SNPs are least tolerated 
and under negative selection. Moreover, we predict that approximately 400,000 SNPs 
may alter different functions. On top of that, most of the functionally important SNPs are 
also under negative selections. These observations indicate that:  1. the regulatory 
elements e.g. ISRE are functionally important hence polymorphisms are less tolerated in 
these regions; 2. SNPs that affect the regulatory sites could be deleterious to the gene 
functions. Furthermore, 97% of the positively selected functional SNPs are outside 
coding sequences. Therefore, we would like to further characterize the potentially 
functional SNPs in the human genome, and in this thesis, we focus on the polymorphisms 












3.2 Genetic variants that affect miRNA regulation in HapMap populations 
3.2.1 Polymorphisms are selectively constrained in miRNA genes and target sites 
 
In the human genome, 305 SNPs and 11 INDELs (dbSNP131) reside in 20% 
human pre-miRNAs. Within the mature sequences, 71 SNPs and 3 INDELs are identified 
to affect 6% mature miRNAs. Furthermore, the seed regions (2-7
th
 base from the 5’ end 
of the mature sequences), which are critical for miRNA targeting [179], contain 20 SNPs 
and 1 INDEL. The observations imply that although miRNA genes are under strong 
selective constraints [36], a number of polymorphisms could be identified in their 
transcripts and may have impacts on miRNA processing and/or targeting. 
Based on bioinformatics predictions in the previous studies [17, 18], more than 
20,000 SNPs in 3’UTR are found to potentially affect miRBS. Approximately 40% of the 
human genes contain at least one potentially functional SNP in 3’UTR. HLA-DQA1, a 
MHC class II gene that is involved in immune responses, could be affected by the highest 
number (39) of 3’UTR potentially functional SNPs. Furthermore, compared with the non-
functional SNPs in the same regions, potentially functional SNPs show significantly 
higher percentage of rare alleles (Figure 3.1.5 a-c). It indicates that the putatively 
functional SNPs in 3’UTR are selectively constrained and their functionality should be 
further investigated. 
3.2.2 Three SNPs in miRNAs are associated with miRNA or target gene expression 
 
In the HapMap samples, 154 and 224 SNPs are detected in the CEU and YRI 
populations (1000 Genomes pilot phase) respectively. These polymorphisms are analyzed 
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for associations with the mature miRNA expression. Two SNPs are significantly 
associated with mature miRNA expression in either population. Rs2910164 changes the 
4
th
 nucleotide of a star sequence, miR-146a* (miR-146a-3p), from C to G, and is 
associated with decreased expression of miR-146a* in YRI and CEU populations (Figure 
3.2.1a). MiR-146a* resides in an AGO binding site that was determined by a previous 
study [167, 168], and is likely to be incorporated into RISC which targets 3’UTR of 
human genes. Rs2910164 in miR-146a* was also associated with papillary thyroid 
carcinoma in a previous study [35]. Rs9589207, causing G to A change at the 12
th
 
nucleotide of miR-92a-1* (miR-92a-1-5p), shows association with decreased expression 
of the star sequence only in YRI population (Figure 3.2.1b). The SNP locus is non-
polymorphic in CEU samples, thus the association is not investigated in CEU population. 
The phenotype association and molecular functions or rs9589207 have not been 
understood yet. 
In the YRI, CEU and pooled CHB+JPT populations, 41, 23 and 30 SNPs in the 
mature miRNA sequences are identified, and their associations with whole-genome 
transcript expression, as profiled by Stranger et al. [5], are analyzed. The most significant 
association is identified between rs66683138, which causes G to A substitution at the 8
th
 
nucleotide of miR-3622a-5p, and SLC6A8 gene expression in the pooled CHB and JPT 
populations (Figure 3.2.1c). This trans-association might be contributed by the 
differential binding affinity between miR-3622a-5p and SLC6A8 caused by the SNP 
rs66683138. However, there is no experimental evidence or prediction results from 
miRanda [166] or TargetScan [180] of any binding sites for miR-3622a-5p in the entire 
3’UTR of SLC6A8. Therefore, the effect of rs66683138 within miR-3622a-5p on 
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SLC6A8 expression could not be explained by the conventional miRNA-mRNA 
interaction model and might be indirect through other genes involved in the regulation of 
SLC6A8. 
 
3.2.3 415 3’UTR SNPs potentially affect gene expression via changing miRBS 
 
By associating genotypes of 3’UTR SNPs with gene expression, which was 
profiled in individuals from four HapMap populations using microarray or RNA-seq 
Figure 3.2.2 Three SNPs in miRNA
genes associated with miRNA or 
gene expression.     a. rs2910164 in 
pre-miR-146a associated with miR-
146a* expression. b. rs9589207 in 
pre-miR-92a-1 associated with miR-
92a-1* expression. c. rs66683138 in 
miR-3622a-5p associated with 
SLC6A8 expression.
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Figure 3.2.1 SNPs in miRNA genes 
associated with miRNA or ge e expression.     
a. rs2910164 in pr -mir-146a associated with 
miR-146a* expression in YRI population. b. 
rs9589207 in pre-mir-92a-1 associated with 
miR-92a-1* expression in YRI population. c. 
rs66683138 in miR-3622a-5p associated with 
SLC6A8 expression in pooled CHB and JPT 
population. All the associations are 
statistically significant (corrected P-
value<0.05) by both linear regression test and 




platforms [6, 10, 11], we identify that 1280 3’UTR SNPs potentially exert cis-effects on 
gene expression (corrected P-value<0.001). About 300 to 500 SNPs significantly 
associated with gene expression could be found in each population group (CEU, YRI, 
CHB+JPT) using the microarray data, while associating with expression data from RNA-
seq, 101 and 131 candidate SNPs are identified in CEU and YRI populations respectively 
(Table 3.2.1). By comparing the SNP-transcript associations identified using microarray 
data [6], it is observed that 11-18% significant SNP-transcript associations are shared 
among the three population groups, whereas 48-66% associations are specific to single 
population. The result indicates the population differences for SNPs associated with gene 
expression, which could be contributed by different allele frequencies, differential gene 
expression and/or different gene regulation mechanisms amongst individuals from 
various populations.  
Table 3.2.1 Summary of significant 3’UTR SNP-expression associations in HAPMAP 
populations. 
Platform Microarray RNA-seq 
Study  Stranger [6] Montgomery [11] Pickrell [10] 
Population     CEU CHB+JPT YRI CEU CEU YRI 
#  samples   43 59 42 56 58 55 
# expression-
associated SNPs 
309 514 356 294 101 131 
Adjusted R
2   
  0.13-0.86 0.15-0.90 0.17-0.91 0.10-0.93 0.16-0.63 0.16-0.66 
 
Out of the 1280 SNPs that are associated with differential gene expression, 415 
SNPs are predicted as potentially functional to alter miRBS by the miRanda algorithm 
[166], as described in section 2.2.3. 576 3’UTR SNPs show associations with gene 
expression while do not change putative miRBS, thus might alter gene expression via 
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other mechanisms e.g. affecting polyadenylation events [181]. In addition, there are 264 
SNPs that create putative miRBS and show association with increased target gene 
expression and vice versa. The observation is not consistent with the classical miRNA 
regulation model that miRNA binding leads to down-regulation of gene expression [23]. 
Nevertheless, there was experimental evidence of an alternative mechanism that miRNA 
binding stabilizes target mRNA and up-regulates its expression [182]. It indicates that 
3’UTR SNPs may affect gene expression via other mechanisms, while in this thesis, we 
refer to the typical miRNA regulation model in animals and focus on SNPs that 
increase/decrease miRNA binding and down/up-regulate gene expression. In total, 415 
SNPs that are associated with expression and potentially alter miRBS are classified as 
putatively functional and expression-associated SNPs. 
According to results from expression association and functional prediction, it is 
estimated that 302 human gene expression levels could be affected by 3’UTR SNPs via 
altering miRNA targeting. 71 genes contain more than one potentially functional SNP, 
and variation in gene expression might be contributed by changes in more than one 
miRBS in the same 3’UTR. Taking BTN3A2, an immunoglobulin gene as an example, 
10 3’UTR SNPs are associated with gene expression in CEU and/or pooled CHB and JPT 
populations (Figure 3.2.2). In particular, the nucleotide changes from reference to 
alternative alleles in four SNPs (as represented by green lines) are predicted to enhance 
the bindings of miR-191*, miR-216a, miR-762 and miR-3191 respectively and could 
decrease the gene expression level. It is observed that the closest distance is only 12bp 
between two adjacent SNPs, rs68072215 and rs66823108, which might affect the same 
miRBS. Due to the existence of multiple SNPs in the same 3’UTR and two SNPs in close 
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distance, it is proposed that the ten expression-associated SNPs significantly associated 
with gene expression might exert combinatorial effect on miRNA targeting and gene 





Eleven out of 415 potentially functional SNPs in 3’UTR reside in experimentally 
characterized miRBS, as identified by AGO CLIP-seq [167, 168] (Table 3.2.2). Among 
these SNPs, rs1051690 has been associated with sporadic colorectal cancer [43]. This 
SNP resides in a putative miRBS bound by AGO in the 3’UTR of INSR gene, and is 
associated with decreased gene expression (Figure 3.2.3a). In a previous study, 
rs1051690 was bioinformatically predicted to alter miR-618 binding, however, the results 
from luciferase reporter assay did not validate the involvement of miR-618 in the SNP-




























rs1985732   rs13218591  rs9393716    rs9366655       rs1977            rs1978          rs1979       rs68072215   rs66823108    rs72841536 
SNP associated with expression SNP associated with expression & potentially affect miRBS
Figure 3.2.2 Ten 3’UTR SNPs significantly associated with BTN3A2 expression. 
CEU array (blue diamond): microarray expression data in CEU population. CHBJPT 
array (red square): microarray expression data in CHB and JPT populations. CEU seq 
(green triangle): RNA-seq expression data in CEU population. P-values are obtained 
from linear regression test.  
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changes the binding site of miR-3654 more significantly (Δalignment=32, Δenergy=5.33) 
compared to its effect on miR-618 binding (Δalignment=8, Δenergy=3.84). Hence, miR-
3654 is proposed as the new candidate involved in the underlying mechanisms for 
rs1061690 affecting gene expression and clinical phenotypes. 
Table 3.2.2 Eleven expression-associated and potentially functional SNPs in AGO binding 
sites.   
 
We further search for disease associations of the 415 3’UTR SNPs associated 
with changes in miRBS and expression levels, and identify 3 were reported in GWAS  
and 28 in individual studies (Table 3.2.3). These are most significant candidates for 
further characterization. Taking rs4560 as an example, the SNP was significantly 
associated with fasting glucose level in a previous GWAS study [183, 184]. However, the 
underlying mechanism was not elucidated. According to our analysis, C to T change of 
rs4560 potentially decreases miR-583d-3p and miR-490-3p binding and is associated 
with increased expression of EIF2AK1 gene (Figure 3.2.3b). EIF2AK1 encodes a protein 
SNP Gene  Population  miRBS affected  
rs1060238  CHMP2B  YRI  miR-2052  
rs76979273  COMMD2  CEU  miR-936  
rs6852659  TMEM33  YRI  miR-155; miR-586  
rs75844864  ZBTB24  YRI  miR-1827  
rs1803622  GAPDH  YRI  miR-3202; miR-3179  
rs1133044  SIVA1  CEU  miR-583  
rs17035  MRPL10  CEU  miR-185; miR-1252; miR-4306; miR-3153  
rs2070107  SUPT4H1  CHB+JPT  miR-3615  
rs1049230  
TRIP10  
CEU  miR-365*  
rs1049232  CEU  
miR-3135; miR-515-3p; miR-519e; miR-373; 
miR-33b*; miR-661  
rs1051690  INSR  CEU  miR-3654  
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that is involved in translation initiation to down-regulate protein level in response to 
stress (NCBI Entrez Gene Database http://www.ncbi.nlm.nih.gov/gene/27102). Based on 
our results that C to T change of rs4560 potentially deletes miR-583d-3p and miR-490-3p 
binding and previous finding about significant association between rs4560 and fasting 
glucose level, a hypothetical model is proposed: rs4560 alters the binding sites of two 
miRNAs and affects expression of EIF2AK1, and further leads to change in translation of 
proteins involved in metabolism of glucose. This model explains how the genetic variant 
contributes to the phenotypic difference. In this section, the findings about the effects of 
SNPs on miRNA regulation help to understand the genetic basis and miRNA 
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Figure 3.2.3 3’UTR SNPs affect experimentally verified miRBS and/or associated 
clinical phenotypes. a. rs105690 in 3’UTR of INSR associated with gene expression 
and affect putative miRBS. b. rs4560 associated with EIF2AK1 expression and affect 
putative miRBS. Both associations show P-value<0.001 after permutation-based 
correction (see section 2.4.2). 
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rsNo Gene miRBS affected Phenotype 
rs1044825 CACNA2D4 miR-192;miR-215;miR-649 asthma[185] 
rs1045238 NOP10 miR-1183;miR-1205 cancer[21] 
rs1048155 BHLHE41  
miR-320a;miR-320b;miR-
320c;miR-320d;miR-3607-3p 
bipolar disorder susceptibility and 
dysfunctional circadian rhythm[186] 
rs1049174 KLRK1 miR-3663-5p colorectal cancer [187] 
rs1051690 INSR miR-3654 colorectal cancer[43] 
rs1065154 SQSTM1 miR-466 






rs27582 ERAP1 miR-505* ankylosing spondylitis[190] 
rs11325 IL16 miR-4313 
follicular lymphoma survival[191]; late 
survival in diffuse large B-cell 






cognitive ability and cognitive ageing 
[195] 
rs2056443 B3GALTL  miR-875-3p 
esophageal squamous cell carcinoma 
[196] 
rs2290351 AP3S2 miR-887 chronic hepatitis C infection[197] 
rs2336219 ERCC1 miR-191 bladder cancer risk[198] 
rs735482 ERCC1 miR-3126-5p;miR-873 bladder cancer risk[198] 
rs284856 C10orf26 miR-3622b-5p late-onset Alzheimer disease[199] 
rs3129883 LOC100294223 miR-197 type 1 diabetes [200] 
rs3735172 ZBED6CL miR-4296 waist/hip ratio[183] 







rs4560 EIF2AK1 miR-490-3p;miR-548d-3p fasting glucose[183] 
rs4846049 MTHFR miR-555 
menarche and natural menopause[203]; 
cerebral palsy[204]  
rs552282 PPFIA1 miR-204;miR-211;miR-3938 allele-specific gene expression [205] 




autosomal recessive retinitis 
pigmentosa[207] 
rs7555 B4GALT2  miR-1321 schizophrenia[208] 
rs768489 ZNF557 miR-186;miR-541* Crohn's disease[209] 
rs8063 UBE2I  miR-1237 late-onset Alzheimer's disease [210] 
rs8150 RHBDF2 miR-1973;miR-3678-5p autism[211]; depression[212] 
rs8176318 BRCA1 miR-3140 Parkinson disease[213] 






    
Table 3.2.3 Summary of candidate 3’UTR SNPs associated with phenotypic differences. 
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3.3 Genetic variants that affect miRNA regulation in HCC patients  
 From the investigation of miRNA-related SNPs in general populations, we 
elucidate their contribution to miRNA or gene expression, which could be implicated in 
human diseases. In this thesis, we further investigate these polymorphisms in HCC 
patients from the TCGA project, in order to understand the contribution of genetic 
variants to the miRNA expression levels in HCC patients.  
3.3.1 410 pre-miRNA SNPs identified in the HCC patients 
From the WGS of the DNA from blood samples or non-tumorous liver tissue 
samples of 17 HCC patients (see section 2.1.4), 410 SNPs are detected in the miRNA 
precursor transcripts. Out of the 1881 pre-miRNAs as recorded in miRBase release 21 
[25], 347 (18%) are polymorphic in the HCC patients. We further identify that 139 SNPs 
reside in 135 mature sequences and 40 SNPs in the seed regions of 39 mature miRNAs 
(Figure 3.3.1). 


















Pre-miRNAs Mature miRNAs Seed regions
#
SNPs polyrmophic miRNAs
Figure 3.3.1 Distribution of miRNA SNPs in HCC patients.  
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Not all the 410 SNPs reside in miRNAs expressed in the non-tumorous liver 
tissues of the HCC patients, hence we focus on the SNPs associated with expressed 
mature miRNAs. In total, 107 SNPs are identified in 95 pre-miRNAs, from which the 
mature miRNAs are transcribed and expressed in at least one of the 17 patients. Table 
3.3.1 shows the 20 SNPs that reside in the mature sequences, and five in the seed regions. 
We incorporate the allele frequency data from HapMap CEU population as a control, as 
76% of this group of HCC patients are of European ancestry, according to the clinical 
information in the TCGA database (Table 2.1). It is observed that 60% of the SNPs 
within mature sequences show low frequency (minor allele frequency<10%) in both the 
HCC cohort and general population. Among the common SNPs (minor allele 
frequency>10%), rs2910164, which was previously identified to be associated with 
mature miRNA expression in CEU and YRI populations (see section 3.2.2) and risk of 
papillary thyroid carcinoma [35], shows marginally significantly association with HCC 
risk (P-value=0.078 by Fisher's exact test).  We did not observe any statistically 
significant association (P-value<0.05 by Fisher’s exact test) between the mature miRNA 
SNPs and HCC, which might be due to the limitation of small sample size (n=17 for 
HCC group). However, three common SNPs, including rs3746444 in miR-499a-3p, 
rs73239138 in miR-1269a and rs2241347 in miR-3130, reside in the commonly 
expressed mature miRNAs (detected in more than >50% patients) in HCC patients. These 
variants might be able to affect miRNA targeting and mediate downstream gene 





Table 3.3.1 Twenty SNPs in the mature miRNAs expressed in HCC patients.  
Allele change: reference/alternative allele; Allele frequency: alternative allele frequency. 
Alternative allele with frequency>10% is considered as common allele and is labelled in bold.  
  
3.3.2 Four pre-miRNA SNPs associated with mature miRNA expression 
 
After identification of common mature miRNA SNPs in HCC patients, we next 
investigate the effects of pre-miRNA SNPs on miRNA expression. In total, 174 
associations including 140 SNPs and 142 miRNAs are analyzed in this section. Four 





SNP Seed  
Allele 
change 








mir-146a miR-146a-3p rs2910164 Y C/G 61.76 77.50 0.078 0.47 
mir-296 miR-296-3p rs117258475   G/A 2.94 2.50 1 1.18 
mir-412 miR-412-3p rs61992671   A/G 32.35 46.70 0.171 0.55 
mir-499a miR-499a-3p rs3746444 Y A/G 20.59 17.50 0.801 1.22 
mir-548l miR-548l rs13447640   G/A 2.94 0.80 0.394 3.57 
mir-585 miR-585-3p rs62376935 Y C/T 2.94 4.20 1 0.70 
mir-590 miR-590-3p rs6971711   C/T 2.94       
mir-629 miR-629-5p rs78212770   C/G 5.88       
mir-636 miR-636 rs201537332   G/A 2.94       
mir-1269a miR-1269a rs73239138   G/A 32.35 25.80 0.514 1.37 
mir-1322 miR-1322 rs59878596   C/T 2.94       
mir-3116-
1/2 
miR-3116 rs192207383 Y G/A 5.88       





rs115772313   G/A 2.94       
rs2241347   C/T 17.65 12.50 0.411 1.50 
mir-3144 miR-3144-3p rs67106263   G/A 26.47 26.70 1 0.99 
mir-3159 miR-3159 rs79957895   G/A 2.94       
mir-3198-1 miR-3198 rs56660112   C/G 5.88       
mir-3622a miR-3622a-5p rs66683138   G/A 17.65 21.70 0.811 0.78 
mir-4284 miR-4284 rs11973069   C/T 2.94       
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both linear regression test and Spearman’s rank correlation, as described in section 2.4.1), 
as summarized in Table 3.3.2 and Figure 3.3.2. However, no association remains 
statistically significant after correction.  
In the four polymorphic pre-miRNAs, nucleotide changes of rs7911488 in mir-
1307, rs78212770 in mir-629 and rs56103835 in mir-323b are associated with decreased 
miRNA production, while A to C change in mir-618 SNP, rs2682818, increases the 
mature miRNA expression. For all the four SNPs, only the heterozygote and one 
homozygote genotypes are observed in the HCC patients. By Mann-Whitney test, we 
identify significant differences of the miRNA expression between patients with two 
different genotypes (P-value<0.05). 
Table 3.3.2 Four pre-miRNA SNPs associated with mature miRNA expression in 
HCC patients.  
P-values are from linear regression tests. ΔΔG was predicted by Gong et al. and retrieved 











mir-1307 rs7911488 A/G miR-1307-3P ↓ 2.08E-03 0 
mir-629 rs78212770 C/G miR-629-5p ↓ 7.97E-03 5.7 
mir-323b rs56103835 T/C miR-323b-3p ↓ 9.66E-03 -0.3 
mir-618 rs2682818 A/C miR-618 ↑ 1.88E-02 -3.5 
 
We further investigate the potential functions of the pre-miRNA SNPs by 
evaluating their effects on pre-miRNA structures. Mir-629 SNP rs78212770, located 
within the mature sequence, could change the hairpin structure to a less stable state, 
hence lead to decreased production of the mature forms, which is consistent with the 
expression data (Figure 3.3.2b). On the other hand, the nucleotide change of the mir-618 
SNP, rs2682818, creates the complementary base pair to the 4th nucleotide of the mature 
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sequence miR-618, and stabilizes the hairpin structure. This SNP is associated with 
increased mature miRNA expression (Figure 3.3.2d). The SNPs in mir-1307 and mir-
323b do not affect the pre-miRNA structure significantly, but may alter the expression 




Figure 3.3.2 Four SNPs in pre-miRNAs significantly associated with mature miRNA 
expression.  a. rs7911499 associated with miR-1307-3p. b. rs78212770 associated with miR-
629-5p. c. rs56103835 associated with miR-323b-3p. d. rs2682818 associated with miR-618. 
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3.3.3 7976 SNPs identified in the genes involved in miRNA machinery 
 
 Genetic polymorphisms could affect the genes involved in miRNA machinery e.g. 
XPO5 and are associated with HCC [150]. In this study, we investigate the genetic 
variants in 52 genes in miRNA machinery pathway, as retrieved from Patrocles database 
[18], and identify 7976 SNPs from the non-tumorous liver tissues or blood of the 17 HCC 
patients. 
 Figure 3.3.3 shows the distribution of SNPs in the genes involved in the miRNA 
machinery. All the 52 genes contain at least SNP, and the highest number (822) of SNPs 
is found in SND1, a gene involved in RISC. More than 90% SNPs reside in introns, while 
within exons, 230 SNPs are identified in 3'UTR and show to be the most abundant form 
of exonic SNPs (Figure 3.3.3). We observe 43 nsSNPs in 14 genes, and GEMIN4 
contains the highest number (12) of nsSNPs among all the miRNA machinery genes. 
Functional prediction by SIFT algorithm [154] identifies a total number of 9 SNPs, 
including 6 in GEMIN4 (rs7813, rs8078660, rs910925, rs14389256, rs111822058 and 
rs61753060), rs76192856 in GEMIN5, rs34830321 in CNOT1 and rs149389256 in 
DROSHA being deleterious to protein function. Most of the potentially damaging 
nsSNPs have minor allele frequency (MAF)<0.05, possibly because they are less 
tolerated and constrained by negative selection . However, rs7813 and rs910925 in 









3.3.4 Twenty-one coding SNPs overlap with somatic mutations in the miRNA 
machinery genes 
 
 We next compare the SNPs in miRNA machinery genes with the somatic 






























































































































































































































































































































































































































































































































Figure 3.3.3 Distribution of the SNPs within miRNA machinery genes in the HCC patients.        




in miRNA regulation among HCC patients, while somatic mutations may lead to changes 
in the tumor tissues. Genetic differences identified in both groups are proposed to play 
important roles in mediating miRNA regulation in HCC.   
  Using whole-genome and/or whole-exome sequencing (WXS) of 202 HCC 
patients in TCGA project, more than 80,000 somatic mutations are identified in the 
coding sequences of all the human genes. Most of the non-coding mutations have not 
been identified in the TCGA data, hence we mainly focus on the coding polymorphisms 
and mutations. Within genes involved in miRNA machinery, 273 mutations are found 
specific in the tumor tissues, including 91 silent mutations, 1 splice site mutation and 181 
mutations that affect protein sequences. Comparing with the SNPs identified in the 17 
HCC patients in this study, we find 21 variants showing the same nucleotide changes, 
including 15 silent and 6 missense mutations/SNPs (Table 3.3.3), accounting for 19% 
total SNPs and 7% mutations detected in the coding regions.  
Out of the 21 SNPs, 17 are commonly found in the HCC patients (MAF>0.1). 
However, only rs910925 in GEMIN4 are recurrent in the tumor tissues of 2 patients, 
while the rest are mutated only in one patient. We further investigate the functional 
effects of the missense variants, and find two damaging variants, rs7813 and rs910925 in 
GEMIN4 gene. It indicates that the function of GEMIN4 could be frequently affected in 
HCC, as both SNPs and mutations could exert deleterious effects. In addition, DDX20 
and TNRC6A in RISC, also carry missense mutation and SNPs. However, the changes of 
the protein sequences are predicted to be neutral and may not have profound effects on 

















AGO4 rs4652895 Silent A/C 23.53% 1 S798S   
CNOT1 rs246258 Silent C/T 26.47% 1 L1376L   
CNOT3 rs77902046 Silent A/T 2.94% 1 T670T   
DDX20 
rs197392 Silent A/G 32.35% 1 A12A   
rs197412 Missense T/C 50.00% 1 I636T Tolerated 
rs197413 Silent G/A 50.00% 1 V642V   
rs85276 Missense T/C 29.41% 1 I762T Tolerated 
EIF4ENIF1 rs5997988 Silent G/A 50.00% 1 S742S   
FMR1 rs25707 Silent G/A 2.94% 1 R138R   
GEMIN4 
rs3744742 Silent C/T 8.82% 1 A359A   
rs7813 Missense G/A 47.06% 1 R1033C Damaging 
rs2740349 Missense C/T 20.59% 1 D929N Tolerated 
rs910925 Missense G/C 47.06% 2 A579G Damaging 
MOV10 
rs3748656 Silent C/T 23.53% 1 G394G   
rs883593 Silent A/G 23.53% 1 T464T   
rs17030651 Silent G/A 20.59% 1 E704E   
rs2306940 Silent T/C 26.47% 1 A820A   
rs6679 Silent C/T 23.53% 1 S977S   
TNRC6A 
rs6497759 Missense G/A 14.71% 1 A592T Tolerated 
rs72770409 Silent C/T 2.94% 1 L790L   
rs2303085 Silent C/T 17.65% 1 H1804H   
  
3.3.5 879 SNPs in miRNA machinery genes significantly associated with miRNA 
expression 
 
After studying the distribution of SNPs in the miRNA machinery genes, we 
investigate their effects on miRNA expression in the non-tumorous liver tissues of HCC 
patients. Based on the linear regression test and 10,000 permutations (see section 2.4.3), 
1343 significant associations are identified (empirical P-value<0.001). In total, nearly 




half (212/436) of the miRNAs expressed in all the HCC patients are associated with 879 
SNPs in 39 (75%) miRNA machinery genes.  
Among all the SNPs showing significant associations with miRNAs, more than 90% 
reside in the intronic regions, while 28 in UTRs, and 12 in coding regions. Only 3 
nsSNPs show associations with miRNA expression. Comparing with the distribution of 
SNPs in the miRNA machinery genes, it suggests that nsSNPs, which could directly 
affect miRNA-processing protein sequences, are not enriched for miRNA expression-
associated SNPs. 
 We next examine the distribution of the expression-associated SNPs in different 
genes, and identify that CNOT6 contains the highest number of miRNA expression-
associated SNPs (Figure 3.3.4). CNOT6 gene encodes a component of the CCR4-NOT, 
which is involved in miRNA-induced repression by de-adenylation of mRNA [216]. 
CNOT6 is not the most polymorphic genes in the miRNA machinery pathway, while 32% 
(124/381) genic SNPs are identified to be significantly associated mature miRNA 
expression. In total, expression levels of 45 miRNAs could be potentially affected by the 





The same number (45) of miRNAs is associated with 28% genic SNPs in AGO2, 
an important gene associated with miRNAs and mediating RNA interference. Compared 
to AGO2, other members of the AGO family (AGO1, AGO3, AGO4) are less 
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polymorphic and associated with fewer than 10 miRNAs. Moreover, SMAD3 and 
DROSHA, which are involved in miRNA maturation, contain 76 and 59 SNPs that affect 
31 and 23 mature miRNAs, respectively. These genes play significant roles in miRNA 
biogenesis and processing and show enrichment of miRNA expression-associated SNPs. 
The observation suggests that their functions could be affected by polymorphisms and 
further influence on mature miRNA production. On the other hand, the gene with the 
highest number of SNPs, SND1, is not enriched for SNPs that are associated with 
miRNA expression, and only 15 miRNAs could be potentially affected by the 
polymorphisms in SND1. 
3.3.5.1 Nine intronic SNPs significantly associated with miRNA expression 
 
 We next determined the SNPs that are most significantly associated with miRNA 
expression. After correction for family-wise error and based corrected P-value<0.05 (see 
section 2.4.3), 9 SNPs in 5 genes show significant associations with mature miRNAs, as 















CNOT6 rs13167069 C/T miR-1296-5p  ↑ 0.75 2.71E-02 
SMAD3 rs4776341 T/G miR-501-5p ↑ 0.73 2.73E-02 
XRN1 
rs7429175 T/G 






miR-7-1-3p  ↑ 0.68 3.45E-02 
rs17409755 G/A 
CNOT10  rs62251886 G/A miR-3664-5p  ↓ 0.67 4.11E-02 
Table 3.3.4 Nine SNPs in miRNA machinery genes significantly associated with miRNA 












































Figure 3.3.5 Five SNPs in miRNA 
machinery genes significantly 
associated with miRNA expression.   
a. rs13167069 associated with miR-
1296-5p b. rs4776341associated with 
miR-501-5p c. rs7349528 associated 
with let-7f-2-3p d. rs17409755 
associated with miR-7-1-3p                             




All the nine SNPs reside in the intronic regions of the miRNA machinery genes.  
Four SNPs in XRN1 (rs7429175, rs62276397, rs35225534 and rs7349528) are in perfect 
LD (r
2
=1) hence show the same association with let-7f-2-3p expression in the HCC 
patients. Similarly, rs17409588 and rs17409755 in DROSHA exhibit perfect LD and  are 
significantly associated with miR-7-1-3p.  
Due to the linkage disequilibrium between the expression-associated SNPs, we 
consider the SNPs in the same gene showing the same association with miRNA 
expression e.g. rs17409588 and rs17409755 with miR-7-a-3p as a single group of 
genotype-expression association. In Figure 3.3.5, the five groups of genotype-expression 
associations are demonstrated. The four intronic SNPs in XRN1 are represented by 
rs7349528 (Figure 3.3.5c), and the two SNPs in DROSHA are represented by 
rs17409755 (Figure 3.3.5d).  
 The intronic SNPs in CNOT6 and SMAD3 are associated with increased 
expression of miR-1269-5p and miR-501-5p (Figure 3.3.5 a, b), while rs62251886 in 
CNOT10 shows association with decrease in miR-3664-5p expression (Figure 3.3.5e). 
These three SNPs reside in the introns and are not in close proximity to intron-exon 
boundary. According to our current knowledge about SNP functions, intronic SNPs 
distant from splice sites could not directly affect gene function. In this case, the three 
SNPs may not be the causal variants, and might be linked to the functional SNPs that 
could affect miRNA-processing genes, but are not determined in this study.  
 In Figure 3.3.5c, rs7349528 shows association with decreased level of let-7f-2-3p. 
Out of the four expression-associated SNPs in perfect LD in XRN1, rs7349528 is the 
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only SNP with predicted effect to create two splicing regulatory elements and might lead 
to change in the splicing pattern of the gene. Alternative splicing has been identified for 
XRN1, and the different functions of the splicing isoforms might affect the miRNA 
machinery pathway. Lastly, rs17409755 and rs17409588 in DROSHA are associated with 
increased level of miR-7-1-3p (Figure 3.3.5d). Rs17409755 is 92bp from the next exon, 
while is not predicted to affect any putative splicing regulatory element using 
bioinformatics method. The effect of the SNP on splicing regulation requires further 
characterization.  
3.3.5.2 Three nsSNPs associated with miRNA expression 
 
 The nine SNPs showing the most significant associations with mature miRNAs all 
reside in introns and could not directly affect protein function. The potential functions of 
most of these SNPs are not understood yet.  In this section, we focus on missense SNPs 
that may affect miRNA expression via altering protein functions of the miRNA-
processing genes. At the stringent cutoff corrected P-value<0.05, no missense SNP shows 
significant association. However, 3 nsSNPs are significantly associated with miRNA 
expression at a less stringent cutoff (empirical P-value<0.001 before correction) and may 
still be causal because they could directly affect the functions of proteins involved in 
miRNA biogenesis and processing. In this section, we highlight these 3 SNPs in 
GEMIN4, DROSHA and TNRC6B genes, as summarized in Table 3.3.5 and Figure 3.3.6. 
Rs3744741 resides in GEMIN4, the miRNA containing the highest number of 
nsSNPs. C to T allele change, corresponding to arginine to glutamine in protein sequence, 
is associated with decreased expression of miR-487-3p (Figure 3.3.6).  However, the SNP 
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is predicted to be tolerated by the SIFT algorithm [154] and the nucleotide change is not 












































GEMIN4 rs3744741 C/T R684Q miR-487b-3p ↓ 3.00E-04 
DROSHA rs55656741 G/A S321L miR-374a-5p ↑ 5.00E-04 
TNRC6B rs9611280 G/A V16M 
miR-26a-5p ↓ 1.00E-03 
miR-3682-3p ↓ 2.00E-04 
Table 3.3.5 Three nsSNPs in miRNA machinery genes associated with mature miRNA 
expression (P-value<0.001 before correction). 
Figure 3.3.6 Three nsSNPs associated with mature miRNA expression.  a. rs3744741 
associated with miR-487b-3p expression. b. rs55656741 associated with miR-374a-5p 
expression. c. rs9611280 associated with miR-26a-5p and d.miR-3682-3p expression 
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 DROSHA contains one expression-associated missense variant, rs55656741, 
which is associated with increased level of miR-374a-5p (Figure 3.3.6b). There is no 
missense somatic mutation in DROSHA, and similar to the GEMIN4 variant, rs55656741 
is not damaging to the protein function. Nevertheless, the polymorphism was associated 
with alternative spicing in a previous study [217] and is located in an exon that is absent 
in several splicing isoforms of DROSHA gene. Therefore, it suggests that other than 
directly altering the protein sequence, rs55656741could affect the splicing patterns of 
DROSHA and lead to change in the miRNA biogenesis and production.  
 Lastly, we observe rs9611280 in TNRC6B being associated with decreased levels 
of two mature miRNA expression (Figure 3.3.6 c, d).  Only two genotypes are observed 
in the HCC patients, and 3.7 fold change of miR-3682-3p expression is identified 
between patients with different genotypes. The SNP causes a neutral change in the 
protein sequence, and is not detected in HCC tumor tissues as somatic mutations. 
 To conclude, it is surprising to observe that all the three expression-associated 
nsSNPs do not exert damaging effects on protein function and they do not overlap with 
somatic mutations in tumor tissues, hence they contribute to differences between 
individuals. One SNP in DROSHA gene, rs55656741, is found to alter the splicing 
patterns, thus the splicing isoforms of the genes are proposed to mediate the miRNA 





 In section 3.2 and 3.3, we characterize the functionality of SNPs involved in 
miRNA regulation by studying their expression associations and potential functions to 
alter miRNA processing or targeting. The results in section 3.2 provide a list of candidate 
polymorphisms that could affect miRNA regulation in human diseases including 2 SNPs 
in pre-miRNAs that are associated with mature miRNA regulation and 415 3’UTR SNPs 
that may affect gene expression via altering miRNA binding sites. 31 SNPs in the second 
category have been associated with clinical phenotypes (Table 3.2.3) and the underlying 
molecular mechanisms elucidated in this thesis could guide future experimental 
validation.  
 The previous studies about the miRNA-related SNPs in HCC were based on 
single or a group of candidate SNPs. In this thesis, using the data from TCGA, we 
conduct a comprehensive investigation of SNPs that are associated with miRNA 
regulation in the HCC patients. Four SNPs in pre-miRNAs and nine SNPs in miRNA-
processing genes are identified to be associated with miRNA expression. These 
polymorphisms may contribute to differences in miRNA regulation involved in HCC. 
The results could guide future investigation about the causal miRNA-related SNPs in 







3.4 Discovering plasma miRNAs as potential biomarkers for HCC 
 
Aberrant miRNA expression in tissues has been extensively studied HCC, and 
commonly de-regulated miRNAs were found to mediate important biological pathways 
and contribute to hepatocarcinogenesis. In the previous section, we investigate the 
polymorphisms that affect miRNA expression patterns in HCC patients. In this part of the 
thesis, I aim to explore miRNAs as novel non-invasive biomarker for HCC.   
3.4.1 68 miRNAs differentially expressed between HCC and normal healthy 
individuals 
 
To identify miRNAs de-regulated in HCC, we profile 751 miRNAs in plasma 
samples from 19 HCC patients and 10 normal healthy (NH) individuals. On average, 249 
miRNAs are detectable per sample and 109 miRNAs are identified in all the 29 samples. 
The heat map in Figure 3.4.1 shows the top 50 miRNAs with the highest variance in their 
expression. The samples are separated into two clusters in the heat map: one group 
contains 14/19 (73%) HCC patients, while the remaining 5 HCC patients and all the 
normal healthy individuals are within another cluster. In the second cluster, the five HCC 
patients are grouped into a distinct sub-cluster, being separated from the normal healthy 
individuals. As represented by the blue boxes in Figure 3.4.1, the miRNA clusters are 
associated with miRNA families. For instance, the members in let-7 (let-7c and let-7d-5p), 
mir-29 (miR-29a-3p and miR-29c-3p) and mir-18 (miR-18a-5p and miR-18b-5p) are 
found in distinct clusters. MiR-223-5p and miR-223-3p from the same precursor are 
grouped together. Moreover, miR-192-5p and miR-215, which are closed in their 
genomic locations (<10kb), are in the same cluster. The results indicate that, miRNAs 
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belonging to the same functional families or the genomic regions tend to show high 




Using Student’s t-test, we identify 61 miRNAs that show fold change>2 and 
corrected P-value<0.05 between HCC and NH groups, including 33 up-regulated and 28 
down-regulated in HCC (Table 3.4.1).  There is another miRNA (miR-100-5p) which is 
only expressed in the HCC (70% of the HCC patients) but not expressed in the normal 
individuals. This miRNA is not selected by Student’s t-test because all the normal 
Figure 3.4.1 Heat Map and hierarchical clustering of the top 50 miRNAs with highest 




subjects have missing values hence the statistical test cannot be performed. However, we 
include miR-100-5p as an up-regulated miRNA because it is specifically expressed in the 
HCC group. As we are also interested in miRNAs that are differentially expressed in both 
the plasma as well as the tissues (tumor vs non-tumor), we lower the fold-change 
threshold to 1.5 and include an additional 6 miRNAs which we also consider as 
differentially expressed.  
 
Category miRNA name 
De-
regulation 
Fold Change Corrected P-value 
Significant difference 
 (fold change>2) 
miR-122-5p ↑ 57.39 1.92E-06 
miR-214-3p ↑ 41.22 1.50E-05 
miR-885-5p ↑ 20.19 3.61E-04 
miR-365a-3p ↑ 13.82 1.65E-06 
miR-142-3p ↓ 9.35 1.68E-08 
miR-193a-5p ↑ 8.35 4.74E-05 
miR-34a-5p ↑ 8.29 4.18E-04 
miR-215 ↑ 7.21 3.02E-05 
miR-375 ↑ 6.68 3.90E-03 
miR-125b-5p ↑ 6.67 9.03E-05 
miR-199a-5p ↓ 6.45 5.88E-06 
miR-99a-5p ↑ 6.36 9.21E-05 
miR-192-5p ↑ 6.19 6.64E-05 
miR-193b-3p ↑ 5.6 4.80E-02 
miR-1972 ↑ 5.06 1.09E-02 
miR-548a-3p ↓ 4.64 4.28E-04 
miR-224-5p ↑ 4.48 2.90E-04 
miR-33a-5p ↓ 4.36 3.41E-04 
miR-145-5p ↑ 4.26 4.86E-07 
miR-30a-3p ↑ 4.17 4.18E-04 
miR-497-5p ↑ 4.03 2.54E-04 
miR-126-3p ↓ 4.03 4.27E-08 
miR-136-5p ↓ 4 2.28E-03 
miR-574-3p ↑ 3.71 7.71E-07 
miR-21-3p ↓ 3.66 6.88E-03 
miR-29c-3p ↓ 3.56 1.51E-06 
miR-22-3p ↓ 3.49 1.40E-06 
miR-590-5p ↓ 3.4 8.54E-07 
miR-194-5p ↑ 3.34 2.86E-03 
miR-195-5p ↑ 3.14 7.86E-04 
miR-342-3p ↑ 3.07 2.50E-05 
Table 3.4.1 68 miRNAs differentially expressed between HCC (n=19) and NH (n=10) groups. 
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miR-95 ↑ 2.99 2.65E-02 
miR-136-3p ↓ 2.9 8.10E-03 
miR-27b-3p ↓ 2.89 3.57E-05 
miR-155-5p ↑ 2.88 1.46E-03 
miR-144-5p ↓ 2.81 5.83E-03 
let-7c ↑ 2.8 2.97E-06 
miR-339-3p ↓ 2.78 9.21E-05 
miR-338-3p ↓ 2.71 1.60E-03 
miR-22-5p ↓ 2.64 4.68E-05 
miR-326 ↓ 2.62 3.70E-03 
let-7d-5p ↑ 2.57 2.56E-04 
miR-210 ↓ 2.52 1.17E-03 
miR-550a-3p ↓ 2.52 3.22E-03 
miR-130a-3p ↓ 2.48 6.09E-05 
miR-148a-3p ↑ 2.45 1.16E-03 
let-7b-5p ↑ 2.44 1.50E-05 
miR-181a-5p ↑ 2.32 4.35E-05 
miR-301a-3p ↓ 2.29 2.45E-02 
miR-26b-3p ↓ 2.29 2.50E-03 
miR-191-5p ↑ 2.27 1.64E-03 
miR-30e-3p ↑ 2.22 2.92E-04 
miR-139-5p ↑ 2.2 1.07E-03 
miR-223-5p ↑ 2.18 2.99E-02 
miR-148b-3p ↓ 2.15 9.42E-06 
miR-151a-3p ↓ 2.15 8.10E-03 
miR-374a-5p ↓ 2.13 2.87E-02 
miR-24-3p ↓ 2.09 1.60E-03 
miR-181c-3p ↓ 2.08 3.10E-03 
miR-21-5p ↓ 2.04 2.72E-07 
miR-532-3p ↑ 2.01 2.30E-03 
Moderate difference 
(1.5<fold change<2) and 
de-regulation in tissues 
miR-423-5p ↑ 1.9 1.71E-03 
miR-361-5p ↑ 1.84 1.81E-03 
let-7a-5p ↑ 1.83 1.16E-03 
miR-221-3p ↓ 1.74 3.86E-02 
miR-222-3p ↓ 1.69 8.11E-04 
miR-320d ↑ 1.64 1.06E-02 
Specific in HCC group miR-100-5p ↑ N.A. N.A. 
 
In total, out of the 751 miRNAs profiled in the discovery phase, 68 miRNAs are 
identified as potential candidates for HCC biomarkers (Table 3.4.1). It is interesting to 
note that four members of let-7 family i.e. let-7a-5p, let-7b-5p, let-7c and let-7d-5p are 
elevated in HCC plasma. MiR-100-5p, miR-125b-5p and miR-99a-5p from mir-10 family 
also show up-regulation. Moreover, miR-221-3p and miR-222-3p from the miR-221 
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family show significant decrease in their plasma expression. The observations suggest 
that these miRNA families are implicated in HCC. 
 
3.4.2 21 miR3NAs associated with clinical characteristics 
 
In addition to de-regulation in HCC samples, we further investigate circulating 
miRNAs associated with clinicopathological parameters within HCC group (n=19). Table 
3.4.2 summarizes 26 significant associations between 21 miRNAs with viral infection, 
histological grade, tumor size, tumor capsule, necrosis, vascular invasion, multifocality, 
normal liver cirrhosis, and/or disease stage. 
 It is interesting to note that six miRNAs are significantly associated with HBV 
infection, and five of them show lower expression in HBV-positive HCC. The fold 
changes caused by HBV infection are higher than those associated with other 
characteristics. The observation indicates that viral infection is an important factor that 
affects circulating miRNA expression, and leads to a further investigation of miRNA de-
regulation in chronic hepatitis B (CHB) carriers in the next section of the thesis.  
Except the viral infection, it is observed that three miRNAs (miR-150-5p, miR-
361-5p and miR-320b) are elevated in patients with high-grade tumors, and miR-320a 
significantly correlates with tumor size. The presence of tumor capsule or complete 
encapsulation down-regulates six miRNAs in plasma. Moreover, several clinical 
characteristics including necrosis, vascular invasion, multifocality, liver cirrhosis or late-
staged HCC tend to up-regulate circulating miRNAs, with one exception that miR-483-5p 
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is negatively affected by presence of normal liver cirrhosis. Moreover, it is found that 
miR-150-5p, miR-483-5p and miR-342-5p are associated with more than one clinical 
parameters, hence might play significant roles in HCC.  
Table 3.4.2 21 miRNAs associated with clinical characteristics. MiRNAs in bold are 
associated with more than one phenotype.                                                                        
All the associations are determined by Mann-whitney tests except the association between 
histological grade and plasma miRNA expression is evaluated by an ordinal logistic regression 
model, and tumor size is associated with plasma miRNA expression via Spearman’s rank 















miR-148a-3p ↓ 3.54 3.45E-05 ↑ 
miR-424-5p ↓ 3.35 6.77E-04 
 
miR-378a-3p ↓ 3.36 8.21E-04 
 
miR-18b-5p ↑ 2.29 8.32E-04 
 
miR-99a-5p ↓ 4.85 9.19E-04 ↑ 
miR-210 ↓ 2.06 2.81E-02 ↓ 
Histological 
grade 
≥3 miR-150-5p ↑ 2.49 4.83E-02 
 
Increasing  
miR-361-5p ↑ N.A. 9.00E-03 ↑ 
miR-320b ↑ N.A. 2.40E-02 
 





miR-142-5p ↓ 2.61 1.56E-02 
 
miR-30e-5p ↓ 2.33 1.93E-02 
 
miR-382-5p ↓ 2.54 3.69E-02 
 
miR-337-3p ↓ 2.20 3.88E-02 
 




Complete miR-150-5p ↓ 2.41 4.34E-02 
 





miR-874 ↑ 2.11 8.26E-03 
 
miR-483-5p ↑ 2.59 1.14E-02 
 
Multifocality Yes 
miR-29a-3p ↑ 2.40 4.27E-03 
 
miR-150-5p ↑ 2.87 3.88E-02 
 





miR-181b-5p ↑ 2.44 6.47E-03 
 
miR-483-5p ↓ 2.36 2.74E-02 
 










To conclude, 21 miRNAs are identified to be associated with several HCC-related 
phenotypes. These miRNAs are incorporated into the candidate miRNA list and 
investigated in a larger cohort during the validation phase of this study. 
3.4.3 Four miRNAs associated with survival time 
 
We further perform survival analysis for all the circulating miRNAs to identify 
prognostic markers. By Cox proportional hazards test, we find expression levels of four 
miRNAs, including miR-769-5p, miR-32-5p, miR-28-5p and miR-199b-5p, are 
significantly associated with overall survival time and/or relapse-free survival (P-
value<0.05).  
Using the median plasma miRNA expression as the cutoff to classify patients into 
high-expression and low-expression groups, it is found that higher expression of miR-
769-5p, miR-32-5p and miR-199b-5p in plasma are associated with longer overall 
survival time (Figure 3.4.2 a, c, d). On the other hand, patients with higher expression of 
miR-28-5p show worse outcome as shorter overall survival time (Figure 3.4.2 e). 
Apart from overall survival, the relapse-free survival time is also analyzed. MiR-
769-5p is the only candidate that shows statistically significant association with relapse-
free survival time (P-value<0.05). It is consistent with the overall survival analysis that 























































































































































Figure 3.4.2 Four miRNAs associated 
with survival time. a. & b. miR-769-5p 
expression associated with overall survival 
and relapse free survival.  c. miR-32-5p,  
d. miR-199b-5p, e. miR-28-5p expression 
associated with overall survival. 
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To summarize, four miRNAs show significant associations with survival time. 
Due to the small sample size (n=19), all the associations do not reach statistical 
significance (P<0.05) after multiple test correction. Nevertheless, we include the four 

















3.5 Validating potential diagnostic and prognostic miRNA markers in HCC 
 
From the whole-genome miRNA expression profiling of plasma samples, we 
identify 68 miRNAs de-regulated in HCC, 21 associated with clinical phenotypes 
(including 4 miRNAs that are also differentially expressed between HCC and NH groups) 
and 4 associated with survival time. We further investigate these miRNAs in independent 
cohorts and include eight stably expressed miRNAs as reference miRNAs, and miR-451a 
as indicator of hemolysis. In total, 98 miRNAs are profiled in the plasma samples from 
three groups: 40 normal healthy (NH) individuals, 30 chronic hepatitis B (CHB) carriers 
and 36 HCC patients.    
 
 Figure 3.5.1 Principal component analysis (PCA) plot for all samples based on the top 50 




 Figure 3.5.1 shows the principal component analysis (PCA) plot of all the samples. 
Based on the top two components (PC1 and PC2), samples generally cluster according to 
their biological groups. Separation between groups is clearer between HCC and normal 
(pink and blue circles), compared to HCC and chronic carriers (green circles). Partial 
overlapping is observed between CHB patients and normal controls. The PCA result is 
coherent with the biological properties of the samples.   
3.5.1 MiRNA signatures in HCC, chronic hepatitis B and normal individuals 
 
From the 98 assays included in the validation phase, we compare the miRNA 
expression in the three pairs of groups (NH vs CHB, NH vs HCC and CHB vs HCC) 
using Student’s t-test. In total, 45 miRNAs show significant difference between at least 
one pair of groups (fold change>2, corrected P-value<0.05) and are identified to be de-
regulated in CHB and/or HCC patients.  
3.5.1.1 38 miRNAs differentially expressed between HCC patients and normal 
controls 
 
From the finding of the discovery phase, 68 miRNAs are identified to be de-
regulated in HCC. 32 out of the 68 miRNAs are validated in the new cohort including 36 
HCC patients and 40 NH individuals, and show the same trends of significant de-
regulation (fold change>2, corrected P-value<0.05) between the two groups (Table 3.5.1). 
They include 27 up- and 5 down-regulated miRNAs, consistently de-regulated in HCC 













miR-214-3p ↑ 11.39 4.07E-10 ↑ 
miR-122-5p ↑ 6.22 2.76E-07 ↑ 
miR-210 ↓ 6.06 1.47E-16 ↓ 
miR-550a-3p ↓ 5.87 2.52E-11 ↓ 
miR-195-5p ↑ 4.45 1.03E-09 ↑ 
miR-483-5p ↑ 4.31 2.76E-07   
miR-30e-3p ↑ 4.18 2.91E-13 ↑ 
miR-574-3p ↑ 4.16 8.01E-16 ↑ 
miR-34a-5p ↑ 3.87 2.33E-08 ↑ 
miR-423-3p ↑ 3.56 2.83E-20   
miR-1972 ↑ 3.44 2.04E-05 ↑ 
miR-365a-3p ↑ 3.43 1.87E-05 ↑ 
miR-497-5p ↑ 3.38 7.30E-08 ↑ 
miR-193a-5p ↑ 3.35 1.81E-08 ↑ 
miR-885-5p ↑ 3.26 2.13E-05 ↑ 
miR-199a-3p ↑ 3.18 6.08E-17   
miR-100-5p ↑ 3.12 6.05E-06 ↑ 
miR-191-5p ↑ 2.94 4.09E-11 ↑ 
miR-99a-5p ↑ 2.88 4.22E-07 ↑ 
let-7c ↑ 2.88 8.28E-12 ↑ 
miR-145-5p ↑ 2.82 1.19E-11 ↑ 
miR-125b-5p ↑ 2.80 1.75E-05 ↑ 
miR-21-3p ↓ 2.72 1.46E-05 ↓ 
miR-148a-3p ↑ 2.67 8.01E-08 ↑ 
miR-28-5p ↑ 2.63 4.74E-07   
let-7d-5p ↑ 2.63 2.48E-10 ↑ 
miR-30a-3p ↑ 2.62 8.32E-05 ↑ 
miR-136-3p ↓ 2.61 4.62E-04 ↓ 
miR-95 ↑ 2.57 9.16E-05 ↑ 
miR-181a-5p ↑ 2.36 2.76E-07 ↑ 
miR-139-5p ↑ 2.33 1.50E-06 ↑ 
miR-361-5p ↑ 2.25 2.29E-18 ↑ 
miR-224-5p ↑ 2.24 8.20E-04 ↑ 
miR-155-5p ↑ 2.21 5.53E-05 ↑ 
miR-223-5p ↑ 2.09 2.04E-05 ↑ 
miR-301a-3p ↓ 2.06 3.00E-04 ↓ 
miR-410 ↑ 2.01 2.85E-03   
miR-23a-3p ↑ 2.00 8.28E-12   
 
In addition to the 32 miRNAs that show consistent de-regulation, six miRNAs are  
up-regulated in this validation phase while not differentially expressed between HCC and 
NH in the first cohort. These include two miRNAs associated with clinical phenotypes in 
Table 3.5.1 38 miRNAs differentially expressed between HCC (n=36) and normal healthy 




the discovery cohort: miR-410 down-regulated in patients with tumor capsules, and miR-
483-5p elevated in patients with vascular invasion and under-expressed in patients with 
normal liver cirrhosis. Both miRNAs are up-regulated in the validation cohort. Higher 
expression of miR-28-5p is significantly associated with shorter survival time in the first 
cohort, and up-regulation of this miRNA is observed in the HCC group in the second 
cohort. Lastly, miR-23a-3p, miR-199a-3p and miR-423-3p, which are stably expressed in 
all the samples of the discovery phase, are up-regulated in the validation phase.   
3.5.1.2 Seven miRNAs differentially expressed between patients with chronic 
hepatitis B and normal controls 
 
 HBV infection is an important risk factor for HCC, and in our discovery study, six 
miRNAs show significant associations with viral infection in HCC group (see section 
3.4.2). In the validation cohort, we include 30 patients with CHB and compare the 
miRNA signatures with NH controls. Seven miRNAs are significantly increased in the 
CHB group, with fold change>2 and corrected P-value<0.05 by Student’s t-test (Table 
3.5.2). 
 We further compare the expression changes of the 7 miRNAs between HCC and 
normal groups. Except miR-194-5p, all the miRNAs show up-regulation in HCC 
compared to normal controls (fold change>1.5, corrected P-value<0.05). MiR-194-5p is 
up-regulated in CHB while down-regulated in HCC, thus are not differentially expressed 
between HCC and NH individuals. On the other hand, miR-122-5p is one of the most up-
regulated miRNAs in HCC, and also exhibits the highest increase (fold change=3.46) in 
CHB (Table 3.5.2).  We further evaluates the difference of these up-regulated miRNAs 
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between CHB and HCC groups. It is found that miR-30e-3p is further elevated in HCC 
compared to CHB, while the rest do not exhibit significant change between the two 
groups (Table 3.5.2). The results indicate that up-regulation of miR-122-5p, miR-125b-5p, 
miR-885-5p, miR-99a-5p and miR-193b-3p is mainly contributed by HBV infection and 
might be used as marker for CHB. However, the occurrence of HCC may not further 
affect the expression of these miRNAs in plasma. 
 In the previous results, six miRNAs show differential expression between HCC 
patients with and without HBV infection. However, none exhibits the same trend of de-
regulation in CHB carriers, and miR-99a-5p previously down-regulated in HepB-positive 
HCC is up-regulated in Hepatitis B carriers in the validation phase. The discrepancy 
might be contributed by the heterogeneity of our patient group, in which etiological 
factors other than HBV infection could affect miR-99a-5p expression via different 
mechanisms during HCC development, and up-regulate the miRNA more significantly 
than the change caused by HBV infection. Therefore, in different contexts (HCC present 
and absent), different trends of associations with HBV infection are observed for miR-
99a-5p. 
MiRNA name 








miR-122-5p ↑ 3.46 4.57E-04 - 
miR-99a-5p ↑ 2.8 4.57E-04 - 
miR-194-5p ↑ 2.58 5.06E-04 ↓  
miR-885-5p ↑ 2.25 3.78E-03 - 
miR-125b-5p ↑ 2.1 1.86E-03 - 
miR-193b-3p ↑ 2.07 5.08E-03 -  
miR-30e-3p ↑ 2.02 5.06E-04 ↑ 
Table 3.5.2 Seven miRNAs differentially expressed between patients with chronic hepatitis B 




3.5.1.3 36 miRNAs de-regulated between HCC and chronic hepatitis B patients 
 
After analyzing the differential expression with the NH controls, we next compare 
HCC and CHB groups, to identify the miRNAs specifically affected by HCC occurrence. 
In total, 29 up- and 7 down-regulated miRNAs are determined (Table 3.5.3). 
 
MiRNA  
CHB vs HCC Normal vs HCC 
De-regulation Fold Change Corrected P-value De-regulation 
miR-214-3p ↑ 13.04 2.80E-10 ↑ 
miR-199a-3p ↑ 5.04 3.48E-15 ↑ 
miR-210 ↓ 5.03 1.53E-14 ↓ 
miR-550a-3p ↓ 4.57 4.23E-08 ↓ 
miR-195-5p ↑ 4.19 2.06E-07 ↑ 
miR-1972 ↑ 4.07 4.55E-06 ↑ 
miR-497-5p ↑ 3.91 5.55E-09 ↑ 
miR-193a-5p ↑ 3.81 1.52E-09 ↑ 
miR-34a-5p ↑ 3.8 3.46E-08 ↑ 
miR-483-5p ↑ 3.8 8.72E-06 ↑ 
miR-423-3p ↑ 3.7 1.59E-15 ↑ 
miR-194-5p ↓ 3.68 2.09E-06   
miR-95 ↑ 3.21 4.33E-04 ↑ 
miR-410 ↑ 3.09 3.19E-05 ↑ 
miR-136-3p ↓ 2.97 2.17E-04 ↓ 
miR-191-5p ↑ 2.97 1.71E-10 ↑ 
miR-574-3p ↑ 2.81 1.40E-07 ↑ 
miR-365a-3p ↑ 2.71 6.30E-04 ↑ 
miR-361-5p ↑ 2.7 7.20E-18 ↑ 
miR-146a-5p ↑ 2.67 7.57E-08   
miR-23a-3p ↑ 2.66 8.22E-15 ↑ 
miR-223-5p ↑ 2.64 1.16E-06 ↑ 
miR-224-5p ↑ 2.62 1.90E-03 ↑ 
miR-145-5p ↑ 2.55 8.58E-10 ↑ 
miR-301a-3p ↓ 2.42 3.16E-05 ↓ 
let-7d-5p ↑ 2.37 4.23E-08 ↑ 
miR-148a-3p ↑ 2.28 2.10E-05 ↑ 
miR-136-5p ↓ 2.22 1.19E-02   
miR-21-3p ↓ 2.16 1.04E-03 ↓ 
miR-382-5p ↑ 2.13 2.58E-03   
miR-139-5p ↑ 2.11 2.42E-05 ↑ 
miR-181a-5p ↑ 2.11 1.32E-05 ↑ 
miR-30e-3p ↑ 2.07 1.97E-08 ↑ 
miR-155-5p ↑ 2.06 8.88E-04 ↑ 
miR-221-3p ↑ 2.04 1.44E-03   
miR-326 ↑ 2.01 1.19E-02   
Table 3.5.3 36 miRNAs differentially expressed between chronic hepatitis B (n=30) and 
HCC patients (n=36) in the validation phase. 
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We observe that the majority (30/36) of the differentially expressed miRNAs 
between HCC and CHB overlap with the de-regulated miRNAs in HCC compared to 
normal group and exhibit consistent trends of de-regulation. The most up-regulated 
miRNA between HCC and CHB, miR-214-3p, also shows the highest fold change 
between HCC and normal individuals. Of these miRNAs, the differences between HCC 
and NH are mainly contributed by the cancer occurrence, while the viral infection does 
not significantly affect the expression.  
To conclude, from the comparison among the three groups, we observe 45 de-
regulated miRNAs in HCC and/or CHB. Except miR-194-5p that is up-regulated in CHB 
and under-expressed in HCC, all the other miRNAs could be used for differentiating the 
disease group from normal healthy population. The performance of these miRNAs as 
diagnostic markers is analyzed and presented in the following sections.    
3.5.2 Diagnostic potential of circulating miRNAs for HCC and/or chronic hepatitis 
B 
 
 Among the de-regulated miRNAs in CHB and/or HCC, we observe that the 
majority of the miRNAs show differential expression between HCC and non-HCC 
groups, while seven miRNAs exhibit significant differences between the normal and 
chronic carrier groups. Based on the expression patterns, we further classify the miRNAs 
in three categories: 1. miRNAs up-/down-regulated in both CHB and HCC; 2. miRNAs 
de-regulated in CHB while no significant change in HCC; 3. miRNAs de-regulated in 
HCC compared to non-HCC groups. These three categories of miRNAs could be used for 
different purposes of discrimination between disease group(s) and normal controls.    
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3.5.2.1 Four miRNAs as potential biomarkers for both chronic hepatitis B and HCC  
 
 We first focus on the four miRNAs that are up-regulated in both chronic carriers 
and HCC, including let-7c, miR-28-5p, miR-30e-3p and miR-574-3p (Figure 3.5.2). The 
miRNA expression is significantly elevated in CHB compared to normal, and further 
increased in HCC. Therefore, the miRNA expression levels could be used for detection of 
































































Figure 3.5.2 Four miRNAs up-regulated in both chronic hepatitis B and HCC.  a. miR-30e-







MiRNA name Group comparison 
Area Under Curve 
Sensitivity Specificity 
AUC 95% CI 
miR-30e-3p 
NH vs CHB 0.79 0.69-0.90 0.60 0.87 
CHB vs HCC  0.89 0.80-0.97 0.83 0.87 
NH vs HCC 0.98 0.94-1.00 1.00 0.92 
miR-574-3p 
NH vs CHB 0.68 0.55-0.81 0.67 0.68 
CHB vs HCC  0.88 0.80-0.96 0.72 0.87 
NH vs HCC 0.96 0.93-1.00 0.86 0.95 
let-7c 
NH vs CHB 0.79 0.68-0.90 0.73 0.75 
CHB vs HCC  0.73 0.60-0.85 0.64 0.73 
NH vs HCC 0.94 0.88-0.99 1.00 0.75 
miR-28-5p 
NH vs CHB 0.67 0.54-0.80 0.80 0.54 
CHB vs HCC  0.65 0.52-0.79 0.89 0.40 
NH vs HCC 0.81 0.71-0.91 0.97 0.57 
 
We evaluate the diagnostic performance of the four plasma miRNAs based on 
receiver operating characteristic (ROC) analysis (Table 3.5.4). All the four miRNAs 
show AUC>0.8 for distinguishing HCC from normal individuals. For diagnosis of HCC 
from CHB patients, both miR-30e-3p and miR-574-3p show good performance with 
AUC>0.8, while miR-30e-3p outperforms miR-574-3p with higher sensitivity (0.83 vs 
0.72). Of the four miRNAs, the diagnostic performance for CHB is sub-optimal, as 
shown by the relatively low AUC (highest AUC=0.79 for miR-30e-3p and let-7c). Taken 
all the evidences together, miR-30e-3p is the best diagnostic marker in this group, though 
it lacks sensitivity (sensitivity=0.6) for detection of CHB. It might be solved by 
incorporating other serum markers, e.g. HBV DNA or HBV surface antigen, for better 
diagnostic performance. The changes of the miRNA can also be used to monitor the 
disease progression, especially in HBV-related HCC.  
 
Table 3.5.4. Receiver operting characteristic analysis of the four miRNAs up-regulated in 






Among the four miRNAs that show up-regulation in HepB and HCC, only let-7c 
and miR-574-3p are expressed in all the samples and a logistic regression is performed 
using both miRNA expression levels as predictors. The combination of the two miRNAs 
(1.05×let-7c + 1.16×miR-574-3p) shows AUCs less than the best single marker i.e. miR-



























































































Normal vs Chronic Carriers Chronic Carriers vs HCC Normal vs HCC
Figure 3.5.3 Receiver operating characteristic curves of the four miRNAs up-regulated 




3.5.2.2 Seven miRNAs as potential biomarkers for chronic hepatitis B 
  
 The analysis of the differentially expressed miRNAs between CHB and normal 
groups identifies seven miRNAs showing significant differences (fold change>2, 
corrected P-value<0.05). Among the seven miRNAs, miR-30e-3p is further elevated in 
HCC while miR-194-5p expression decreases. All the others have no significant 
difference between HCC and chronic carriers (Table 3.5.2). Moreover, we identify two 
additional miRNAs, miR-100-5p and miR-30a-3p that exhibit moderate increase 
(1.5<fold change<2, corrected P-value<0.05) in CHB and no further change in HCC. In 
total, seven miRNAs could be used for diagnosing CHB, as shown in Table 3.5.5. It is 
observed that miR-100-5p, miR-125b-5p and miR-99a-5p all belong to the same mir-10 
family, and these miRNAs are likely to be co-regulated during HBV infection.   
From the ROC analysis, all the miRNAs show better performance of diagnosing 
CHB than distinguishing HCC from chronic carriers (Table 3.5.5). It suggests that these 
miRNAs are more suitable for detection of chronic HBV infection. MiR-99a-5p shows 
the best diagnostic performance with the highest AUC and sum of sensitivity and 
specificity. The second best miRNA is miR-122-5p, showing highest specificity (0.9) 






Table 3.5.5  Receiver operating characteristic analysis of the seven miRNAs up-regulated in 
chronic hepatitis B. 
MiRNA name Group comparison 
Area Under Curve 
Sensitivity Specificity 
AUC 95% CI 
miR-99a-5p 
NH vs CHB 0.82 0.71-0.93 0.77 0.88 
CHB vs HCC 0.53 0.39-0.68 0.33 0.80 
miR-122-5p 
NH vs CHB 0.81 0.70-0.91 0.63 0.90 
CHB vs HCC 0.63 0.50-0.77 0.50 0.80 
miR-125b-5p 
NH vs CHB 0.78 0.66-0.89 0.63 0.85 
CHB vs HCC 0.58 0.44-0.72 0.61 0.67 
miR-885-5p 
NH vs CHB 0.75 0.64-0.87 0.53 0.90 
CHB vs HCC 0.63 0.49-0.77 0.58 0.70 
miR-193b-3p 
NH vs CHB 0.75 0.63-0.77 0.83 0.64 
CHB vs HCC 0.51 0.36-0.65 0.43 0.73 
miR-100-5p 
NH vs CHB 0.71 0.58-0.83 0.83 0.53 
CHB vs HCC 0.69 0.56-0.82 0.67 0.73 
miR-30a-3p 
NH vs CHB 0.70 0.56-0.83 0.59 0.79 












Figure 3.5.4 Receiver operating characteristic curves of the best two miRNAs for 
differentiating between chronic hepatitis B patients and normal individuals.                  
a . miR-99a-5p, b.miR-122-5p  
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Among the seven miRNAs that are up-regulated in HepB, miR-193b-3p and miR-
30a-3p are not expressed in all the samples hence are excluded from the analysis of 
combinatory miRNA marker. Model selection suggests that removal of miR-125b-5p 
improves the quality of the model.  The combination of the four miRNAs (1.14×miR-
122-5p - 1.22×miR-885-5p + 1.77×miR-99a-5p - 0.88×miR-100-5p) shows AUC=0.86, 
0.88 sensitivity and 0.8 specificity, hence outperforms any single marker. 
3.5.2.3 Thirty-three miRNAs as potential biomarkers for HCC 
 
 We identifiy 33 miRNAs de-regulated in HCC, including 27 up-regulated and 6 
down-regulated, and show no significant difference between CHB and normal groups. 
We further prioritize the most promising markers by ROC analysis, as summarize the 
result in Figure 3.5.5. It is observed that 19 miRNAs show AUC>0.8 in both NH vs HCC 
and CHB vs HCC comparisons, and 10 exhibit both sensitivity and specificity >0.8 and 
are listed in Table 3.5.6.  
The 10 candidate miRNAs include eight up-regulated and two down-regulated in 
HCC. They do not show good performance when discriminating CHB and NH (AUC 
between 0.52 and 0.77), hence are HCC-specific markers in this study. We further 
compare with their diagnostic performance in the discovery phase, and find that except 
miR-199a-3p and miR-23a-3p, all the miRNAs show the same trends of de-regulation 
and AUC>0.8 in the smaller cohort with 19 HCC and 10 NH individuals. Two down-
regulated miRNAs, miR-210 and miR-550a-3p, and six up-regulated miRNAs, miR-361-
5p, miR-423-3p, miR-191-5p, miR-214-3p, miR-145-5p and miR-193a-5p are proposed 


























































































































































































































































































































































































































































































































































































































































































































































Figure 3.5.5 Summary of the receiver operating characteristic analysis of the 33 
miRNAs de-regulated in HCC. a. area under curve for differentiating HCC from normal 
(blue bars) and chronic carriers (red). b. sensitivity and specificity for normal vs HCC c. 
sensitivity and specificity for chronic carriers vs HCC 
 111 
 
Table 3.5.6 Receiver operating characteristic analysis of 10 miRNAs with the best 








Area under curve 
Discovery phase  
(NH vs HCC) 





NH vs HCC 
↑ 
2.25 0.99 0.98-1 ↑ 0.91 
CHB vs HCC 2.7 0.99 0.98-1     
miR-423-3p 
NH vs HCC 
↑ 
3.56 0.99 0.97-1 ↑ 0.92 
CHB cs HCC 3.7 0.98 0.95-1     
miR-199a-
3p 
NH vs HCC 
↑ 
3.18 0.97 0.94-1 - 0.62 
CHB vs HCC 5.04 0.98 0.96-1     
miR-210 
NH vs HCC 
↓ 
5.03 0.97 0.92-1 ↓ 0.89 
CHB cs HCC 5.03 0.96 0.90-1     
miR-550a-
3p 
NH vs HCC 
↓ 
5.87 0.99 0.97-1 ↓ 0.86 
CHB vs HCC 4.57 0.92 0.84-1     
miR-23a-3p 
NH vs HCC 
↑ 
2.66 0.93 0.88-0.99 - 0.77 
CHB vs HCC 2.66 0.97 0.94-1     
miR-191-5p 
NH vs HCC 
↑ 
2.94 0.94 0.86-1 ↑ 0.92 
CHB vs HCC 2.97 0.92 0.84-1     
miR-214-3p 
NH vs HCC 
↑ 
11.39 0.92 0.84-1 ↑ 1.00 
CHB vs HCC 13.04 0.93 0.85-1     
miR-145-5p 
NH vs HCC 
↑ 
2.82 0.92 0.84-0.99 ↑ 0.99 
CHB vs HCC 2.55 0.91 0.84-0.99     
miR-193a-
5p 
NH vs HCC 
↑ 
3.35 0.87 0.78-0.97 ↑ 0.94 
CHB vs HCC 3.81 0.89 0.80-0.98     
 
Using the eight miRNAs identified to be most promising HCC biomarkers, we 
perform analysis of combinatory miRNA markers as described in section 2.6.1. It is 
found that the combination of miR-423-3p and miR-193a-5p (51.05×miR-423-3p + 
29.52×miR-193a-5p) gives the highest (100%) accuracy, sensitivity and specificity to 
distinguish the HCC patients from normal healthy or CHB individuals. In addition, 
combined miR-423-3p and miR-145-5p (106.64×miR-423-3p+41.79×miR-145-5p) gives 
100% accuracy for distinguishing HCC from normal, and 100% sensitivity and 97% 
specificity for distinguishing HCC from HepB carriers. These combinations outperform 
any single miRNA biomarker. 
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3.5.3 Nine miRNAs associated with clinicopathological phenotypes 
 
In the validation phase, we analyze the associations between the circulating 
miRNA expression and clinical characteristics in the 36 HCC patients. Nine miRNAs 
were found to be associated with viral infection, tumor invasion, necrosis, vascular 
invasion, multifocality, normal liver cirrhosis and steatosis (Table 3.5.7). Among the nine 
candidates, the associations of miR-874 and miR-150-5p with vascular invasion and 
normal liver cirrhosis respectively are consistent with the findings in the first cohort 
including 19 HCC individuals (Table 3.4.2).  Moreover, we find that let-7c associated 
with HBV infection is de-regulated in both CHB and HCC. In addition, miR-1972 being 
associated with vascular invasion shows up-regulation in HCC and miR-193b-3p 
decreased in HCC patients with necrosis is up-regulated in chronic carriers. In the 
following paragraphs, we focus on the two miRNAs that show the same associations in 
both discovery and validation cohorts, and let-7c that could be affected by HBV infection 

















miR-32-5p ↓ 2.10 3.85E-02 
   
let-7c ↑ 1.62 1.10E-02 ↑   ↑ ↑ 
Tumor 
Invasion 
miR-22-3p ↑ 2.15 2.60E-02 
   
Tumor 
Necrosis 




miR-1972 ↑ 2.34 3.85E-02 
 
   ↑ ↑ 
miR-874  ↑ 1.59 2.27E-02 
   
Multifocality miR-338-3p ↑ 2.19 2.30E-02 
   
Normal liver 
cirrhosis 
miR-150-5p ↑ 2.62 7.96E-03 
   
Steatosis miR-151a-3p ↑ 2.33 3.62E-02 
   
Table 3.5.7 Nine miRNAs significantly associated with clinical phenotypes. 
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3.5.3.1 Let-7c associated with viral infection 
 
Let-7c is identified to be up-regulated in CHB and further elevated in HCC. 
Within HCC group, the miRNA expression is higher in HBV-positive compared to HCC 
patients without HBV infection (Figure 3.5.6). The differences between normal and 
chronic carriers, as well as in patients with and without HBV infection, indicate that HBV 
infection could be an important factor that increases the circulating let-7c expression.  
 
3.5.3.2 MiR-874 associated with vascular invasion 
 
 By comparing the miRNA expression in patients with and without vascular 
invasion, it is identified that two miRNAs, miR-1972 and miR-874 show up-regulation. 
MiR-874 is not differentially expressed between HCC and normal groups. However, 
within HCC group, moderate increase (1.5<fold change<2, corrected P-value<0.05) is 
Figure 3.5.6 Plasma let-7c associated with HBV infection. 
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observed in patients with vascular invasion (Figure 3.5.7b). This observation is consistent 
with the previous finding in a smaller cohort (n=19) (Figure 3.5.7a).  
 
 
3.5.3.3 MiR-150-5p associated with normal liver cirrhosis 
 
In the discovery phase, we find that normal liver cirrhosis could increase miR-
150-5p level in the plasma (Figure 3.5.8a). In the validation phase, moderate decrease of 
the miRNA is observed in HCC patients (1.5<fold change<2, corrected P-value<0.05), 
and up-regulation is associated with normal liver cirrhosis within HCC group, consistent 
with the finding in the discovery cohort (Figure 3.5.8b). Though liver cirrhosis is 
frequently observed in HCC patients [63], in our result, cirrhosis and HCC have opposite 
effects on plasma miR-150-5p expression.  Therefore, miR-150-5p might be used as a 
marker for cirrhosis patients without HCC, and further investigation about miR-150-5p 
levels in NH, patients with cirrhosis, HCC patients with and without normal liver 
cirrhosis helps to understand the involvement of the miRNA in cirrhosis and HCC. 
Figure 3.5.7 Plasma miR-874 associated with vascular invasion in a. discovery cohort 





3.5.4 Four miRNAs associated with survival time 
 
Using Cox proportional hazards analysis, we identify that none of the clinical 
characteristics is associated with overall or relapse-free survival. On the other hand, miR-
22-3p, miR-30e-3p and miR-222-3p are significantly associated with overall survival 
time (P<0.05) (Table 3.5.8). In the Kaplan-Meier curves, the higher expression of miR-
22-3p and miR-222-3p correspond to shorter survival time (Figure 3.5.9 a, b). In addition, 
miR-22-3p expression also shows elevation in patients with tumor invasion (Table 3.5.7). 
MiR-30e-3p is found to be up-regulated in CHB and HCC, hence is considered as a 
marker for disease progression. Among HCC patients, higher expression of miR-30e-3p 





Figure 3.5.8 Plasma miR-150-5p associated with normal liver cirrhosis in a. discovery 
cohort (n=19) b. validation cohort (n=36)  
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Table 3.5.8 Four miRNAs associated with overall survival or relapse-free survival time  
  miRNA name coefficient hazard ratio 95% CI ratio P-value 
Overall survival 
hsa-miR-30e-3p -1.35 0.26 0.08-0.80 1.89E-02 
hsa-miR-22-3p 0.89 2.43 1.14-5.18 2.17E-02 
hsa-miR-222-3p 1.12 3.07 1.06-8.83 3.79E-02 




Figure 3.5.9 Three SNPs associated with 
overall survival time in the validation 








In addition to the overall survival time, the association between relapse-free 
survival and circulating miRNA expression is investigated. MiR-326 is the only miRNA 
exhibiting significant association and increase in level corresponds to low survival rate 
(Table 3.5.8). The same trend is observed for overall survival though not statistically 
significant (Fig 3.5.10). The miRNA shows up-regulation in HCC compared to CHB. 
From the ROC analysis, it shows that miR-326 is not a good diagnostic marker for HCC 
(AUC<0.8), However, combining the evidence from survival analysis, we propose that 
the miRNA is significantly implicated in HCC, and up-regulation of the miRNA in 










































































Figure 3.5.10 MiR-326 associated with survival in the validation phase.  a. relapse-free 
survival and  b. overall survival  
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In section 3.4 and 3.5, we profile circulating miRNA expression in HCC patients 
and identify potential diagnostic and prognostic markers. We determine 33 HCC-specific 
markers, in which miR-361-5p shows the best diagnostic performance, and the 
combination of miR-423-3p and miR-193a-5p shows 100% accuracy. I compare with the 
diagnostic markers identified in previous studies and summarize in Table 3.5.8. Both 
single and combined miRNA markers in this thesis show better performance, as 
represented by higher AUC, sensitivity and specificity, than the diagnostic markers 
identified in other studies. Moreover, four up-regulated miRNAs that were previously 
identified as potential markers show the same trend of de-regulation in our patients’ 
cohort.  One caveat of this study is the limitation of samples size, which only includes 36 
HCC and 40 normal healthy individuals in the validation phase.  Future validation of the 
single and combined miRNA markers is needed in an independent cohort.  
Table 3.5.8  HCC diagnostic markers in this thesis and previous studies. 













 100% 100% 100% ↑  
miR-193a-5p 





↑ 98% 98% 92% -  [120] 
miR-375 ↑ 96% 96% 100% ↑   [112]  
miR-885-5p ↑ 90% 91% 79% ↑  [116] 
miR-18a ↑ 88% 86% 75% -   [119]  
miR-122 ↑ 87% 82% 83% ↑  [117] 
miR-215 ↑ 82% 80% 91% ↑ 
 [125] 
miR-143 ↑ 80% 73% 83% - 
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Chapter 4: Discussion 
4.1 Architecture of human polymorphisms reveals functionally important and 
positively selected variants in immune-response genes 
 
In this thesis, we comprehensively investigate the architecture of the genetic 
polymorphisms in the human genome, and identify that polymorphisms in the coding 
regions, especially those affecting protein sequences and/or functions, are most 
constrained. This is consistent with a previous study using HapMap phase II data that 
identified negative selection reducing population differentiation at non-synonymous sites 
[22]. Analysis incorporating genotype data from five more global populations in this 
thesis demonstrates nearly 1.8 fold decrease of population differentiation at non-
synonymous sites compared to genic level and confirms the previous finding. Moreover, 
the lowest SNP density, 1.5 fold enrichment of rare alleles and nearly 4 fold enrichment 
of SNPs with no population differentiation all indicate that nsSNPs show strong evidence 
of purifying selections. It is further strengthened by the result that higher percentage (1.5 
fold increase) of rare alleles is observed in potentially deleterious nsSNPs, compared to 
the non-deleterious missense variants. In addition to nsSNPs, the density of coding 
INDELs which cause frame-shift is only 5% compared to the genic level. All these 
observations indicate that polymorphisms that potentially disrupt protein functions are 
under the strongest purifying selections in the human genes.  
In addition to the deleterious nsSNPs, we also investigate the potential functions 
of the other polymorphisms. A previous study by Vernot et al. found that greater number 
of functionally important variants could be identified in the regulatory regions, marked 
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by DNase hypersensitive sites, compared to coding regions [218]. The functionality of 
genetic variants was evaluated based on the evolutionary constraints, instead of the 
effects on gene regulation. In this study, we utilize computational approaches to predict 
the functions of SNPs that affect TFBS and protein functions, and observe the similar 
trend: putatively functional SNPs are more abundant in regulatory regions compared to 
non-synonymous sites.  
We next study the signatures of natural selections in the potentially functional 
SNPs and include those that may affect various molecular functions. It is observed that 
compared to the non-functional SNPs in the same genic regions, potentially functional 
polymorphisms show significant enrichment of rare alleles. The only exception occurs in 
promote, in which the percentage of rare alleles in the potentially functional SNPs that 
may affect TFBS does not differ significantly from that of the non-functional variants. 
The result suggests that the potential regulatory sites i.e. ESE, ESS, ISRE and miRBS are 
functionally significant, hence SNPs that change these sequences are suppressed by 
selective pressures. It agrees with the previous result which demonstrated stronger 
negative selection on conserved miRBS than other conserved 3’UTR sequences [41], 
though different prediction algorithms and SNP data are used in this thesis. Moreover, 
Levenstien et al. showed similar observations that SNPs in a few functional classes e.g. 
non-synonymous, methylation sites and miRBS are under negative selection compared to 
the rest of the genome [219]. Taken together, it implies that conservation in the 
regulatory elements, including ESE/ESS, ISRE and miRBS, is a general phenomenon in 
the human genome.  
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At the SNP level, I show that coding regions are most constrained by purifying 
selection, and hypothesize that genes that do not contain nsSNPs or INDELs within 
coding sequences might be of functional importance. Combining with the ultra-conserved 
coding sequences [157], we demonstrate that genes involved in fundamental biological 
processes, in particular, those that regulate the expression of other genes, show 
enrichment of conserved coding sequences, which are not affected by nsSNPs or INDELs, 
as well as conserved sequences between species (ultra-conserved elements). On the other 
hand, from bioinformatics prediction, we observe that changes in TFBS and/or splicing 
regulatory elements by genetic variants are more abundant than amino acid changes 
caused by nsSNPs. By analyzing the signatures of natural selections, it is found that 
intronic variants that may alter ISREs contain an excess of SNPs under recent positive 
selection. These findings illustrate that the SNPs in genes that mediate expression (e.g. 
transcription factors, splicing factors) tend to be functionally conserved and maintained 
during evolution, while the SNPs in their target sites (e.g. TFBS) are more tolerated. 
Similar trend was identified in non-coding regulators, miRNAs, in a previous study, 
which showed that genetic variants occur more frequently in the miRNA target regions, 
compared to the mature sequences within pre-miRNAs [36]. Our study expands to other 
regulators e.g. transcription factors, splicing regulators, and identifies the consistent 
pattern from a comprehensive perspective.  
In contrast to the conserved genes being involved in gene regulation, the highly 
polymorphic genes play important roles in modulating responses to environmental 
changes. We observe that genes with the highest SNP densities show most significant 
enrichment in MHC class I and class II families, which reside in the most polymorphic 
 122 
 
region of the human genome [177, 220].  From functional analysis, it shows that these 
genes are involved in pathogenesis of a number of autoimmune diseases. The 
polymorphisms in the MHC genes have also been associated with other clinical 
phenotypes, including responses to infections, drug sensitivity, etc [220]. Many previous 
studies focused on the coding variants of the MHC genes, and the polymorphisms 
flanking the genic regions were considered to be caused by ‘hitch-hiking’ effects [221]. 
In this thesis, we identify that in addition to the extreme number of polymorphisms 
within the coding sequences, the non-coding regions of MHC class I and class II genes 
also show high SNP densities and over-representation of potentially functional SNPs that 
may affect various regulatory elements including TFBS, ESE/ESS, ISRE and miRBS. 
More than 60% of RPS and potentially functional SNPs in the MHC genes could change 
TFBS, while none of them is predicted to be damaging to protein function. Previous 
studies proposed that MHC gene loci are under balancing selection, which maintains 
multiple alleles that can respond to different pathogens [37], while a recent study 
identified signatures of strong positive selection in the MHC regions among Chinese 
populations [222]. Combining the previous findings and the results in this thesis, we 
hypothesize that in the MHC genes, potentially functional polymorphisms that alter 
regulatory sites (e.g. TFBS) are under stronger recent positive selection compared to 
deleterious nsSNPs. Furthermore, SNPs in the promoter regions are not simply ‘hitch-
hiking’ variants. They could affect the gene expression and contribute to phenotypic 
changes. The most well-studied polymorphism, rs9378249 upstream the HLA-B gene, 
has been associated with bipolar disorder [223, 224] and hypertension [224]. As this 
polymorphism is predicted to alter TF binding sites and shows signature of RPS, it is 
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likely to be the causal variant, and the underlying molecular mechanism is worth 
experimental validation.   
In addition to the immune-related genes, genes involved in drug response also 
show to be highly polymorphic. In particular, abundance of functional nsSNPs is 
observed in the coding regions of ABC transporters and CYP450 genes. Furthermore, 
both RPS and high-FST SNPs are over-represented in the ABC transporters, but not in the 
CYP450 genes. It indicates that drug transporters tend to be under stronger positive 
selection and variants in these genes might contribute to phenotypic differences among 
populations. A classical example is an ABCC11 coding variant, rs17822931, which was 
found to determine earwax type. This SNP is highly differentiated between population 
groups, and the A allele is associated with advantageous trait to adapting to cold climate 
[225].  
From the analysis of the highly polymorphic genes, we conclude that genes 
involved in regulating responses to environmental changes tend to be more polymorphic 
and subjected to positive selections. It agrees with recent finding that genetic variants 
associated with inflammatory diseases show evidence of recent positive selection [226], 
and genes implicated in pharmacogenomics show higher level of population 
differentiation, as signatures of positive selections [227]. Though many previous genome-
wide scans for natural selections identified a list of candidate regions, the knowledge 
about how these variants contribute to phenotypes is far from comprehensive [228]. In 
this thesis, we identify that in addition to the evidence of natural selections, over-
representation of potentially functional polymorphisms is also observed in the immune-
related and drug transporter genes. Interestingly, many of the genetic variants affect 
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TFBS and splicing regulatory sites. This implies that within these highly polymorphic 
genes, recent positive selection targets the regulatory elements instead of the non-
synonymous sites, and the genetic variants that alter the gene expression or splicing 
patterns could be the causal variants for phenotypic differences.  
The overall architecture of the genetic polymorphisms in the human genome 
reveals that the genes involved in immune responses and drug transport show enrichment 
of functionally important and recently positively selected SNPs. Though we utilize a 
comprehensive database, there is unavoidable ascertainment bias inherent in the data 
source. However, we show that the nsSNPs and INDELs that cause frame-shifts in 
coding regions are least tolerated, despite the fact that the coding polymorphisms are 
more frequently investigated. Another concern is that we identify the immune-related and 
drug-response genes being highly polymorphic simply because the variants in these genes 
are most extensively studied. To further validate our observation, we use the sequencing 
data from 179 HapMap individuals [151], which give an unbiased representation of 
genomic polymorphisms, and find that MHC class I and II are significantly more 
polymorphic than other human genes (P<0.001 by Mann-Whitney test). On the other 
hand, no polymorphism is detected in 45% histone 2A and 2B genes. All these 
observations from the sequencing data are consistent with our results. It suggests that in 
spite of the ascertainment biases inherent in the dbSNP data source, the findings in this 
thesis give a comprehensive and valid view of the architecture of SNPs in the human 
genome. Lastly, there is one caveat in our study that bioinformatics predictions used for 
determining the potential functions of the polymorphisms may have unavoidably 
generated false positive results. However, to experimentally validate the functions of all 
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the candidate polymorphisms is time-consuming in a genome-wide analysis. Therefore, 
we combine the signatures of natural selections on these potentially functional SNPs, and 
propose that polymorphisms showing both potential function(s) and signature of selection 
are likely to contribute to phenotypic differences.  
 
 
4.2 Genetic polymorphisms affect miRNA regulation and are associated with 
phenotypic differences 
 
 From the overall architecture of human polymorphisms, we highlight the 
importance of functional SNPs in regulatory elements, as they are more abundant than 
nsSNPs and enriched for RPS polymorphisms. These polymorphisms could affect gene 
functions via different molecular mechanisms and lead to changes in gene expression and 
splicing patterns. The SNPs that affect miRNA regulation were further investigated in 




this thesis, and their effects on miRNA regulation pathways have been identified in both 
general populations and HCC patients. 
4.2.1 Polymorphic miRNA regulation contributes to differential miRNA and gene 
expression in general populations 
 
 In this study, we identify that approximately 20% pre-miRNAs are polymorphic, 
based on the dbSNP data and the WGS data from 17 HCC patients.  When we started the 
project, there lacked a comprehensive knowledge about the miRNA expression-
associated SNPs. Though other studies identified the genetic variants associated miRNA 
expression in the LCLs and livers, most of the significant associations are trans 
associations and the molecular basis of the genotype-expression associations were 
difficult to interpret [229-231]. Therefore, we focus on the SNPs within miRNA genes 
and identify their contribution to mature miRNA expression. Two SNPs are found to be 
associated with miRNA expression in the LCLs of HapMap individuals.  
 Mir-146a polymorphism, rs2910164, is associated with decreased passenger 
miRNA (miR-146a*) expression in LCLs of normal individuals (Figure 3.2.1a). This 
common SNP has been investigated by many studies and associated with a variety of 
disease risks, including cancers [35, 232-236], tuberculosis [237] and asthma [238], while 
the underlying mechanisms are not well understood. An early study by Jazdzewski et al. 
predicted that C to G change of the SNP leads to stabilization of the hairpin structure, 
enhances miRNA processing and increases mature miRNA (miR-146a) expression [35]. 
Consistent with this model, the same SNP-miRNA association was found in patients with 
sepsis [239], lung cancer [236] and prostate cancer [234], while contradictory observation 
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came from a study that showed the nucleotide change (C to G) corresponds to lower miR-
146a expression in patients with coronary artery disease [240]. In our analysis, the mature 
form miR-146a is not affected by the SNP, while the passenger strand, miR-146a*, is 
significantly down-regulated by rs2910164. The observation is consistent with a previous 
finding that rs2910164 significantly decreases the miR-146a*C passenger miRNA while 
has negligible effect on miR-146a [241]. The previous study further demonstrated that 
both forms of the passenger strands (miR-146a*C and miR-146a*G) are incorporated 
into active RISC with AGO2 and could exert suppressive effects on target mRNAs. In 
addition, the SNP resides in the seed region of the passenger miRNA and the nucleotide 
change could significantly affect target recognition. Our result and the recent studies 
indicate that different from the previous understanding that rs2910164 alters the mature 
miRNA (miR-146a) production, the SNP is significantly associated with passenger 
miRNA (miR-146a*) production and could affect target recognition. Furthermore, we 
identify marginally significant association between the C allele of rs2910164 and the risk 
of HCC. Hence, the involvement of rs2910164, and the two forms of miR-146a*, should 
be further investigated from a new perspective in cancers that have been associated with 
the mir-146a SNP. 
 A mir-92a-1 SNP, rs9589207 residing in the mature sequence but outside seed 
region of miR-92a-1-5p, is associated with decreased expression of miR-92a-1-5p in the 
YRI population (Figure 3.2.1b). The alternative allele is at 12% frequency in YRI 
subjects, while is not detected in the HCC cohort of the TCGA project, hence the effect 
of the SNP in HCC disease is not elucidated in this study. Moreover, possibly due to the 
relatively low frequency in non-African populations, the SNP is not a popular candidate 
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in association studies, and its implication in human diseases is largely unknown. 
Nevertheless, the associated mature miRNA, miR-92a-1-5p, is expressed in both LCLs 
and HCC patients, as well as in different types of cancers (expression data from TCGA 
database as recorded in miRNASNP v2.0 database [37]).  The SNP resides in the mir-17-
92 cluster that is frequently over-expressed in cancers including HCC [111], therefore the 
SNP-mediated effect on miRNA expression may be involved during carcinogenesis. The 
polymorphism is proposed as a candidate for future association study and is worthwhile 
for experimental characterization.  
 In this study, we also investigate all the 3’UTR SNPs identified in the 179 
individuals in 1000 genomes pilot phase. A previous study on cis-eQTLs revealed that 
the expression-associated SNPs are enriched in 3’UTRs compared to intronic regions 
[242], and implied the significance of miRNA-mediated gene regulation. In this study, 
we identify 1280 3’UTR SNPs associated with host gene expression in LCLs of subjects 
from four HapMap populations, and 663 human genes could be affected. Only 11-18% 
SNP-expression associations are shared among all the populations, and 48-66% of the 
associations are population-specific. The observation indicates that in addition to the 
tissue-specificity [243], expression-associated SNPs identified in the same tissue also 
exhibit population differences. 
 From the functional prediction of the expression-associated 3’UTR SNPs, we 
identify 415 (32%) SNPs could affect potential miRNA binding sites. Interestingly, we 
observe 71 genes containing multiple SNPs that might affect miRNA targeting and gene 
expression. In BTN3A2, it is found that 10 3’UTR SNPs, including adjacent SNPs within 
12bp, are significantly associated with expression, and four putative miRNA binding sites 
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are altered. The linkage disequilibrium analysis shows that among the 10 expression-
associated SNPs, six are in high LD (r
2
>0.9) in CEU population, including rs1978 that 
potentially affects miR-216a binding, rs1979 affecting miR-3191 and rs68072215 
affecting miR-762. Similar observations are identified in the CHB+JPT and YRI groups. 
As more than one potentially SNPs are identified in this high-LD block, it suggests that 
the expression variations of BTN3A2 could be contributed by several SNPs that alter 
more than 1 miRBS, hence the effect of the combination of SNPs (haplotype) is in fact 
more important than single SNP association. In addition, another two SNPs in the same 
3’UTR, rs1985732 and rs132185921, show perfect LD in Asian population, while only 
rs1985732 affects miR-191* binding. As neither of the SNPs is significantly associated 
with the other group of high-LD SNPs in the same 3’UTR, the two groups might affect 
the miRNA regulation and gene expression independently. From the finding in BTN3A2 
gene, we propose that there are two models of combinatorial effects: within a haplotype 
block containing several SNPs in high LD, functional 3’UTR SNPs could affect more 
than one miRNA binding sites simultaneously; in a group of SNPs that are not linked to 
each other, they can have additive effects on gene expression. Future investigation of 
haplotype-based expression association could deepen our understanding about the genetic 
basis of miRNA regulation, while these studies are currently not as extensive as SNP 
eQTL analyses and limited to certain cell types [244].    
In addition to the expression association and functional prediction, we incorporate 
the experimentally characterized AGO binding site and prioritize 11 SNPs for further 
validation, including rs1051690 that was associated with colorectal cancer risk [245]. A 
recent study demonstrated that T allele of the SNP is associated with higher gene 
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expression in tumor tissues of the CRC patients [246], which is consistent with the 
finding in this thesis (Figure 3.2.3a). Moreover, among the 415 SNPs with potential 
functions and expression associations, 31 have been associated with phenotypic 
differences. Our results identify the changes in miRNA regulation by these disease-
associated SNPs, which could explain the molecular mechanisms underlying the 
genotype-phenotype associations.  
4.2.2 Genetic polymorphisms contribute to differences in miRNA expression in HCC 
patients 
 
 The investigation of SNP-mediated miRNA regulation in general population lays 
the foundation for understanding the SNP functionality, however, may not show the same 
trends in disease group, due to the tissue specificity of gene regulation [243]. In this 
thesis, we further investigate the genetic variants that are associated with miRNA 
expression in 17 HCC patients. There has not been a comprehensive study characterizing 
all the miRNA-related SNPs in HCC, while results from independent studies showed 
evidences of associations between several pre-miRNA SNPs and HCC disease risk. After 
comparing with the previous findings, we only observe rs2910164 exhibiting marginally 
significant association (P-value=0.078) with HCC risk. 
 In this thesis, we identify four miRNA expression-associated SNPs, which have 
not been investigated in HCC before. Functional prediction indicates that mir-629 SNP, 
rs78212770, and mir-618 SNP, rs2682818, could change the stability of the hairpin 
structures and affect mature miRNA expression, while mir-1307 SNP, rs7911488 and 
mir-323b SNP, rs56103835, might alter the miRNA expression via other mechanisms.  
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A recent study demonstrated that rs56103835 in mir-323b is associated with HBV 
persistence via enhancing the viral replication [247]. The SNP resides within the hairpin 
structure but outside the mature sequence, and the nucleotide change should not affect 
target recognition, and is likely to alter miRNA processing. The result in this study shows 
that miRNA expression in the patients with TT genotype is about 2.4 fold compared to 
those with CT genotype  (Figure 3.3.2c), hence the T to C change may lead to decrease in 
miRNA expression level, and may contribute to differences in viral replication, as 
identified in the previous study [247]. As HBV infection is a major etiological factor in 
HCC [248], rs56103835 that affects HBV infection could also be implicated in HCC 
pathogenesis. 
 Another interesting candidate is rs2682818 in mir-618, being associated with 
increased mature miRNA expression in HCC patients (Figure 3.3.2d). The polymorphism 
has been associated with non-Hodgkin lymphoma via affecting mature miRNA 
expression and the miRNA-regulated pathway [249]. Moreover, aberrant expression of 
miR-618 was observed in the urine samples of patients with HCV-related HCC [250]. 
Therefore, the SNP might be involved in HCC via affecting miR-618 expression. 
 In addition to the pre-miRNA polymorphisms, we also investigate all the SNPs 
identified in the 52 miRNA machinery genes from WGS of 17 HCC patients in the 
TCGA project. Despite the relative small samples size, nearly 8000 SNPs are identified 
in these miRNA machinery genes. We further analyze their effects on the mature miRNA 
expression. Based on a conservative cutoff (empirical P-value<0.001), we identify 879 
SNPs associated with mature miRNA expression. Only three are nsSNPs are associated 
with miRNA expression, while more than 90% expression-associated SNPs reside in 
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introns. None of the three nsSNPs is predicted to cause deleterious effect on protein 
functions. At a more stringent cutoff (corrected empirical P-value<0.05), nine intronic 
SNPs are significantly associated with mature miRNA expression. 
 Previous studies focused on the polymorphisms that could alter the protein 
sequence of the miRNA-processing genes [18]. However, from the analysis of the SNPs 
in miRNA machinery pathway, it is found that expression-associated SNPs are not 
enriched for missense variants. On the other hand, intronic SNP rs7349528 in XRN1, is 
associated with mature miRNA expression (Figure 3.3.5c). The SNP is predicted to 
create two splicing regulatory elements and might affect the splicing patterns of the gene. 
In addition, a missense SNP in DROSHA, rs55656741, was associated with differences 
in splicing patterns by a previous study [217] and is associated with miR-374a-5p 
expression (Figure 3.3.6b) . All these results suggest that SNPs in miRNA machinery 
genes might affect miRNA expression via more moderate mechanisms than directly 
altering protein functions. Previous miRNA eQTL study in general populations 
demonstrated that SNPs contributing to miRNA expression are enriched for mRNA 
eQTLs [230]. Therefore, the candidate SNPs identified in this thesis may lead to change 
in transcript isoform expression of the miRNA machinery genes and further affect 
miRNA biogenesis and processing. A comprehensive analysis involving the miRNA 
machinery gene expression, miRNA expression and the miRNA expression-associated 
SNPs will help to decipher the underlying mechanisms.  
To validate the effects of SNPs on the miRNA machinery pathway, nsSNPs are 
still the best candidates, as they directly affect protein sequence. We identify three 
candidate SNPs in GEMIN4, DROSHA and TNRC6B being significantly associated with 
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mature miRNAs. In the three genes, GEMIN4, an important molecule in RISC [251], 
contains the highest number of nsSNPs and missense mutations among all the miRNA 
processing genes. The SNPs in this gene have been extensively studied in other diseases 
[147, 148, 251-253], while not systematically investigated in HCC yet. In this thesis, we 
find that a missense SNP in GEMIN4, rs3744741, is associated with decreased miR-
487b-3p expression (Figure 3.3.6a). The SNP was implicated in prostate cancer [251], 
and a haplotype containing rs3744741 and five other nsSNPs in GEMIN4 gene was 
associated with bladder cancer risk [252]. Due to its association with miRNA expression 
in HCC and its involvement in other cancers, we propose that the GEMIN4 nsSNP 
rs3744741 as a potentially functional SNP involved in HCC and is worth further 
investigations.  
To summarize, in this study, we elucidate the genetic polymorphisms associated 
with differences of miRNA expression in HCC patients. Both SNPs within pre-miRNAs 
and in miRNA machinery genes could affect the mature miRNA expression, including 
miRNAs known to be involved in HCC pathogenesis. However, we do not observe 
overlap of miRNA expression-associated SNPs identified in LCLs of HapMap 
individuals and non-tumorous liver tissues of HCC patients. It suggests that the SNP-
miRNA expression association is tissue-specific, and caution needs to be taken when 






4.3 Circulating miRNAs are promising biomarkers for HCC and chronic hepatitis B 
 
 In this thesis, we perform a comprehensive analysis on the plasma miRNAs in 
HCC patients by two phases. In the discovery phase, we measure 751 human miRNAs in 
19 HCC patients compared to 10 normal individuals, and identify 68 differentially 
expressed miRNAs. A number of circulating miRNAs that were previously de-regulated 
in HCC show consistent trends of de-regulation in our result. MiR-122, a liver-specific 
miRNA that showed elevation in HCC [115, 117], is the most up-regulated one in the 
discovery cohort. Up-regulation of miR-885-5p by 20-fold is consistent with the finding 
of a previous study [116].  On the other hand, the majority of the de-regulated circulating 
miRNAs have not been well studied in HCC, including the second most up-regulated 




miRNA, miR-214-3p, whose down-regulation was observed in the HCC tumors [254] 
while the change in blood circulation was not determined.   
 To further validate the results, expression profiling of the de-regulated and/or 
clinically associated miRNAs was performed in plasma samples from 36 HCC patients, 
compared to 30 normal healthy individuals. In addition, we include 30 patients with CHB 
to investigate the changes of miRNAs by HBV infection, which occurs in 60% of our 
patients’ cohorts, and is an important etiological factor for HCC [248]. Comparing with 
the discovery phase, 32 miRNAs are successfully validated in the second cohort, while 
only two miRNAs exhibit different trends of de-regulation. MiRNA signatures in the 
three groups are compared, and seven miRNAs specific to CHB, 33 specifically de-
regulated in HCC, and four miRNAs associated with both CHB and HCC are identified 
in this study.   
4.3.1 Circulating miRNAs for diagnosis of chronic Hepatitis B 
 
In this study, we identify seven miRNAs up-regulated in patients with CHB but 
show no significant difference in HCC compared to chronic carriers. Though these 
miRNAs exhibit higher expression in HCC compared to normal, their expression changes 
are associated with HBV infection rather than occurrence of HCC, therefore are potential 
biomarkers for CHB.  
Among the seven miRNAs associated with CHB, MiR-122 is the most commonly 
studied miRNAs in HCC and liver pathologies. A previous study identified miR-122 up-
regulated in CHB patients and further elevated in HCC, while the change  between 
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chronic carriers and HCC was just at border line (P=0.043) [117]. It is consistent with our 
finding that 3.5- and 6.2- fold changes are identified in CHB and HCC compared to 
normal control, while the increase in HCC compared to chronic carriers is less than two-
fold and not statistically significant. The result indicates that miR-122 could be used as 
an indicator of chronic HBV infection, an early event that is prevalent in HCC. However, 
it lacks specificity (0.5) for diagnosis of HCC when CHB is present. A more recent study 
also shows that serum miR-122 expression could be used for early detection of HBV 
infection [255].  
Serum miR-125b is up-regulated in both CHB, cirrhosis and HCC, and the highest 
fold change was found in chronic carriers compared to normal controls [123]. In this 
study, we identify the consistent up-regulation of the miRNA in plasma samples of CHB 
patients, and no significant difference between CHB and HCC patients. Similarly, our 
finding is consistent with a previous study that showed up-regulation of serum miR-885-
5p associated with liver pathologies, including both CHB and HCC [116]. Lastly, miR-
100 was found to be up-regulated in HBV-related HCC in a previous study [124], and 
from our result, this miRNA is affected by chronic HBV infection and is likely to be 
elevated in the early phase of  HBV-related HCC.  
In addition to the four consistently up-regulated miRNAs, plasma or serum levels 
of miR-99a-3p, miR-30a-3p and miR-193b-3p have not been associated with HCC or 
CHB before. MiR-99a-5p is transcribed from the same pre-miRNA as miR-99a-3p, 
which was found to be up-regulated in CHB and considered as a liver-specific miRNA 
[255]. Our study identifies similar levels of expression for miR-99a-3p between HCC and 
chronic carriers (fold change=1.03), which suggests that this miRNA de-regulation is 
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solely affected by HBV infection. In addition, miR-99a-3p could distinguish CHB from 
normal individuals with sensitivity=0.77 and specificity=0.88. Among all the seven up-
regulated miRNAs in CHB, miR-99a-5p is the best biomarker for detection of chronic 
HBV infection. 
From the analysis of miRNA expression in HCC, chronic carriers and normal 
healthy individuals, we find that several miRNAs identified to be up-regulated in HCC by 
previous studies. These miRNAs might be used in combination of the current diagnostic 
marker e.g. HBV surface antigen for CHB or HBV-related HCC. However, they are not 
specific to the HCC occurrence and might be more suitable for early detection of HBV-
related HCC. 
4.3.2 Circulating miRNAs for diagnosis of HCC 
 
In this study, we identify 33 HCC-specific miRNAs, that are de-regulated HCC 
and show no significant difference between chronic carriers and normal individuals. The 
occurrence of HCC could affect the expression of these miRNAs in plasma, hence they 
are potential candidates for diagnosis of HCC. 
Among the 33 miRNAs, miR-483-5p was previously identified to be up-regulated 
in HCC plasma samples, and not associated with HBV or HCV infection in non-HCC 
controls [121]. It is consistent with our finding that the miRNA is over-expressed in HCC, 
while does not change in chronic carriers compared to normal. Similarly, circulating 
miR-145 was previously found to be up-regulated only in HCC [124], and identified to be 
a HCC-specific over-expressed miRNA in our study as well. On the other hand, miR-
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223-3p was de-regulated in HCC by several studies, but it is controversial whether the 
miRNA is under- or over-expressed in the plasma or serum of HCC patients [113, 115, 
123, 124], which might be explained by the difference in etiology of patients from 
different studies. In our cohort including a heterogeneous group of HCC patients, we 
identify that the miRNA is up-regulated in HCC, and is not affected during chronic HBV 
infection.  
By ROC analysis, we find six up-regulated and two down-regulated miRNAs that 
are consistently de-regulated in discovery and validation cohorts, and exhibit the best 
diagnostic performance. They include miR-210 and miR-550a-3p down-regulated in 
HCC, and miR-361-5p, miR-423-3p, miR-191-5p, miR-214-3p, miR-145-5p, miR-193a-
5p show increased expression. Except miR-145 that was previously found to be de-
regulated [124], all the circulating miRNAs have not been associated with HCC before. 
On the other hand, the most up-regulated miRNA, miR-214, was found to be up-
regulated in serum samples of breast cancer patients [256]. Therefore, it is more likely to 
be a cancer-specific biomarker rather than liver pathologies.   
To conclude, we identify 33 HCC-specific miRNAs, in which 8 miRNAs show 
high accuracy for distinguishing HCC and non-HCC groups, hence are the most 
promising candidates for HCC biomarkers. Most of the miRNAs have not been 
extensively studied, hence serve as a group of novel markers and are worthwhile for 
future characterization. In spite of the diagnostic accuracy, some practical issues need to 
be taken into consideration when developing the circulating miRNAs as biomarkers. For 
example, though miR-214 shows to be the most up-regulated miRNA, it is not 
abundantly expressed in plasma, and is not detected in 10% samples of the second phase. 
 139 
 
MiR-361-5p shows the best performance in the ROC analysis, but the fold change is 
much more moderate compared to the most de-regulated miRNA e.g. miR-214. Therefore, 
whether the miRNA could be developed as a sensitive marker to distinguish HCC from 
non-HCC groups requires confirmation from an independent larger cohort. Moreover, in 
order to develop clinical assays, the stability of the candidate miRNAs needs to be 
monitored to avoid confounding factors that can affect the miRNA expression levels and 
compromise their accuracy. Lastly, using combination of 2 miRNA expression shows 
100% accuracy for diagnosis of HCC and is worthwhile for validation. 
4.3.3 Circulating miRNAs for diagnosis of HBV infection and HCC occurrence 
 
From the analysis of three groups of samples (normal, CHB and HCC), we 
identify four miRNAs, including let-7c, miR-28-5p, miR-30e-3p and miR-574-3p up-
regulated in chronic carriers, and further increased in HCC compared to CHB patients. 
The elevation in both chronic carriers and HCC suggest that taking different thresholds, 
these miRNAs could be used to determine the disease status, and possibly to monitor the 
disease progression in HBV-related HCC. 
Among the four miRNAs, under-expression of let-7c, a member of let-7 family, 
and de-regulation of its target genes in tumor tissues, were extensively investigated [78-
80]. However, the change of this miRNA in blood circulation has not been determined. 
On contrast to the under-expression of let-7c in tumor tissues, we observe up-regulation 
of the miRNA in the plasma of HCC patients. Moreover, the up-regulation of let-7c was 
associated with HBV infection in a previous study [257] and is found in HBV-positive 
HCC compared to patients without HBV infection in this thesis. Therefore, the miRNA is 
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likely to be involved in HBV infection and HCC occurrence, and might be used as a 
diagnostic marker for disease progression in HBV-related HCC.  
Our knowledge about the other three markers, miR-28-5p, miR-574-3p and miR-
30e-3p in HCC and liver diseases are limited. Similar to let-7c, all the three miRNAs are 
significantly down-regulated (corrected P-value<0.05) in tumors compared to non-
tumorous liver tissues in the HCC patients of the TCGA project. Therefore, the elevation 
of these miRNAs in blood circulation might be reflective of the changes in the tumour 
tissues. Among the four miRNAs, miR-30e-3p shows the best diagnostic performance 
while has not been investigated before. All the miRNAs are commonly expressed in all 
the chronic carriers and HCC patients, and future investigation in a training cohort is 
required to determine the cutoffs for diagnosing different disease stages (viral infection 
and transformation to HCC). Reliable and sensitive clinical assays of these miRNAs 
might be useful for monitoring the disease progression, as well as better surveillance and 
treatment.   
4.3.4 Circulating miRNAs as prognostic marker for HCC 
 
 In both discovery phase including 19 patients and validation phase with 36 
patients, we explore the potential prognostic markers by associating plasma miRNA 
expression with clinical characteristics and survival time. Due to the limitation of small 




 MiR-150-5p, a miRNA that shows no significant de-regulation in chronic carriers 
or HCC, is up-regulated in HCC patients with normal liver cirrhosis (Figure 3.5.8). The 
miRNA was previously identified to be down-regulated in HCC tissues and involved in 
metastasis [258]. Our result indicates that cirrhosis could be an important factor that 
increases the circulating miRNA expression. MiR-874 shows no difference between 
disease groups and normal individuals, while is up-regulated by vascular invasion (Figure 
3.5.7). Moderate increase of miR-874 expression in tumor tissues of patients with 
vascular invasion is identified in the same cohort of patients. This miRNA has not been 
investigated in HCC previously while the study in other cancers demonstrated that it has 
suppressive role in cell migration, invasion and proliferation [259, 260]. Moreover, 
vascular invasion is associated with survival time in early HCC [261]. The involvement 
of miR-874 in HCC and the link between miR-874, vascular invasion and survival need 
to be further investigated in an independent group with larger sample size. 
 
Figure 4.3 Significant findings about the circulating miRNAs as diagnostic and prognostic 
markers in HCC. 
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4.4 Conclusions and Perspectives 
 
In conclusion, by elucidating the architecture of polymorphisms in the human 
genome, we identify that polymorphisms are selectively constrained in the coding regions, 
while enriched in genes that are responsible for immune responses. We further identify a 
catalogue of SNPs that could affect miRNA regulation. A subset of the expression-
associated and potentially functional SNPs have been associated with phenotypic 
differences, hence our findings extend the knowledge about the effects of SNPs on 
miRNA regulation in a variety of human diseases. In particular, the genetic variants 
associated miRNA expression in HCC patients are elucidated, and 50% of expressed 
miRNAs could be mediated by polymorphisms within miRNAs and/or the miRNA 
machinery genes. Future studies will focus on characterizing the miRNA expression-
associated SNPs which might help in the diagnosis of HCC. 
As the miRNA de-regulation is important in HCC disease, we explore the 
circulating miRNAs as non-invasive biomarkers for HCC. We systematically analyze 
more than 700 miRNAs, and identified 44 being de-regulated in chronic hepatitis and/or 
HCC, that could be used as potential diagnostic markers. Our findings indicate that: 1. 
several miRNAs that were previously identified as HCC biomarker e.g. miR-122, are 
elevated in the stage of HBV infection and are more suitable for diagnosing chronic 
hepatitis B;   2. four miRNAs showing up-regulation in both CHB and HCC can be used 
for monitoring the disease progression in HBV-related HCC; 3. the majority of the 
potential HCC biomarkers have not been found in previous studies hence are novel 
markers for diagnosing HCC. Our findings give a comprehensive view about the miRNA 
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signatures in HCC and chronic hepatitis B, and the list of the de-regulated miRNAs could 
be used for development of non-invasive biomarkers. 
4.5 Future Direction 
 
In this study, we elucidate both miRNA-related SNPs and miRNA signatures in 
HCC, and believe that to understand the SNP-regulated miRNA regulation in HCC will 
be beneficial for diagnosis of HCC. Future studies that characterize and experimentally 
validate the functions of the miRNA-related SNPs might lead to exploration of 
personalized treatment and therapeutic intervention. However, our knowledge in this field 
is far from complete, although a great number of studies focusing on single or a subset of 
candidate SNPs have been conducted. In order to obtain a comprehensive view, the 
effects of miRNA-related SNPs on target gene expression need to be further elucidated.  
The miRNA expression, combinatorial effect of SNPs in a haplotype, need to be 
incorporated into a more complex model. With the advent of high-throughput techniques 
and availability of cancer genome data e.g. TCGA, we believe that the genetic basis for 
differences in miRNA regulation, and their effects on HCC disease risks and progression, 
will be unraveled in the near future, and the knowledge about polymorphic miRNA 
regulation in HCC will definitely benefit the disease diagnosis, surveillance and treatment. 
The HCC biomarkers identified in this study should be further validated in larger 
independent cohorts from both local population and other ethnic groups. In addition, the 
miRNA expression change during disease development needs to be determined, and 
future study that profiles miRNA expression at multiple time points for the same patient 
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needs to be conducted. Combination of miRNA with other serum markers, e.g. AFP, 
could be explored in the next phase. Moreover, before clinical application, 
standardization of the plasma preparation, RNA isolation and miRNA quantification from 
patients’ samples need to be optimized. We believe that circulating miRNAs that show 
excellent diagnostic potential in our preliminary study in this thesis could be used as an 
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Supplementary Figure 1 Empirical distribution of changes in alignment scores 
and energy scores of putative miRNA targets by miRanda algorithm. Negative 
correlation was observed between the changes of the two parameters (P<0.001 by 
























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Supplementary Figure 2 Summary of RNA-sequencing reads mapped to reference 
genome. a. YRI samples sequenced in Argonne and b. Yale centers by Pickrell et al.  




Supplementary Table 1 174 HapMap samples with gene expression and/or miRNA expression 
included in the expression-associated SNP analysis 
Population HapMap ID Gene expression Platform MiRNA 
expression 
platform 
CEU NA06985 RNA-seq & microarray microarray 
CEU NA06994 RNA-seq & microarray microarray 
CEU NA07000 RNA-seq & microarray microarray 
CEU NA07357 RNA-seq & microarray microarray 
CEU NA10847 RNA-seq & microarray microarray 
CEU NA10851 RNA-seq & microarray microarray 
CEU NA11829 RNA-seq & microarray microarray 
CEU NA11830 RNA-seq & microarray microarray 
CEU NA11831 RNA-seq & microarray microarray 
CEU NA11832 RNA-seq & microarray microarray 
CEU NA11840 RNA-seq & microarray microarray 
CEU NA11881 RNA-seq & microarray microarray 
CEU NA11992 RNA-seq & microarray microarray 
CEU NA11993 RNA-seq & microarray microarray 
CEU NA11994 RNA-seq & microarray microarray 
CEU NA11995 RNA-seq & microarray microarray 
CEU NA12003 RNA-seq & microarray microarray 
CEU NA12004 RNA-seq & microarray microarray 
CEU NA12005 RNA-seq & microarray microarray 
CEU NA12006 RNA-seq & microarray microarray 
CEU NA12043 RNA-seq & microarray microarray 
CEU NA12044 RNA-seq & microarray microarray 
CEU NA12144 RNA-seq & microarray microarray 
CEU NA12154 RNA-seq & microarray microarray 
CEU NA12155 RNA-seq & microarray microarray 
CEU NA12156 RNA-seq & microarray microarray 
CEU NA12234 RNA-seq & microarray microarray 
CEU NA12249 RNA-seq & microarray microarray 
CEU NA12716 RNA-seq & microarray microarray 
CEU NA12717 RNA-seq & microarray microarray 
CEU NA12750 RNA-seq & microarray microarray 
CEU NA12751 RNA-seq & microarray microarray 
CEU NA12760 RNA-seq & microarray microarray 
CEU NA12761 RNA-seq & microarray microarray 
CEU NA12762 RNA-seq & microarray microarray 
CEU NA12763 RNA-seq & microarray microarray 
CEU NA12812 RNA-seq & microarray microarray 
CEU NA12813 RNA-seq & microarray microarray 
CEU NA12814 RNA-seq & microarray microarray 
CEU NA12815 RNA-seq & microarray microarray 
CEU NA12872 RNA-seq & microarray microarray 
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CEU NA12873 RNA-seq & microarray microarray 
CEU NA12874 RNA-seq & microarray microarray 
CEU NA06986 RNA-seq & microarray   
CEU NA07037 RNA-seq & microarray   
CEU NA07051 RNA-seq & microarray   
CEU NA07346 RNA-seq & microarray   
CEU NA07347 RNA-seq & microarray   
CEU NA11894 RNA-seq & microarray   
CEU NA11918 RNA-seq & microarray   
CEU NA11920 RNA-seq & microarray   
CEU NA11931 RNA-seq & microarray   
CEU NA12045 RNA-seq & microarray   
CEU NA12287 RNA-seq & microarray   
CEU NA12414 RNA-seq & microarray   
CEU NA12489 RNA-seq & microarray   
CEU NA12776 RNA-seq & microarray   
CEU NA12828 RNA-seq & microarray   
YRI NA18501 RNA-seq & microarray microarray 
YRI NA18502 RNA-seq & microarray microarray 
YRI NA18504 RNA-seq & microarray microarray 
YRI NA18505 RNA-seq & microarray microarray 
YRI NA18507 RNA-seq & microarray microarray 
YRI NA18508 RNA-seq & microarray microarray 
YRI NA18516 RNA-seq & microarray microarray 
YRI NA18517 RNA-seq & microarray microarray 
YRI NA18522 RNA-seq & microarray microarray 
YRI NA18523 RNA-seq & microarray microarray 
YRI NA18853 RNA-seq & microarray microarray 
YRI NA18856 RNA-seq & microarray microarray 
YRI NA18858 RNA-seq & microarray microarray 
YRI NA18861 RNA-seq & microarray microarray 
YRI NA18870 RNA-seq & microarray microarray 
YRI NA18871 RNA-seq & microarray microarray 
YRI NA18912 RNA-seq & microarray microarray 
YRI NA19093 RNA-seq & microarray microarray 
YRI NA19098 RNA-seq & microarray microarray 
YRI NA19099 RNA-seq & microarray microarray 
YRI NA19102 RNA-seq & microarray microarray 
YRI NA19116 RNA-seq & microarray microarray 
YRI NA19131 RNA-seq & microarray microarray 
YRI NA19137 RNA-seq & microarray microarray 
YRI NA19138 RNA-seq & microarray microarray 
YRI NA19141 RNA-seq & microarray microarray 
YRI NA19143 RNA-seq & microarray microarray 
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YRI NA19144 RNA-seq & microarray microarray 
YRI NA19152 RNA-seq & microarray microarray 
YRI NA19153 RNA-seq & microarray microarray 
YRI NA19159 RNA-seq & microarray microarray 
YRI NA19160 RNA-seq & microarray microarray 
YRI NA19171 RNA-seq & microarray microarray 
YRI NA19172 RNA-seq & microarray microarray 
YRI NA19200 RNA-seq & microarray microarray 
YRI NA19201 RNA-seq & microarray microarray 
YRI NA19204 RNA-seq & microarray microarray 
YRI NA19207 RNA-seq & microarray microarray 
YRI NA19209 RNA-seq & microarray microarray 
YRI NA19210 RNA-seq & microarray microarray 
YRI NA19119 microarray microarray 
YRI NA19129 microarray microarray 
YRI NA18486 RNA-seq   
YRI NA18498 RNA-seq   
YRI NA18499 RNA-seq   
YRI NA18510 RNA-seq   
YRI NA18511 RNA-seq   
YRI NA18519 RNA-seq   
YRI NA18520 RNA-seq   
YRI NA18909 RNA-seq   
YRI NA18916 RNA-seq   
YRI NA19108 RNA-seq   
YRI NA19114 RNA-seq   
YRI NA19147 RNA-seq   
YRI NA19190 RNA-seq   
YRI NA19225 RNA-seq   
YRI NA19257 RNA-seq   
CHB+JPT NA18526 microarray   
CHB+JPT NA18532 microarray   
CHB+JPT NA18537 microarray   
CHB+JPT NA18542 microarray   
CHB+JPT NA18545 microarray   
CHB+JPT NA18547 microarray   
CHB+JPT NA18550 microarray   
CHB+JPT NA18552 microarray   
CHB+JPT NA18555 microarray   
CHB+JPT NA18558 microarray   
CHB+JPT NA18561 microarray   
CHB+JPT NA18562 microarray   
CHB+JPT NA18563 microarray   
CHB+JPT NA18564 microarray   
CHB+JPT NA18566 microarray   
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CHB+JPT NA18570 microarray   
CHB+JPT NA18571 microarray   
CHB+JPT NA18572 microarray   
CHB+JPT NA18573 microarray   
CHB+JPT NA18576 microarray   
CHB+JPT NA18577 microarray   
CHB+JPT NA18579 microarray   
CHB+JPT NA18582 microarray   
CHB+JPT NA18592 microarray   
CHB+JPT NA18593 microarray   
CHB+JPT NA18603 microarray   
CHB+JPT NA18605 microarray   
CHB+JPT NA18608 microarray   
CHB+JPT NA18609 microarray   
CHB+JPT NA18940 microarray   
CHB+JPT NA18942 microarray   
CHB+JPT NA18943 microarray   
CHB+JPT NA18944 microarray   
CHB+JPT NA18945 microarray   
CHB+JPT NA18947 microarray   
CHB+JPT NA18948 microarray   
CHB+JPT NA18949 microarray   
CHB+JPT NA18951 microarray   
CHB+JPT NA18952 microarray   
CHB+JPT NA18953 microarray   
CHB+JPT NA18956 microarray   
CHB+JPT NA18959 microarray   
CHB+JPT NA18960 microarray   
CHB+JPT NA18961 microarray   
CHB+JPT NA18964 microarray   
CHB+JPT NA18965 microarray   
CHB+JPT NA18967 microarray   
CHB+JPT NA18968 microarray   
CHB+JPT NA18969 microarray   
CHB+JPT NA18970 microarray   
CHB+JPT NA18971 microarray   
CHB+JPT NA18972 microarray   
CHB+JPT NA18973 microarray   
CHB+JPT NA18974 microarray   
CHB+JPT NA18975 microarray   
CHB+JPT NA18976 microarray   
CHB+JPT NA18980 microarray   
CHB+JPT NA18981 microarray   




Supplementary Table 2 17 HCC samples with both whole-genome sequencing and miRNA-
sequencing data included in this study 
Patient 
Barcode 
Whole-Genome Sequencing MiRNA Sequencing 










































































































































































Supplementary Table 3 Putatively functional and recently positively selected SNPs in MHC 
class I and class II genes.  




rs4529296 TBX5, PPARalpha:RXRalpha 
rs9295687 Sn 




rs9366775 GC box, HSF 
rs4361609 LEF1, C1, TBX5 
rs9264679 CDP CR3+HD 
rs2524079 AP 
rs3132491 GEN_INI, Pbx, Pbx-1b 
rs3132490 MADS-A, Tst-1 
rs2040748 AP, Nkx2-5 
rs3130696 POU3F2 
rs2844612 HOXA7 
rs2524074 HOXA5 (Hox-1.3) 
rs9264731 Cdx-2, Muscle TATA box, TATA 
rs9264740 AP-1, Sn 
rs9264742 FOX factors, HFH3 (FOXI1), HNF3 




Elk-1, HNF4 direct repeat 1, STAT1, Xvent-1 
rs189992 HOXA5 (Hox-1.3) 
rs3763342 
HLA-DOA 
OCT-1, Brn-2, CF1A, Nkx2-5 
rs3763341 cap 
rs4713603 Pax-2 
rs4713604 VDR, CAR, PXR 
rs4559122 Pax-4 
rs4486068 MEIS1A:HOXA9, HSF, STAT 
rs6457699 c-Myb, MYBAS1 




rs2061952 CF2-II, Oct-4 (POU5F1) 
rs17429444 BPC1, C/EBP 
rs3763355 Pax-3, TGA1a 
rs3763354 MATalpha2 
rs2857106 Pax-6, Elk-1, ZAP1 




rs2071353 Pax-4, Eve, OCSBF-1, Pax-6 






rs6914849 FACB, TFII-I 
rs2301220 Pit-1 




rs9268614 Muscle initiator sequence-20 
rs2027856 HES1 
rs3757335 HLA-E RUSH-1alpha, SGF-3 
rs1632956 HLA-F XFD-3 
rs2301750 
MICA 
AP-1, MyoD, USF 
rs3763288 MZF1 
rs2844524 Sp1, Sp3, CACD 




rs6915833 GATA-1, GATA-2, GATA-3 
 
 
